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ABSTRACT
Cerebral white matter hyperintensities (WMH) on MRI are an indicator of cerebral
small vessel disease, a major risk factor for vascular dementia and stroke. DNA methylation
may contribute to the molecular underpinnings of WMH, which are highly heritable. We
performed a meta-analysis of 11 epigenome-wide association studies in 6,019 middle-aged to
elderly subjects, who were free of dementia and stroke and were of African (AA) or
European (EA) descent. In each study, association between WMH volume and each CpG was
tested within ancestry using a linear mixed model, adjusted for age, sex, total intracranial
volume, white blood cell count, technical covariates, BMI, smoking and blood pressure (BP).
To detect differentially methylated regions (DMRs), we also calculated region-based pvalues accounting for spatial correlations among CpGs. No individual CpG reached
epigenome-wide significance, but suggestive novel associations were identified with
cg17577122 (CLDN5, P=2.39E-7), cg24202936 (LOC441601, P=3.78E-7), cg03116124
(TRIM67, P=6.55E-7), cg04245766 (BMP4, P=3.78E-7) and cg06809326 (CCDC144NL,
P=6.14E-7). Gene enrichment analyses implicated pathways involved in regulation of cell

development and differentiation, especially of endothelial cells. We identified 11 DMRs
(PSidak<0.05) and two were mapped to BP-related genes (HIVEP3, TCEA2). The most
significant DMRs were mapped to PRMT1, a protein arginine methyltransferase involved in
glioblastomagenesis (P=7.9E-12), and mapped to CCDC144NL-AS1, an antisense transcript
of CCDC144NL (P=1.6E-11). Genes mapping to DMRs were enriched in biological
processes related to lipoprotein metabolism and transport. Bi-directional Mendelian
randomization analysis showed that DNA methylation level at cg06809326 influenced WMH
burden (OR [95% CI] = 1.7[1.2-2.5], P=0.001) but not the reverse (P=0.89). Additionally,
increased methylation at cg06809326 was associated with lower expression of CCDC144NL
(P=3.3E-2), and two-step Mendelian randomization analysis supported its mediating role in
the association of cg06809326 and WMH burden. CCDC144NL is known to be associated
with diabetic retinopathy and the coiled coil proteins in general promotes integrin-dependent
cell adhesion. Integrin-related pathway was further supported by integrative genetic analyses.
In conclusion, we identified novel epigenetic loci associated with WMH burden, and further
supported the role of cg06809326 in the WMH etiology implicating integrin-mediated
pathology.
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BACKGROUND
Literature Review
Cerebral Small Vessel Disease: Definition and classifications
Small vessel disease is a general term for various abnormalities related to small blood
vessels often referred to in the cardiovascular system.1 Blood vessels play a crucial role in the
cardiovascular system, and any abnormalities can lead to severe sequelae. Small vessel
disease in the heart involves coronary arterioles and the sub-endocardial plexus of
microvessels.2 Abnormalities developed in the heart vessels can lead to acute or stable
coronary syndromes, as well as heart failure in the long term.3,4 Cerebral small vessel disease
is an umbrella term for a group of abnormalities of the small arteries, arterioles, venules, and
capillaries in the brain.5 Most often, cerebral small vessel disease studies paid attentions to
the arterial part.6 A single occlusion of these vessels may result in lacunar stroke syndrome.
The main focus of this dissertation is on cerebral small vessel disease (CSVD).
Blood vessels are widely and densely dispersed in the brain. These perforating vessels
play a crucial role of carrying essential amount of oxygen and nutrients, thus maintaining
optimal functioning of the brain’s metabolically active nuclei and complex white matter
networks.7 The brain greatly depends on the circulatory system in that it receives up to 20%
of cardiac output and consumes up to 20% of the total body’s oxygen, though it only
constitutes ~2% of total body mass.8 Arterial blood is supplied to the brain by two major sets
of vessels: carotid and vertebral arteries.9 Large arteries - anterior cerebral artery (ACA) and
middle cerebral artery (MCA) - which supply blood to most parts of the cerebral hemispheres
arise from carotid arteries; while posterior cerebral arteries (PCA) are formed from vertebral
1

arteries. The two major circulation arteries divide into smaller branch vessels to reach out to
every corner of the brain. Small vessels in the brain originate from two sources: superficial
and deep.10–13 Superficial small vessels, stemming from the subarachnoid circulation, pass
the cortical layers and meet the deep originated small vessels which have passed the deep
grey matter in the deepest areas of the subcortical white matter.
Since abnormalities of brain vessels can be characterized clinically differently by
size, they are conveniently called either as a “large” with a diameter larger than 0.5 to 1.0
millimeter or a “small” vessel with a diameter less than 0.5 millimeter. In CSVD, “small”
vessels generally means those with a diameter less than 0.2 millimeter.14 Clinical trials
performed to develop the ischemic stroke classification system, also named as the TOAST
(Trial of Org 10172 in Acute Stroke Treatment), claimed that stroke caused from large artery
atherosclerosis should be differentiated from that caused from small-vessel occlusion.15
Additionally, two other widely used classification systems distinguish these two origins of
ischemic stroke.16,17
Small vessel disease is the most common pathological neurological process;18 its
consequence can be pathologically discerned either as hemorrhagic or ischemic.5 A disease
with ischemic origin occurs when blood flow is blocked by a blood clot; while that with
hemorrhagic origin happens when a weakened blood vessel wall bursts and bleeds into the
lesion. Ischemic small vessel disease accounts for a third of acute cerebral ischemic events.19
In terms of stroke, a recent study on behalf of the American Heart Association reported that
87% of all stroke is ischemic.20 Hemorrhagic stroke accounts for a relatively small portion of
all strokes, but the consequence is more acute and devastating.21 Ischemic stroke subtypes
2

can be further divided into large artery atherosclerotic stroke (LAS), cardioembolic stroke
(CES), stroke due to small vessel disease (SVS), stroke of other known etiologies, and stroke
of undetermined etiologies according to the TOAST criteria. Small vessel disease can explain
about a quarter of ischemic strokes.22–24
Small vessel disease systematically affects multiple organs and areas of the body and
can be classified based on its etiopathogenesis. There has been proposed six subtypes of
small vessel disease; the most prevalent forms are type 1: arteriolosclerosis and type 2:
sporadic and hereditary cerebral amyloid angiopathy.5 A group of inherited CSVDs such as
CADASIL (cerebral autosomal dominant arteriopathy with subcortical ischemic strokes and
leukoencephalopathy) and Fabry’s disease have been recently reported,25 and these forms are
crucial to understand the pathogenesis of sporadic CSVDs.

3

White matter hyperintensity (WMH)
White matter lesions are confluent areas on brain magnetic resonance image (MRI)
that are bilaterally and symmetrically sited in the periventricular and deep white matter of the
cerebral hemispheres, the basal ganglia which is deep grey matter, the pons, and occasionally
in the other parts of the brainstem and cerebellar white matter.5,26 It appears hyperintense on
T2-weighted and fluid-attenuated inversion recovery (FLAIR) images (Figure 127) or
appears with decreased signal on T1-weighted MR imaging.5,26 It is unclear whether
differential locations of white matters indicate different disease stages or distinct
mechanisms, but white matter tends to be numerously distributed in the cerebral hemispheres
first and then to appear in the brainstem.

Figure 1 Signs of cerebral small vessel disease Adapted from Inzitari
et al, BMJ. 2009 Jul 6;339:b2477. doi: 10.1136/bmj.b2477

The confluent areas in the brain first drew scientific attention more than 30 years ago
with the term leukoaraiosis.28 At the time that the term “leukoaraiosis” was introduced, most
4

studies measured the lesion with computed tomography (CT) imaging, while the most
updated white matter lesion studies do so with MRI. The lesions are developed by chronic
hypoperfusion of the white matter and disruption of the blood-brain barrier which cause
chronic leakage of plasma into the white matter. Pathological studies on the lesions included
myelin pallor, tissue rarefaction associated with loss of myelin and axons, and mild
gliosis.13,29 A further study with consideration of the lesion’s location and risk factors found
that leukoaraiosis is likely to be another expression of CSVD.30 As MRI has become widely
available in various clinical settings, the data on white matter lesions becomes tremendously
abundant and white matter lesions are now generally considered a consequence of CSVD.
WMH is widely used as a surrogate of CSVD.31–33 Symptomatic presentations can be
used as markers of CSVD since it is difficult to visualize small vessels in vivo.34 As
mentioned above, CSVD affects the brain vessels which include the perforating cerebral
arterioles, capillaries, and venules resulting in brain damage in the cerebral white and deep
grey matter.5 On conventional brain MRI taken at 1.5 or 3T, CSVDs manifest in several
forms such as lacunar infarcts or hemorrhages, lacunes,35 WMH (mostly clinically silent),36
visible perivascular spaces,37 and microbleeds38. As one of the key markers of CSVD, WMH
is more common in lacunar stroke, which is a clinical manifestation of CSVD, than other
subtypes of stroke.36 Additionally, WMH is correlated with other CSVD correlates i.e.
lacunes,39 perivascular spaces,37 microbleeds38 and brain atrophy.40 With the advance of
imaging techniques, large population studies and clinical trials use white matter lesion traits
as a surrogate marker of CSVD in that WMH can be measured quantitatively via noninvasively means.32 Epidemiologic studies employ several different endpoints of white
5

matter. Frequently used terms are white matter hyperintensities (WMH), white matter
lesions, white matter progression, and white matter changes. WMH is a term for white matter
lesions appearing hyperintense on brain MRI. This dissertation will focus on WMH, which is
the most commonly studied marker of CSVD, to provide an additional body of evidence to
the current knowledge in CSVD with comparability to other studies.

Epidemiology of WMH
As WMH is highly prevalent in the aging population and associated with age-related
neurological changes;41,42 it has been hypothesized that WMH is a neuroimaging correlate of
age-associated disabilities.43 Even though white matter lesions may develop in young
age,44,45 prevalence increases with age in a “dose-response relationship”. WMH becomes
universal in the older ranging from 11-21% in adults aged around 64 to 94% at age 82.32,35,46–
50

Furthermore, white matter lesions are associated with many geriatric disabilities which

include cognitive disorders, gait and mood disturbances, and urinary problems.51
Risk factors for WMH are a similar set to those for vascular diseases;52 hypertension
plays a crucial role in WMH.53,54 Large population-based studies have shown that advancing
age, female gender, higher blood pressure or hypertension, African American ethnicity,
smoking, alcohol use, lower education attainment, low income, silent infarct, diabetes, and
lower forced expiratory volume in 1 second (FEV1) are associated with WMH as a marker of
CSVD.55 Hypertension is considered as the most important modifiable risk factor for CSVD
and, particularly, WMH and lesions.48,49,56–63 Some of those studies have also shown that
6

duration of hypertension is associated with WMH.60,61 In this perspective, the
pharmacological treatment standard of CSVD has been designed to manage blood pressure.64
Despite that the pathophysiology of WMH is little known and that various
pathologies can lead to WMH,33,65 it is likely to have ischemic or degenerative origin that
damages the small vessels of the brain, leading to chronic cerebral hypoperfusion and myelin
rarefaction.66 Large-scale brain imaging studies have shown that WMH is associated with
incident stroke, vascular cognitive impairment, dementia, Alzheimer’s disease or death.42,67
Specifically, the association of cognitive decline with WMH has been reported for more than
20 years.31,32,68 A meta-analysis of 23 cross-sectional and 14 longitudinal studies reported
that presence of WMH was associated with concurrent cognitive deficits in every test
domain, and the effect was constant over time.69 Studies in older subjects without
neurological diseases reported mixed results on individual domains, but WMH is considered
to be particularly correlated with decline in information-processing speed and executive
function.70

7

Physiological characteristics of cerebral small vessels
As mentioned earlier, blood flow to the brain is crucial. A few minutes interruption of
blood flow can cause severe brain damage and even the slightest insufficient blood flow can
lead to chronic brain injury.71 The brain exhibits unique functional properties to ensure this
crucial blood flow.72 First, since the brain has little means to store energy, the brain works to
regulate vessels to sustain an adequate supply of blood in cerebral blood flow (CBF) under a
variety of conditions. CBF is primarily determined by mechanisms including perfusion
pressure, autoregulatory mechanisms, and vascular reactivity to the partial pressure of arterial
CO2.73 Second, the brain has an auto-regulation mechanism to maintain the constant
transmural pressure against variations in arterial pressure during daily activity. Myogenic
reactivity is known to play a major role in auto-regulation, and there are other candidate
mechanisms to be studied.73,74 Third, the brain has a unique anatomical structure called the
blood-brain-barrier (BBB), which is an important mechanism to regulate the entry and exit of
blood composites including ions, nutrients, macro molecules and energy metabolites.75
Specifically, BBB protects the brain from physiological fluctuation in plasma composites,
and from harmful agents circulating in the blood supply.76 In essence, the homeostasis in the
brain is precisely controlled by an elaborate system of unique physiological structures and
mechanisms.
Physiological studies found that the unique feature of the cerebral vasculature, BBB
does not function independently, but as a module called the neurovascular unit (NVU),75
which enables tight regulation of blood flow to the brain. The NVU consists of endothelial
cells and smooth muscle cells, and are surrounded by a basement membrane, the perivascular
8

(Virchow-Robin) space, pia mater, and astrocyte endfeet.77 Pial arteries running on the brain
surface in the subarachnoid space branch out into the smaller, penetrating arteries. Likewise,
penetrating arteries further branch out into parenchymal arteriole and further into capillaries.
As shown in Figure 2,77 pial arteries and penetrating arteries are covered by smooth muscle
cells and are separated from brain tissues by parenchymal basement membrane. Branching
out into parenchymal arterioles, both parenchymal basement membrane and pia matter
disappears; further branching out into the capillaries, eventually smooth muscle cells
disappear. Without smooth muscle cells and pia mater, capillaries gain pericytes between
endothelial cells and astrocytes; thus, neurons and astrocytes are in direct contact with them.

Figure 2 Blood-brain Barrier (BBB) and the neurovascular unit (NVU) Adapted from Yu
Yamazaki et al. 2017

9

Mechanisms underlying CSVD: Current understanding
Animal models are useful to simulate ischemic changes in the brain; however, due to
the lack of pathological understanding the optimal animal models in CSVD or WMH have
not yet been developed. Hypertension, as an important risk factor in CSVD, has been
thoroughly studied in rodents and other model animals. Studies confirmed deleterious effects
of hypertension on the cerebral vascular structure and functions; those changes are thought to
be associated with cerebral blood flow (CBF) reduction, impaired vasodilation and
vasodilator reserve, and shifts in the autoregulatory curve.78,79 The studies suggested several
underlying mechanisms, and the effect of angiotensin II mediated by oxidant-dependent and
immune-dependent mechanisms also seems to play a crucial role in the pathology.78,79
Angiotensin II mechanism is often a therapeutic target in hypertension and other
cardiovascular disease treatments. Although animal models showed the effect of
hypertension on vasculature, the causal relationship with brain lesions is lacking.72 Also, a
common animal model known as “sporadic small vessel disease model” typically induces
malignant severe hypertension which is beyond the range of autoregulation;72,80 thus, the
sporadic model cannot show the specific influence of modest blood pressure variability. A
recent animal study for dementia implemented a device called an ameroid constrictor that
precisely replicates chronic cerebral hypoperfusion by gradually narrowing cerebral
vessels.81 A study with a novel animal model using this device showed the role of reduced
CBF in white matter damage.82
Modern concepts in CSVD etiopathology originate in the post-mortem work of C.
Miller Fisher during 1955-1973, which took clinicopathological-vascular examinations in 20
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patients with lacunes, lacunar infarcts, and perforating arterioles.83–87 Lacunar ischemic
stroke is a type of stroke attributable to a recent small infarct in the white matter, basal
ganglia, pons, or brainstem. Lacunar stroke patients provided a clue about the CSVD
etiology, as a clinically overt stage of CSVD. Historically, it was believed that symptomatic
lacunar infarcts are due to atherosclerosis or embolism in larger arterioles and the silent ones
are due to lipohyalinosis or fibrinoid necrosis in the smaller arterioles.87
More recently, three possible etiologies for lacunar ischemic stroke are suggested:26,88
atheroma, embolism, and intrinsic small vessel disease. Atherosclerosis in the middle
cerebral artery (MCA), a type of parent artery, has been suspected as a common cause of
lacunar stroke in Fisher’s studies, but stenosis does not seem to address lacunar strokes. In
the Wafarin Aspirin Symptomatic Intracranial Disease (WASID) trial in subjects with stroke
history and current stenosis, only 11% (38/347) of randomized subjects had lacunar stroke as
an index.89 Also, intracranial stenosis is rare in the Caucasian population at less than a 1 to
2 % prevalence, but still a quarter of ischemic stroke is lacunar in the population.90 To
address this discrepancy it was hypothesized that there are two distinct subtypes of lacunar
stroke: those due to proximal perforating arteriolar atheroma and the others due to
lipohyalinosis/arterioloscerosis.91 However, it is unclear how to differentiate them reliably.
The next possible mechanism is embolism, but it also does not appear to be a common
cause of CSVD. Although embolism can cause an acute lacunar infarct, cohort studies and
meta-analyses showed that only 10-15% of lacunar infarcts and few WMH are explained by
embolism.92–94 Also, a systematic review of experimental studies that induced stroke in
animals concluded that emboli mostly caused cortical, but not small subcortical, lesions.95
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One of the studies reported that only less than 6% of emboli injected into the carotid arteries
entered the perforating arterioles.96 Thus, lacunar stroke is less likely to be associated with
overt emboli compared to non-lacunar stroke,92,93 and, thusly, the stenosis is unlikely to cause
the infarct93 or WMH94.
In his post-mortem studies Fisher claimed blood pressure is the cause of pathologies in
CSVD i.e. arteriolosclerosis, lipohyalinosis or fibrinoid necrosis; however, the relationship
between blood pressure and CSVD or WMH is not clearly understood yet. In a study of 70
brain autopsies, many CSVD patients did not have classic vascular risk factors including
hypertension.97 Blood pressure is still considered as an important risk factor for
WMH,57,60,61,63,98 but the relationship between blood pressure and WMH is complex. It is still
unclear whether systolic63 or diastolic62,99 BP is important in WMH; it is not consistent if BP
does predict WMH progression57 or not100.
The emerging hypothesis in CSVD pathology is that the loss of normal endothelial
function in the blood-brain barrier (BBB) causes pathological changes in the brain. BBB
consists of endothelial cells tightly anchored to each other. The failure of the cerebral
arteriolar and capillary endothelium could explain the arteriolar wall infiltration and
thickening via perivascular tissue changes (e.g. damaged arteriolar smooth muscle and fibrin
deposition known as lipohyalinosis and fibrinoid necrosis).101 These changes were referred to
as “microvascular pathology” in Fisher’s original paper.102 Cumulative microvascular
pathology in perivascular tissue can lead to rarefaction and demyelination, which are
pathologically observed in WMH carriers.29 More severe consequences of endothelium
failure include vessel lumen dilation and narrowing and stiffened vessels with loss of normal
12

autoregulation; as scientists long suspected for CSVD etiology.103,104 As the mechanism
involving endothelium dysfunction has been hypothesized relatively recently, our
understanding of the role of cerebrovascular endothelium in CSVD pathology is lacking.105
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Previous Genetic Studies of CSVD and WMH
Even though a myriad of studies put intensive efforts to decipher molecular
mechanisms underlying CSVD, the precise mechanism is not fully understood. Poor
understanding of biological mechanisms behind the disease continues to impede the
development of effective and precise treatments for CSVD. Studying microvessels in the
brain has been a struggle due to the limited accessibility to them, the difficulties of in-vivovisualization, and the lack of adequate animal models.106 However, genetic studies have been
expanding our understanding of CSVD mechanisms; monogenic forms of CSVD were
discovered and results from large-scale studies are promising to decode the genetic basis of
sporadic CSVDs. From the current understanding it is hypothesized that CSVDs are likely to
result from various pathogeneses such as atheroma (decreased blood flow), emboli
(blockage-causing piece of material inside a blood vessel), inflammation with BBB
disruption, cell degeneration, and myelin breakdown. Genetic studies are designed both to
investigate whether or not WMH is developed by these mechanisms and to identify genetic
markers for prevention or intervention purposes.
Animal model
Transgenic mouse models have been numerously employed to study mechanisms of
known causal genes in monogenic CSVDs such as CADASIL. Vascular protein deposits
(granular osmiophilic material) containing the Notch3 extracellular domain have been
identified in transgenic mouse models expressing a pathogenic mutant,107–111 but not in
knockout mice.112–114 Through these animal studies NOTCH3 is now strongly claimed to
have a gain-of-toxic-function rather than a loss-of-function mechanism.114,115 Proteomic
14

profiles of HTRA1 gene knockout mouse was shown to overlap with the protein profiles of
CADASIL patients.114 Unlike monogenic CSVD, animal studies in common and complex
form of CSVD are lacking. Since large-scale epidemiologic studies have recently identified
genetic variants associated with common and complex form of CSVDs presented as WMH,
brain infarcts, and other clinical manifestations; it is necessary to confirm the mechanistic
function of those genes in transgenic animal studies. A recent study using CRISPR/Cas9
models examined the role of a SNP (rs9349379) located in PHACTR1 gene on five vascular
diseases including hypertension.116 This suggests a potential utility of the modern geneediting technology with WMH and CSVD causal variants.
Compared to non-cases a family history of stroke is more likely to be found in stroke
patients, and a positive family history of stroke is strongly associated with CSVDs [odds
ratio of 1.93 to 2.76].117,118 Specifically for WMH, twin studies showed that correlations of
WMH volume in pairs are greater in monozygotic twins than dizygotic twins, and the
heritability estimate of 71% adjusted for age and head size was very high.119 High heritability
in WMH volume was also estimated in family-based studies ranging from 52 to 78%.120–122
The Framingham Heart Study suggested that the heritability estimate may depend on gender
and age.120 However, heritability estimates based on common genetic variants, known as
narrow-sense heritability, is generally lower; the estimate in small vessel-related stroke and
deep intracerebral hemorrhage ranged from 15 to 30%,123,124 and was only 6.4 % for WMH
specifically.125 This discrepancy between the estimates can be explained by other genomic
variants or mechanisms not included in GWASs (i.e. rare variants, DNA methylation, gene
expression, gene-gene interaction, and gene-environment interaction).
15

Genetic studies have identified nine genes for mendelian forms of CSVD including
NOTCH3, COL4A1, COL4A2, TREX1, HTRA1, FOXC1, PITX2, CECR1, and CTSA.126
NOTCH3, known to be associated with CADASIL,127–130 encodes the NOTCH3
transmembrane receptor involved in arterial differentiation and vascular smooth muscle cell
remodeling.131 HTRA1 (high temperature requirement protein A1) is involved in TGF-β
signaling, playing an important role in vessel development and maintenance.132 Also, HTRA1
is associated with cerebral autosomal recessive arteriopathy with subcortical infarcts and
leukoencephalopathy (CARASIL).25,133 Studies also identified that some genes cause specific
CSVD in a monogenic manner; basement membrane abnormality related to COL4A1 and
COL4A2, which are associated with COL4-related angiopathies,134,135 changes in endothelial
and pericyte proliferation as well as impairment of BBB integrity were found to be associated
with FOXC1/PITX2 in animal models,136–138 and CECR1 is associated with ADA2 deficiency
leading to early-onset strokes and inflammations.139,140 Additionally, TREX1 is associated
with retinal vasculopathy with cerebral leukodystrophy and systemic manifestations (RVCLS) and the gene plays a role in basement membrane defects in capillaries.141,142 Recently,
investigators found a novel association of CTSA with a subtype named cathepsin A-related
arteriopathy with strokes and leukoencephalopathy (CARASAL). CTSA encodes cathepsin A
which is involved in the inactivation of neuropeptides and regulation of a lysosomal pathway
of protein degradation and pathological change leads to fibrous thickening of the small
vessels.143,144 Mutations in NOTCH3, COL4A1 and COL4A2 are thought to explain a large
portion of familial CSVDs, and penetrance of these genes are high so that individuals with
even a single mutation are at almost 100% risk of the disease.126 Even though monogenic
16

CSVDs are considered genetically heterogeneous and rare, the shared clinical and
radiological features between monogenic and sporadic CSVD implies that the genetic
underpinning of monogenic CSVDs provides important information to understand the
genetics of the common and prevalent forms of CSVD.106
Knowing the presence of genetic components in WMH, scientific efforts to map the
trait-associated locus were made with linkage studies. Linkage studies test a genetic locus
transmitted with the disease in larger regions (tens of centiMorgans). The co-transmission of
two close-enough genetic loci is called “linkage disequilibrium (LD)” and the degree of LD
is assessed with a logarithm of the odds (LOD) score, the odds of co-transmission compared
to expected independent inheritance. Linkage studies of WMH identified the locus at 4 cM
on chromosome 4 in healthy elderly white subjects.145,146 Also suggestive LOD scores have
been reported at 95cM on chromosome 17 (LOD=1.78)145, at 118 cM on chromosome 11
(LOD=2.21), and at 13 cM on chromosome 21 (LOD=1.75) in white subjects, and at 36 cM
on chromosome 22 (LOD=2.02) as well as at 58 cM on chromosome 21 (LOD=1.99) in
black subjects.147 Additionally, bivariate linkage analysis suggested that 1q24, 1q42, 10q22q26 and 15q26 loci are in LD both in WMH volumes and BP measurements, indicating
pleiotropic effects in the regions.148
Moreover, candidate gene studies investigated dozens of biologically plausible genes in
the association with WMH. A recent systematic review described46 candidate gene studies
having investigated the association between WMH and 19 genes which are mostly involved
in lipid metabolism, control of vascular tone, or blood pressure regulation.149 The study also
performed a meta-analysis for four genes (APOE, ACE, MTHFR, and AGT), and none of
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them were significantly associated with the WMH grade.149 However, the AGT gene has been
repeatedly implicated in WMH linkage studies and the most studied SNP in the gene,147,148
M235T has been reported in a genome-wide association study150 suggesting that M235T is
likely to be in LD with functional causal variants for WMH.151
The advance of genotyping and computational technologies enabled finer mapping of
causal loci associated with WMH. In addition to the linkage findings, genome-wide
association studies (GWAS) explored which single nucleotide polymorphism (SNP) is
associated with WMH (Table 1). The Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) consortium has published GWAS associations of WMH in
disease-free populations. These studies excluded subjects with stroke history due to WMH
being prevalent in stroke patients and thus discounting the cases of WMH formed as a stroke
comorbidity. The first large-scale association study by CHARGE identified SNPs in six
genes (TRIM65, TRIM47, WBP2, MRPL38, FBF1, and ACOX1) at 17q25;150 a follow-up
study with a larger number of subjects in a multiethnic population additionally mapped
SH3PXD2A at 10q24, HAAO at 2p21, PMF1-BGLAP at 1q22, and EFEMP1 at 2p16.152
Under the hypothesis of shared genetics among stroke and stroke-free populations, a metaanalysis of the latter CHARGE GWAS and a GWAS in 3,670 ischemic stroke patients was
performed for the previously reported 15 SNPs.153 This candidate-gene meta-analysis
identified four significant loci, NBEAL1 at 2q33, EVL at 14q32, C1QL1 at 17q21, and
COL4A2 at 13q34.153 The most recent and largest meta-analysis of GWASs, including 2,797
stroke subjects and 8,429 stroke-free individuals from UK Biobank, identified a novel locus
in PLEKHG1 at 6q25 and confirmed two previously reported loci i.e. 17q25 and 2p16.125 The
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novel gene PLEKHG1 was also suggestively significant in a GWAS of stroke-free population
(P value=7.9x10-7).125 There was also an effort to identify rare variants associated with
WMH. Jian et al. performed an exome-wide association analysis including up to 250,000
exonic variants in 20,719 individuals.154 In this analysis the known loci 17q25 and 2q33 were
confirmed and a novel gene in the locus (MRPL38) was identified at the genome-wide
significance level. Most recently, a meta-analysis of two of the exclusively largest GWASs
from CHARGE and UK Biobank confirmed previous findings and additionally identified ten
novel loci for WMH. This study is currently under review for publication, and the identified
genome-wide significant loci were informed during personal communications with the
authors.
Functions of some genome-wide significant SNPs can be plausibly explained in
relation to the CSVD pathology. HAAO at 2p21 encodes 3-hydroxyanthranilate 3,4dioxygenase, which catalyzes the synthesis of quinolinic acid (QUIN). QUIN has been
identified in studies of Alzheimer’s disease and Huntington’s disease. PMF1-BGLAP at 1q22
encodes polyamine-modulated factor 1, a nuclear protein regulated by polyamines. This
protein is required in chromosome alignment and segregation during mitosis. Genes
including NEURL (neuralized E3 ubiquitin protein ligase 1), TRIM47 (tripartite motif
containing 47), SH3PXD2A (tyrosine kinase substrate with five SH3 domains), EEMP1
(endothelial cell membrane glycoprotein fibulin-3) and NBEAL1 (neurobeachin like 1) were
implicated in white matter-related malignant brain tumors involving glial cells.152 COL4A2,
aforementioned in relation to the monogenic form of CSVD, encodes one of the six subunits
of type IV collagen, the major structural components of the basement membrane. Variants in
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this gene were reported to be associated with intracerebral hemorrhage and ischemic smallvessel stroke.155,156 Lastly, PLEKHG1 encodes pleckstrin homology and RhoGEF domain
containing G1 which is one of the Rho guanine nucleotide exchange factors (Rho-GEFs).
Rho-GEFs are involved in cyclic stretch-induced cell reorientation in the vascular
endothelium.157
Table 1 Genome-wide significant loci associated with WMH
Locus
1q22
1q24
1q31.3
1q42s
2p16
2p21
2q32.1
2q33
4p
5q23.2
6q25.1
7q22.1
10q24-26s
10q24
11s
13q34
14q32.2
15q22.31
15q26s
16q12.1
16q24.2
17s
17p11.2
17q21.31

Gene
PMF1, BGLAP
200cM
DENND1B
272cM
EFEMP1
HAAO
AC007319.1
NBEAL1
WDR12
CARF
4cM
CTC-441N14.4
PLEKHG1
ZAN
15cM
PDCD11
NEURL
SH3PXD2A
PDCD11
118cM
COL4A2
EVL, DEGS2
MTFMT, SLC51B
94cM
RP11-437L7.1
C16orf95
95CM
EPN2
DCAKD, NMT1

Population
Pooled
Hispanic
EA
Hispanic
Pooled, EA
EA
EA
Pooled, EA
Pooled, EA
Pooled, EA
EA
EA
EA
EA
Hispanic
EA
Pooled, EA
Pooled, EA
Pooled
EA
EA
EA
EA
Hispanic
EA
EA
EA
EA
EA
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Analysis Method
GWAS
Bivariate Linkagea
GWAS
Bivariate Linkagea
GWAS
GWAS
GWAS
GWAS
GWAS
GWAS
Linkage
GWAS
GWAS
GWAS
Bivariate Linkagea
GWAS
GWAS
GWAS
GWAS
Linkage
GWAS
GWAS
GWAS
Bivariate Linkagea
GWAS
GWAS
Linkage
GWAS
GWAS

Ref
152
148

PC
148

125,152
152

PC
152–154
154
154
145,146

PC
125

PC
148
152
152
152
152
147

PC
PC
PC
148

PC
PC
145

PC
PC

152
UNC13D
Pooled, EA
GWAS
125,150,152,154
TRIM65
Pooled, EA
GWAS
150,152
TRIM47
EA
GWAS
150
17q25
WBP2
EA
GWAS
152,154
FBF1
Pooled, EA
GWAS
152,154
ACOX1
Pooled
GWAS
154
MRPL38
EA
GWAS
19q13.32 APOE
EA
GWAS
PC
147
21s
13cM, 58cM
AA, EA
Linkage
147
22s
36cM
AA
Linkage
a Bivariate analysis of WMH and blood pressure measures (pulse pressure and
arterial blood pressure). s Linkage result with suggestive LOD score. EA: Subjects of
European ancestry, AA: Subjects of African ancestry. PC: based on personal
communication
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Epigenetic studies and integrative analysis
In genetic epidemiology “missing heritability” has been a mystery to unravel.
Although GWASs found a myriad of common variants associated with complex diseases, a
large portion of heritability is not completely accounted for yet. This unexplained portion of
heritability (“missing heritability”) can be due to overestimated heritability or underestimated
SNP effects in GWASs. In the post-genome era, several additional explanations are
suggested to fill this gap. Rare alleles with bigger effects are being studied actively as the
first alternative explanation. Tagger SNPs in GWASs do not cover rare alleles enough plus
the ability to impute those is limited;158 exome-wide association studies covering rare alleles
(i.e. minor allele frequency <0.01 or 0.05) may find extra genetic variants. Some rare variants
may have greater effects than common variants which may indicate a single-gene disorder.159
Secondly, it is shown that genetic interactions or epistasis account for a significant portion of
missing heritability. Estimation of heritability requires an assumption that there is no genetic
interactions or epistasis in the heritability estimation; thus, existence of epistasis can lead to
over-estimation. This overestimated gap is referred as “phantom heritability”. Thirdly,
epigenetics is another explanatory factor for the missing heritability. The genome is wrapped
around units of histones, which are collectively called chromatin. Chromatin can be modified
through DNA methylation, modifications of histone proteins, or post-transcriptional silencing
mediated by micro-RNAs (miRNAs).160,161 Epigenetic changes are mostly transient, but some
epigenetic changes can be inherited in the short term.162 Epigenetics is dynamically
influenced by the environmental factors such as smoking, stress, and nutrients161,163 and
22

regulates gene expression; thus being likely to contribute to phenotypic variance and explain
some extent of missing heritability.
Epigenetics receives considerable interest among many aspects of genomics as it
involves the regulatory process of translating encoded DNA into proteins. Since epigenetic
phenomenon is reversible, it provides information on the complex dynamics between genes
and environment. DNA methylation has been most studied of the several epigenetic changes
since it is more feasible to measure in an epidemiological setting.164 DNA methylation is an
epigenetic phenomenon that cytosine in the genome is attached with a methyl group onto its
C5 position by DNA methyltransferases (DNMTs). It is well shown in cancer cells that
changes including chromosomal instability, activation of oncogenes, silencing of tumor
suppressor genes and inactivation of DNA repair systems are not caused only by genetic but
also by epigenetic abnormalities such as genome-wide hypomethylation and regional
hypermethylation of CpG islands.165–169 The role of epigenetics has also been studied in the
epidemiologic settings and studies have identified DNA methylation sites associated with
complex diseases such as cardiovascular diseases and stroke.170–173 In the search for DNA
methylation sites involved in disease etiology, the analytic strategy in GWAS is used in
epigenetic studies. A genome-wide investigation of associations between DNA methylation
levels and a complex trait is now coined as an epigenome-wide association study
(EWAS).174–176
As our understanding broadens with data at different molecular levels (i.e. genome,
epigenome, and transcriptome), an integrative analysis of the multi-omics data became
important. Although GWAS approaches identified genetic loci related to WMH burden, the
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precise mechanistic pathway involving molecular events (e.g. DNA methylation, regulation
of gene transcription, translation, post-translation modification, etc.) is not fully addressed.
Integrative genomics has been introduced to combine genomics and emerging functional
omics (i.e. epigenomics, transcriptomics, proteomics, and metabolomics) and derive a
meaningful causal etiological pathway utilizing multi-omics data. An integrative approach
has been successful in many complex traits including immunology,177 oncology,178,179
cardiovascular diseases,180 and some neurological diseases such as narcolepsy,181
Alzheimer’s disease,182 schizophrenia,183 and autism184.
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Public Health Significance
The use of WMH burden as an endpoint may improve CSVD prevention, thusly
facilitating general brain health. Since brain imaging is non-invasive and became accessible,
prevention strategies based on WMH burden is widely applicable to the public. Large-scale
brain imaging studies have shown that WMH is associated with public health burdens of
extreme significance such as incident stroke, vascular cognitive impairment, dementia,
Alzheimer’s disease, and death.42,67 Early detection of relevant brain diseases is more feasible
with utilizing WMH burden as the accessible endpoint rather than diagnosing based on
symptoms. For instance, using MRI-defined infarcts, silent ischemic stroke was found to be
significantly more prevalent than symptomatic events.185 Furthermore, genetic epidemiology
may enable us to earlier identify individuals at higher risk of WMH burden125,150,152 and
prevent brain diseases before the damage accumulates and the changes become irreversible.
Understanding WMH etiology can help to establish an effective and safe CSVD
treatment strategy. Precision medicine, the medical care designed to optimize efficiency or
therapeutic benefit, can be achieved first by subtyping CSVD.186 Although the
pathophysiology is not fully addressed (and various pathologies can lead to WMH),33,65
WMH is likely to have an ischemic or degenerative origin that damages the small vessels of
the brain, leading to chronic cerebral hypoperfusion and myelin rarefaction.66 Due to the
limited understanding of the etiology, current practice of ischemic vascular disease
prevention is barely limited to management of modifiable risk factors such as high blood
pressure and compositions of lipids;187moreover, these treatments have not shown agreed
upon and consistent effectiveness for CSVD. The current treatments of CSVDs are listed as
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thrombolysis, antihypertensive, statins and antiplatelets. Observational studies - the
Rotterdam Scan Study and the Epidemiology of Vascular Ageing study - showed that
effective hypertension treatment was associated with lower risk of CSVD manifested as
WMH,60,61 while it has shown inconsistent effects in randomized controlled trials.188–190
Likewise, lipid-lowering treatments also did not show optimal effectiveness in preventing
WMH;191,192 even worse, safety issues were elevated with these medications. Excessive
blood pressure decrease may even induce cognitive decline in older patients with extensive
WMH as shown in the Secondary Prevention of Small Subcortical Strokes trial.193A recent
large statin study in a stroke-free population showed that statin use can even increase the risk
of ischemic stroke.194 Also, antiplatelet therapy should be avoided due to the excessive risk
of intracerebral hemorrhage in CSVDs.195 Furthermore, treatments for strokes are not
effective in CSVDs. The gold-standard treatment of acute ischemic stroke, tissue
plasminogen activator (t-PA) showed an increased risk of hemorrhage in patients with
WMH.196–199 Failure of traditional treatment options leads us to the conclusion that CSVD is
etiologically dynamic and heterogeneous; therefore, the treatment strategy needs to be
designed based on its etiology and progression. Subtyping WMH etiology and developing a
precision medicine strategy based on epigenetics can be the new way to achieve the second
prevention of CSVD.
The main goal of this dissertation is to identify the role of DNA methylation in WMH
burden in the reasonable hope that it may provide a key to understanding the CSVD etiology
in relation to aging. As life expectancy increases, disabilities in the older population are even
more subject to public health interest. One of the important risk factors in many neurological
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diseases is advancing age, since many neurological changes develop as an individual ages.200
Senescence, the condition or process of deterioration with age, is composed of many
neurological changes53 - including cerebral white matter development.201 WMH is very
prevalent in the aging population; 95% of older adults aged 60-90 have these signs on brain
MRI. Age-related changes in WM are also associated with increased risk of stroke and stroke
mortality.202 DNA methylation is known to be affected by aging,201,203 and it is suggested as a
biomarker for cognitive dysfunction and brain aging.204 Epigenetics is a composite factor of
genetic composition nurtured by environmental exposures such as aging, making it a useful
tool to study age-related genetics in CSVD.
To summarize, results of this dissertation might bring a few positive impacts to public
health. First, the use of WMH burden as the endpoint would facilitate CSVD prevention.
Since WMH burden can be measured using MRI techniques, it is accessible, non-invasive,
quantitative, and a representative marker of CSVD. Therefore, a prevention strategy based on
WMH burden is more widely applicable to the public. Second, the discovery of epigenetic
risk factors in addition to genetic risk factors may improve personalized medicine for CSVD.
CSVD is a complex disease leading to heterogeneous medical conditions; understanding the
genetic architecture behind WMH burden will help us classify individuals by their potential
risk genotypes. Furthermore, we can develop a more effective treatment strategy that is
customized for distinct etiological pathways associated with each genotype. Thirdly, because
epigenetic factors are influenced by both genetic and environmental exposures, the
identification of CSVD-associated epigenetic changes may provide an avenue to intervene on
“modifiable” environmental risk factors to prevent CSVD.
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Specific Aims and Hypotheses
Emerging evidence suggests that a complex disorder can be understood better with
epigenetics. WMH on magnetic resonance imaging (MRI) are a subclinical marker of
vascular brain injury, therefore a clinical biomarker of CSVD.43 Twin and family studies
have shown that WMH is highly heritable with an estimated heritability ranging from 52 to
78%120–122. However, the underlying genetic architecture is still unresolved in that all
identified risk loci explain only a small portion of the heritability (6.4%).125,150,152–154 To fill
this gap, research has drawn attention to new aspects of genomic variation. In this
dissertation, we aim to investigate one aspect called “epigenetics” in association with WMH
burden. Epigenetics receives increasing attention since it is involved in the regulatory process
of gene expression. Also, epigenetics reflects the complex interactions of gene and
environment, and thus, it is expected to provide novel findings and explain an additional
layer of genetic architecture in WMH, which is previously unrealized.
The objective of this dissertation is to identify novel genes associated with WMH
burden, implicate through variation in DNA methylation - the most commonly studied
epigenetic phenomenon. First, we will complete an epigenome-wide association study
(EWAS) of WMH, where DNA methylation sites associated with WMH will be identified.
Second, we will examine the causal direction between the identified DNA methylation and
WMH using genetic instruments in order both to confirm if the epigenetic association is
under genetic control and to establish directionality of the EWAS associations. Lastly, we
will incorporate multi-omics information (i.e. genetic, epigenetic and transcriptional
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information) to aid in interpretation, and characterize functional relationships that will help
infer etiology of WMH.
Below are the study questions in more scientific forms.
Aim 1: To identify DNA methylation (DNAm) loci associated with WMH burden
(Epigenome-wide association study)
Q1. Are there DNAm loci associated with WMH burden?
Q2. Are the associated DNAm loci implicated in biological pathways or etiology of
relevant diseases or traits?
Aim 2: To identify the causal pathway in DNAm-WMH associations using genetic
instruments
Q1. Are there single nucleotide polymorphisms (SNPs) that influence DNA methylation
levels at loci associated with WMH?
Q2. How is the causal direction between DNAm and WMH burden?
Q3. Is gene expression associated with the WMH-associated DNAm?
Aim 3: To investigate the role of DNAm in WMH etiology using multi-dimensional (genetic,
epigenetic and transcriptional) data
Q1. Are there etiological pathways identifiable by the integrated multi-dimensional
WMH burden associations?
Q2. Does any gene play a mediator role in the association between DNA methylation and
WMH burden?
Q3. Do the genetic associations of multi-dimensions (i.e. DNAm, gene expression and
WMH burden) co-localize at the known WMH loci?
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METHODS
Aim 1: Meta-analysis of epigenome-wide association studies (EWASs) of WMH burden
The overall study design is shown in Figure 3. In this aim (Aim 1), we performed a
meta-analysis of EWASs in WMH burden. Accounting for spatial correlation among
DNAms, P values were collated to identify a group of DNAms associated with WMH
burden. Results were interpreted in the context of biological functions using two strategies
based on: 1) the genes mapped to the identified DNAm and 2) the shared epigenetics.

Figure 3 The schema of overall study designs
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Study subjects
We included ten population- or family-based cohort studies - Alzheimer’s Disease
Neuroimaging Initiative (ADNI), Atherosclerosis Risk in Communities (ARIC) study,
Biobanking and BioMolecular Resources Research Infrastructure (BBMRI), Coronary Artery
Risk Development in Young Adults (CARDIA), Cardiovascular Health Study (CHS),
Framingham Heart Study (FHS) Offspring Cohort, Genetic Epidemiology Network of
Arteriopathy (GENOA), Lothian Birth Cohort 1936 (LBC1936), Rotterdam Study III (RS3)
and The Study of Health in Pomerania TREND (SHIP-TREND). Eligible subjects were
middle-age to elderly, free of stroke or dementia, and of African or European ancestry (AA
or EA). Description of participating cohorts and study-specific methods are described in the
Supplemental Material. Descriptive statistics in participating cohorts are presented in the
Table S1.
Protection of human subjects
All participating studies had received institutional review board approval for its
informed consent process, clinical examinations (brain imaging, anthropometric measures,
blood pressure measures, etc.), methylation sample collection and its use, and data access and
distribution. Approvals were granted to individual studies and the study-specific ethic
statements are presented in Appendix A. Supplemental Material. Subjects who provided
written informed consent for study participation, MRI scanning, and use of methylation data
were entered in this study. Study protocol for this dissertation was also reviewed by the
University of Texas Health Science Center Committee for the Protection of Human Subjects,
the approval letter is attached in Appendix A. Supplemental Material.
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White matter hyperintensity (WMH) measurements
WMH on brain MRI in this study indicates the high-intensity areas within cerebral
white matter on T2-weighted images. MRI was taken in the same or the closest subsequent
visit to the visit where DNA methylation sample was taken. Diagnosis of clinical dementia or
stroke for eligibility were made at MRI scans. MRI was scanned and interpreted according to
the standardized method in each study, with demographic or clinical information of subjects
blinded. Participating studies obtained T2-weighted scans using either spin-echo pulse
sequences or fluid-attenuated inversion recovery (FLAIR) sequences from all subjects. MRI
scan of WMH is measured either on a quantitative volume (mL) or qualitative scale (grade).
Since WMH distribution is typically right-skewed, WMH burden is quantified as the logtransformation of a validated WMH value +1. Addition of 1 is to make the WMH burden be
always a positive value for convenience in later analyses. MRI procedures and WMH
quantification in each study are detailed in Appendix A. Supplemental Material.
DNA methylation profiling
DNA methylation levels have been measured in whole blood samples with the
Illumina Infinium Human450 Methylation BeadChip in most participating cohorts. The
GENOA study measured methylation levels at 26,449 probes with the Illumina Infinium
HumanMethylation 27 BeadChip, which are covered by the Illumina Human450 Methylation
BeadChip. ADNI, CARDIA and SHIP-TREND measured methylation with the Illumina
MethylationEPIC BeadChip with a denser coverage of probes (~850K). Each study
independently performed the quality control (QC) for DNA methylation data, complying the
agreed minimum QC guideline; methylation probes with detection P value < 0.01 were
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selected, and then probes having more than 5% of samples with a detection P value of >0.01
were excluded; a sample was removed if the total proportion of probes with a detection P
value <0.01 is less than 95%. DNA methylation values were then standardized using an intraarray normalization method. Beta values from the output were used as a dependent variable
in an individual EWAS. The details of DNA methylation measurements are described in
Supplemental Material.
Cohort-level epigenome-wide association analyses
Individual CpG probes were tested for the association with the WMH burden in two
linear mixed effect regression models i.e. a reduced- and a full-adjustment model according
to the following formulae. In two models, the untransformed methylation beta value for CpG
sites is the dependent variable and WMH burden is the independent variable of interest. In a
reduced-adjustment model, age, sex, study site if applicable, total cranial volume (cm3),
white blood cell proportion (%), technical covariates (i.e. plate, chip-position, row, and
column) and race-specific genetic principal components of ancestry (PCs) were included as
covariates. In a full-adjustment model, smoking status (pack-year), body mass index (BMI,
kg/m2), systolic blood pressure and diastolic blood pressure (SBP and DBP, mmHg) were
added as covariates. White blood cell proportion was estimated with the Houseman
method.205 In both models, technical covariates were treated as random effects and the
remaining covariates were treated as fixed effects. Family structure was also adjusted
according to cohort-specific strategies. In ARIC, EWASs were performed separately by
ancestry. Multi-ethnic studies with a small number of subjects in each ancestry, namely
CARDIA and CHS, performed the EWAS in a pooled population. Additionally, subgroup
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analyses in hypertensive and normotensive groups were conducted to investigate distinct
etiology depending on the existence of the most important risk factor, hypertension.
Hypertension was defined if either systolic or diastolic blood pressure is greater than 140
mmHg or 90 mmHg, respectively, or if a subject was taking any anti-hypertensive
medication at the time of MRI measurement.
Epigenome-wide meta-analysis
The meta-analysis combined EWAS results based on sample-size weighted z-scorebased fixed-effect method in METAL.206 This study primarily aims to identify novel DNA
methylation loci for WMH burden rather than estimate accurate effect sizes of methylation
probes. For this reason, a fixed-effect model-based meta-analysis was chosen to maximize
statistical power in this study.207 EWASs were first combined altogether for a pooled
analysis, then race-specific EWASs were meta-analyzed within each ancestry. Subgroup
meta-analyses were also performed within either hypertensive or normotensive groups, in a
pooled population and in each ancestry. An association was considered as significant if the P
value is below 0.05 either of Q value (Benjamini-Hochberg false discovery rate208) or of
Bonferroni threshold corrected for the number of methylation probes (approximately 1.0E-7).
The less stringent threshold was also set as 1.0E-06 to detect putative associations. Probes on
sex chromosomes and cross-reactive probes reported by Chen et al.209 were removed from
the meta-analyses post hoc.
Differentially methylated region analysis
We performed a differentially methylated region (DMR) analysis to identify a group
of DNA methylation sites that collaboratively influence WMH burden. Two specific
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methods, Comb-P210 and DMRcate211 compute a region-based P value using summary
statistics of individual DNA methylation sites accounting for their spatial correlations.
Comb-P computes correlations at varying distance lags and uses them to compute correlated
P values at each CpG site. DMRcate collapses contiguous significant CpGs that are within a
certain number of nucleotides from each other. Multiple testing error was corrected with a
one-step Sidak method.212 We considered a DMR as valid if it was identified by both CombP and DMRCate.
Biological functions associated with EWAS findings
To explore population structures and inter-relationships in DNAm, Spearman
correlations among 11 EWAS probes (“target probes”) were calculated in 906 EA and 639
AA subjects in the ARIC study. DNAm may regulate functional DNA elements in specific
tissues. The RegulomeDB213 annotates DNA features and regulatory elements such as
transcription factor binding sites, position-weight matrix for transcription factors (TF)
binding (PWM), DNase footprinting, DNase sensitivity, chromatin states, eQTLs,
differentially methylated regions, manually curated regions and validated functional SNPs to
genomic positions of interest. We scored genomic positions of target probes according to the
RegulomeDB’s criteria ranging from 5 (minimal binding evidence) to 1 (likely to affect
binding and linked to expression of a gene target). Probes at the locations with significant
DNA features or regulatory functions (score 1 or 2) were discussed. Furthermore, we
investigated tissue- and cell type-specific regulation by our target probes using the
experimentally derived database, the Functional element Overlap analysis of ReGions from
EWAS (eFORGE ver. 2.0).214,215 Probes were pruned to be at least 1 kb apart then tested for
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overlap with DNase I hypersensitive sites against 1,000 annotation-matched background
probe sets from the 850K array, ENCODE, and Roadmap Epigenomics data. Hypergeometric
P values were generated from counts of overlaps between a TF and all target probes, and
counts of overlaps between a TF and all probes.214,215 Multiple-testing corrected Q values
were calculated using the Benjamini-Yekutieli method.216 TF binding sites were considered
“significantly enriched” where Q value<0.05.
To explore the shared genetics between WMH burden and its comorbidities, genes
mapped to significant DNAm probes and DMRs were searched within publicly available
GWAS results of relevant traits i.e. blood-pressure, dementia, Alzheimer’s disease (AD),
stroke and white matter abnormalities.217 The search terms for each trait are as below.
Relevant trait
Blood Pressure (BP)

Dementia
Stroke
Alzheimer’s disease (AD)

Search term
BP, Systolic BP, Systolic BP change
measurement, Diastolic BP, Diastolic BP
change measurement, hypertension, mean
arterial pressure, pulse pressure measurement
dementia, vascular dementia, lewy-body
dementia measurement and lewy-body dementia
stroke, ischemic stroke, cardioembolic stroke,
small vessel stroke and small artery occlusion in
brain
AD and late-onset AD

In addition, genes mapped to significant probes and DMRs were tested for geneenrichment. We investigated tissue-specific expression patterns of the genes and biological
pathways that the genes are enriched in via GENE2FUNC analysis using the Functional
Mapping and Annotation of Genome-Wide Association Studies (FUMA)218 platform. Gene
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enrichment was evaluated with a hypergeometric test against the gene sets obtained from two
large databases, namely MsigDB219 and WikiPathways220..
Shared epigenetics with cognitive ability (CA)
Cognitive decline is one comorbidity of CSVD, in particular of WMH.31,32,68,221 To
investigate the shared epigenetics between WMH burden and CA, we compared our WMH
burden EWAS with our recent EWAS of seven cognitive ability tests:222 animal naming
(Semantic Verbal Fluency abbreviated as “Animal”), letter fluency (Phonemic Verbal
Fluency abbreviated as “Verbal Fluency”), executive function (Trail Making Test Part B
abbreviated as “Trails”), verbal declarative memory (Wechsler Logical Memory abbreviated
as “Logical Memory”), processing speed (Wechsler Digit Symbol Test/Symbol digit
Modalities Test/Letter Digit Substitution Test abbreviated as “Digit Symbol”), vocabulary
(Boston Naming Test or National Adult Reading Test abbreviated as “Vocabulary”) and
global cognitive function (Mini-Mental State Examination abbreviated as “MMSE”). Also, a
DMR analysis was performed using summary statistics and regions identified in both WMH
burden and CA. In the CA EWAS, the reduced- and full-adjustment models included similar
sets of covariates as in our WMH EWAS; thus, comparisons were made in both models.
Furthermore, we performed a multivariate association test to identify pleiotropic
DNA methylation which influences both WMH burden and CA. DNA methylation probes
associated with both traits were tested against the null hypothesis H0: βWMH = βCA = 0. The
test uses Z-scores for each trait and estimates multivariate test statistics accounting for the
trait correlation. This method is implemented in the ‘metaUSAT’ software.223 The trait
correlation matrix R, 2 × 2 correlation matrix of two traits, is estimated using Z-scores of the
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null SNPs which are not associated with any trait (PCA and PWMH > 1E-5). P values were
Bonferroni-adjusted with the number of DNA methylation probes included in each analysis.

Aim 2: Genetic control and transcriptional impact of WMH epigenetics
To achieve interventions based on WMH burden epigenetics, it is crucial to
understand the causal relationship with genetics and transcriptome. This aim is designed to
investigate 1) genetic control behind the target probes and 2) the probes’ biological functions
(represented by gene expression). A recent study showed that DNAm is heritable and 50% of
CpG sites had evidence of a significant genetic component.224 To examine genetic control
behind the WMH epigenetics, we estimated heritability of WMH-associated probes (“the
target probes”), and performed a methylation quantitative locus (mQTL) analysis. Based on
the mQTL associations, we also tested the causal direction between each target probe and
WMH burden. Secondly, we investigated gene expressions associated with the target probes
to imply biological functions in action.
Heritability of WMH-associated DNAms
For the target probes, the narrow sense heritability (h2meth) was estimated in the FHS
Offspring Cohort subjects (N= 2,377). The narrow sense heritability is defined as the
proportion of the total phenotypic variance of a DNA methylation level explained by the
additive polygenic variance: h2meth = σ2A/ σ2meth, where σ2A denotes the additive polygenic
genetic variance and σ2meth denotes the total methylation variance at the probe. Age, sex,
blood cell counts, principal components and technical covariates were included for
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adjustment in the reduced model. BMI and smoking status were additionally corrected in the
full model.
Identification of methylation quantitative loci (mQTLs)
DNAm levels at the target probes may be influenced by nearby (cis-effect) or distant
(trans-effect) DNA sequence. Methylation QTL analysis was performed for the target probes
in EA (n=984) and AA (n=2,225) individuals from ARIC. Our target CpGs are from WMH
EWAS (Aim 1). Inverse-normal transformed methylation beta values were regressed for age,
sex, and significant population structure factors (up to the first 10 genetic principal
components (PCs) and the first 10 methylation PCs in each ancestry). A genome-wide
association study was then performed on 1000 Genomes Phase I imputed SNPs
(GRCh37/hg19). SNPs with low imputation quality (r2<0.3) and with low minor allele
frequency (MAF<0.05) were excluded from analyses. Association from mQTL analysis was
regarded as genome-wide significant if the P value is below 5E-8. Since cis-effects tend to be
significantly larger than trans-effects225, our primary mQTL for later analyses was limited to
cis-effect mQTLs. The cis-significance was set to 0.05 divided by the number of mQTLs in
the region (CpG±1Mb). We validated significant mQTL associations with mQTL
associations in the FHS mQTL study of 4,170 EA subjects226.
Bi-directional Mendelian Randomization (MR) analysis
To determine if the DNAm level is a causal factor for WMH burden (Forward MR) or a
secondary outcome of WMH burden (Backward MR), we performed a bidirectional twosample MR analysis.227 Two sample MR analysis requires summary statistics including the
effect size (β) and its standard error for exposure and outcome traits from independent
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samples. For DNAm associations, we used our mQTL analysis result, and for WMH
associations, a previous GWAS in UK biobank (UKBB) participants (n=11,226) was used.125
Summary statistics were downloaded from the GWAS catalog website (Accession ID:
GCST007305) accessed on 01/09/2019. Forward MR analysis tested if any of the target
probes influences WMH. Instrumental variables (IVs) for forward MR analysis are cis-effect
mQTLs identified in ARIC EA participants. To meet the fundamental assumption of
independence in MR analysis, IVs were pruned at r2<0.2. For target probes having at least
three IVs, we performed a multi-instrument MR analysis. The backward MR analysis was
used to test if target probes are influenced by WMH. Twenty three sentinel SNPs were
reported by previous GWASs (including the recent meta-analysis under review) and an
exome-wide association study.125,152,154 The SNP rs12120143 was excluded from analysis
due to low frequency in the UKBB GWAS (minor allele frequency (MAF) =0.02). Sentinel
SNPs that did not exist in the UKBB GWAS were replaced with a SNP in high linkage
disequilibrium (LD) in the HapMap European population - rs7894407 replaced with
rs2176448 (r2=0.94), rs17576323 with rs13417165, rs17148926 with rs11957829 and
rss3215395 with rs3891038 (r2=1.0).
For each target probe in both MR directions, causation was tested based on the inversevariance weighted (IVW) effects across all IV-DNAm and IV-WMH estimates in the R
package TwoSampleMR.228 Causation with P value <0.05 was considered significant. To
validate the MR result, built-in tests for pleiotropy, heterogeneity and directionality were also
performed. For existence of pleiotropy (MR egger intercept test P value <0.05), Egger
regression estimates was assessed instead of the IVW method.
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Gene expression associated with WMH epigenetics
Gene expression associated with target probes was investigated to functionally
annotate target probes. First, we tested associations between a DNAm level at each probe and
an expression level at the nearest gene in 1,966 EA subjects from FHS. The DNAm β score
at each target probe was regressed on the expression level adjusting for age, sex, population
and family structure, blood cell counts and technical covariates. Technical covariates and
family structure were modeled as random effects. Secondly, to explore the genome-wide
effects of target probes, transcriptome-wide association studies (TWASs) were performed in
the FHS (n=1,966) and RS (n=728) subjects. In this analysis, we included the expression
level as a dependent variable and the DNAm level as an independent variable with the same
set of covariates. In RS, mRNA expression levels were dependent variables. Estimates from
two studies were combined for each gene using the sample-sized based meta-analysis method
in METAL. We corrected the associations for multiple-testing burden based on the
Bonferroni method. As a secondary threshold, Q value using the FDR method was
calculated, and associations with Q <0.05 were considered significant.

Aim 3: Integrative genetic analyses of WMH burden
In the last aim, we used multi-dimensional data to get holistic evidence to support
WMH burden etiology. Firstly, we performed gene-based pathway analyses on WMH
association studies at genome-wide, epigenome-wide and transcriptome-wide levels and
merged them to identify the common biological function shared by multiple layers. Second,
we tested co-localization of quantitative trait loci (QTLs) associated with multi-dimensional
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traits (i.e. DNAm, gene expression and WMH burden) at the WMH loci to show how the
genetics influences WMH burden involving different molecular levels. Lastly, causation
from DNAm to WMH mediated by gene expression was tested using two-step MR analysis.
Two-step Mendelian randomization
To confirm if the functionally annotated gene expression mediates the relationship
between the target probe and WMH burden, a two-step Mendelian randomization (2SMR)
analysis was performed.229 In the first step, we tested the directional relationship from “the
exposure” target probes to “the mediator” gene expression. The ARIC mQTL associations
for target probes were selected as IVs after pruning to be independent (r2<0.2). For the IVs,
we confirmed associations with gene expression in the FHS whole blood eQTL data
(n=5,257) and in the GTEx ver.7 brain eQTL data. For brain tissues, cortex, frontal cortex,
anterior cingulate cortex, and caudate basal ganglia were selected. The second step was to
establish the causation from the implicated genes to “the outcome” WMH. For the genes
confirmed significant in the first step, eQTLs were taken as IVs and pruned to be
independent (r2<0.2). Then we evaluated associations with WMH in the UKBB GWAS.125
Gene expression validated in both steps with P value < 0.05 was considered as a mediator in
the directional relationship of the target DNAm and WMH burden.
Identification of biological pathways with multi-dimensional data
Based on hierarchical gene-based permutation, we performed marker set enrichment
analyses (MSEAs) on genetic, epigenetic and transcriptional associations of WMH in the R
package Mergeomics.230,231 For the genetic association, we meta-analyzed two WMH
GWASs (CHARGE152 and UK Biobank125) based on the sample-size weighted z-score based
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fixed-effect. Marker were then pruned to be independent (r2<0.5) based on HapMap3 LD
information. For epigenetic and transcriptional associations, we used our EWAS result and a
recent TWAS of WMH, 232 respectively. Markers were primarily mapped to the nearest
genes. For epigenetic markers, cis-acting genes reported in the MesaEpiGenomics study233
were additionally annotated. We tested marker-level enrichment with permutation size
20,000 based on biological pathways from pre-defined public databases: KEGG,
REACTOME, Biocarta and the Gene Ontology (GO) knowledgebase.234,235 Then, enriched
results from individual studies were meta-analyzed using the Meta MSEA function in the
package. Pathways with a permutation-based P value smaller than 0.05 were considered
significant.
Co-localization of multi-dimensional QTLs
The P value based Bayesian co-localization test was conducted using QTLs
associated with multi-dimensions – genotype associated with WMH (QTL), with DNAm
(mQTL) and with gene expression (eQTL) - at the WMH loci using the R package
“coloc”.236 In this analysis, “the WMH locus” indicates the cytoband where a previously
reported sentinel variant is located. We have selected QTLs ± 500 kb of 23 sentinel SNPs
from WMH GWASs including the recent meta-analysis, 11 sentinel DNAm probes from our
EWAS and 13 genes from WMH TWAS.125,152,153,232 For QTL, we used the UKBB GWAS
associations (n=11,226). For mQTL and eQTL, we identified associations at the target loci
from publicly available data. In FHS, mQTLs and eQTLs were identified using whole blood
samples from 4,170 and 5,257 EA subjects.226,237 To explore co-localization in brain tissues,
we also used the GTEx Consortium data (version 7) in four brain tissues – cortex (n=175),
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frontal cortex (n=143), caudate basal ganglia (n=174) and anterior cingulate cortex
(n=129).238 Due to limited number of subjects in the GTEx brain eQTL data, we took the
FHS whole blood as a primary endpoint.239 The GTEx version 7 data was obtained from the
GTEx Portal on 12/19/19. Out of 13 TWAS loci, the ARL17A locus did not have mQTL
associations, therefore it was excluded from the analysis. We evaluated the posterior
probability of full co-localization (PPFC), that multiple traits (WMH, gene expression and
DNAm) share a causal variant at each locus, given the data, using the R moloc package. Colocalization was tested for a unique combination of DNAm probe and a gene with at least 5
QTLs in common. We considered the WMH locus with a PPFC greater than 80% as a
convincingly co-localized locus.
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RESULTS
Aim 1: Meta-analysis of epigenome-wide association studies (EWASs) of WMH
burden
Study sample characteristics
The number of subjects in each participating study ranged from 194 to 1,545. Mean
age ranged from 49.7 to 74.6 years, and proportion of female participants ranged from 40.5
to 72.8%. Mean BMI was similar among studies ranging from 26.4 to 31.0 kg/m2. Smoking
prevalence was the highest in the ADNI study (40.8%), but similarly low among other
studies (from 5.6% to 20.7%). Prevalence of hypertension ranged from 21.6 to 85.4 %. Two
(ARIC and GENOA) studies included subjects of African ancestry (AA) and seven other
cohorts and ARIC included subjects of European ancestry (EA). CARDIA and CHS
included subjects of multiple ancestries, but they contributed only to the trans-ethnic
analyses due to small sample sizes. Median WMH burden (log transformed WMH grade or
volume) ranged from 0.18 to 2.1 (Q1: 0.10 to 1.81; Q3: 0.41 to 2.56). Numbers of markers
and subjects, and demographic descriptions in participating studies are presented in Table
S1.
Epigenome-wide association study (EWAS) model diagnostics
The genomic inflation statistics (λs) were heterogeneous in studies ranging from
0.71 to 1.33. Individual studies corrected the statistics according to their protocols where
significant inflation exists. The lambdas in the trans-ethnic meta-analyses were 1.03 and
1.01 for the reduced and full-adjustment model, respectively (Table 2 and Figure S2). In
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all meta-analyses including race-specific and blood-pressure subgroup analyses, we did not
observe significant inflation evidence, with the lambdas from 0.93 to 1.02.
Table 2 Genomic inflation in meta-analyses
Pooled
Model

All

Hypertensive

Normotensive

EA

AA

All

EA

AA

All

EA

AA

Reduced 1.03

1.00

0.97

1.02

0.99

0.97

1.01

1.01

0.95

Full

0.99

0.99

1.01

0.97

0.98

0.99

0.99

0.93

1.01

Meta-analysis of EWASs
We included 6,019 (EA: 4,452 and AA: 995) and 5,589 (EA: 4,023, AA: 994)
subjects in reduced- and full-adjustment models, respectively. There was no genome-wide
significant methylation probe either at Bonferroni corrected P value threshold (P value
<1.12 X 10-7) or a Benjamini-Hochberg false discovery rate (Q <0.05). However, with
suggestive significance (P value <1.0 X 10-6), three probes, cg24202936 mapped to septin 7
pseudogene (LOC441601; P value=3.78x10-7), cg06809326 mapped to coiled-coil domain
containing 144 A N-terminal pseudogene (CCDC144NL; P value=6.14x10-7) and
cg03116124 mapped to tripartite motif containing 67 gene (TRIM67;P value=9.32x10-7)
were identified in a reduced model. Adjusting for BMI and smoking, we identified
cg17577122 mapped to claudin 5 gene (CLDN5; P value=2.39x10-7) in addition to
cg24202936 (P value=5.20x10-7) and cg03116124 (P value=6.55x10-7). In a race-specific
analysis, a suggestive association at cg04245766 mapped to bone morphogenetic protein 4
gene (BMP4; P value=3.78E-7) was identified from the full-adjustment analysis in EA
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subjects. Top associations from trans-ethnic analyses are shown in Table 3 and Manhattan
plots of epigenome-wide associations are presented in Figure S1.
Table 3 Top associations from a meta-analysis

Probe
Reduced
cg24202936
cg06809326
cg03116124
Full
cg17577122
cg24202936
cg03116124

Gene

Regulatory
feature

LOC441601 Body
CCDC144NL TSS200
TRIM67

Chr Position

Z score P value Q value Weight

11
17
1

50257256 5.08
20799526 4.99
231293208 -4.91

3.78E-7 0.122
6.14E-7 0.122
9.32E-7 0.122

5,663
5,663
5,433

CLDN5
1st Exon; Body 22
LOC441601 Body
11
TRIM67
1

19511967 5.12
50257256 5.02
231293208 -4.97

2.39E-7 0.106
5.20E-7 0.106
6.55E-7 0.106

5,234
5,234
5,004

Stratified meta-analyses by hypertensive status
At the genome-wide significance level, no probe was further identified in the
stratified analysis (Table 4). However, different sets of putative associations were
identified in hypertensive and normotensive groups. In hypertensive subjects, cg25317585
mapped to FGF14 (fibroblast growth factor 14) showed robust significance in both
reduced- and a full-adjustment models (P value= 2.05E-7 and 2.76E-7). In normotensive
subjects, two probes, namely cg06450373 mapped to CDH18 (cadherin 18) (P
value=3.36E-7) and cg18950108 mapped to DPCR1 (diffuse panbronchiolitis critical region
protein 1) (P value=4.22E-7) were identified as suggestive associations from the reduced
model. We also performed race-specific stratified analyses. In hypertensive AA subjects, a
putative association at cg02741985 mapped to coiled-coil domain containing 57 gene
(CCDC57) was identified (P value=3.93E-7) from the reduced-model. More suggestive
associations were found in normotensive EA subjects; cg07675682 at the SLC26A11 (solute
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carrier family 26 member 11) locus (P value =6.30E-7) and cg10051414 at the MAFF
(MAF bZIP transcription factor F) locus (P value =9.37E-7) in the full model. So far, from
the pooled and stratified analyses, we identified 11 probes in the association with WMH
burden. To evaluate whether the effects of those 11 probes differ by hypertensive status, we
showed the association statistics in hypertensive and normotensive groups (Table S2).
Table 4 Top associations from a stratified meta-analysis
Probe

Gene

Hypertensive subgroup
Reduced
cg25317585 FGF14
cg19059707
cg16790423 HSPA1L
Full
cg25317585 FGF14
cg27501293 SFTPD
cg08106319 ZFAND3
Normotensive subgroup
Reduced
cg06450373 CDH18
cg18950108 DPCR1;
MUCL3
cg20443254 ASCL4
Full
cg25313122
cg12176783 TCEA2
cg06450373 CDH18

Regulatory
feature

Chr Position

Body;1st exon
5'UTR

13
12
6

102568886 5.19
64080622 -4.47
31781328 -4.45

2.05E-07 0.098
7.66E-06 0.594
8.61E-06 0.594

3,006
1,377
1,377

Body;1st exon
3'UTR
Body

13
10
6

102568886 5.14
81697500 -4.86
37849427 -4.61

2.76E-07 0.121
1.16E-06 0.187
4.05E-06 0.470

2,858
2,858
2421

Body
Body

5
6

19766434 -5.10
30920171 -5.06

3.36E-07 0.101
4.22E-07 0.101

2,437
2,599

1st Exon

12

108169020 4.37

1.23E-05 0.797

2,599

6121416 4.81
62694000 -4.69
19766434 -4.62

1.53E-06 0.371
2.74E-06 0.384
3.78E-06 0.384

1,926
2,321
2,186

7
TSS200;5'UTR 20
Body
5

Z score P value

Q value Weight

Differentially methylated regions (DMRs)
Fourteen DMRs were identified from the reduced model (Šidák P value <0.05) and
regions near PRMT1, CCDC144NL-AS1, IFITM10, VARS2, SLC12A4, SLC45A4, KITLG
and ZNF311 loci were overlapped with intron or exon of genes (Table 5). Five regions near
PRMT1, ZNF311, SLC45A4, LCP1 and KAT6B were also identified from the full48

adjustment model as well as six additional regions; DMRs at the PRMT1, ZNF311,
HIVEP3, SLC45A4 and TCEA2 loci were within intron or exon of genes. In a DMR
analysis of EA population, 13 and 15 DMRs were identified from the reduced- and the fulladjustment models, respectively (Table S3). Among DMRs identified from the pooled
analysis, the PRMT1, CCDC144NL-AS1 and LCP1 loci in the reduced model and the
PRMT1, ALLC, ZNF311 and LCP1 loci in the full model were replicated in the EA
population. DMRs at the PRMT1, KDM2B, ATP13A4; ATP13A4-AS1, SPIRE2,
SH3PXD2A, LCP1, RHPN1 and LOC101930114 loci were identified regardless of
adjustment models in EA. In the AA population, 15 and 17 DMRs were identified in the
reduced- and the full-adjustment model, respectively, and none of pooled analysis results
were replicated. Nine loci (MIR596, LOC100294145, LAMB2, C3orf56, FAM120B,
WASH3P, EDARADD, EBF3, and TM9SF2) overlapped in both models. None of the DMRs
overlapped between two races.
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Table 5 DMR analysis result

Chr start

end

#probe

Reduced-adjustment Model
19 50191341 50191882 6/8
17 20799407 20799769 10/13

PComb-P

PDMRCate

7.97E-12 3.25E-11
1.63E-11 5.57E-14

Gene

Distance from
Gene

0
PRMT1
CCDC144NL 0
-AS1
0
IFITM10
0
VARS2
0
ZNF311
-776
ZBTB44
30,615
UBE3C
0
SLC45A4
0
KITLG
-858
LCP1
0
SLC12A4
-12,664
KAT6B
KLHDC7B -1,864
8,977
ALPPL2

11 1769288 1769645 8/10
5.92E-07 2.12E-06
6 30882707 30883203 6/13
4.31E-05 1.11E-06
6 28973317 28973497 9/17
1.86E-04 9.61E-06
11 130185383 130185670 3/3
1.23E-03 7.96E-04
7 157092681 157092982 2/2
1.35E-03 2.64E-03
8 142233381 142233705 5/5
1.35E-03 3.50E-03
12 88974242 88974665 8/11
3.88E-03 1.13E-02
13 46757317 46757415 3/3
4.52E-03 5.25E-03
16 67997857 67998164 4/5
8.70E-03 2.03E-02
10 76573395 76573506 2/4
1.31E-02 4.87E-04
22 50984367 50984597 3/3
2.37E-02 2.74E-02
2 233284401 233284661 2/3
2.81E-02 5.05E-03
Full-adjustment Model
19 50191341 50191683 5/8
1.54E-07 4.58E-07
PRMT1
0
1.52E-04 2.59E-05
ZNF311
6 28973317 28973497 9/17
0
2.79E-04 1.56E-05
HIVEP3
1 42384389 42384564 3/10
0
5.72E-04 5.96E-06
SLC45A4
8 142233426 142233642 3/7
0
76573395
76573506
1.87E-03
KAT6B
10
2/5
8.35E-05
-12,664
3704500
3704793
3.07E-03
ALLC
2
6/7
1.55E-02
-992
46757317
46757415
4.39E-03
LCP1
13
3/3
4.97E-03
-858
8.72E-03 6.92E-03
TCEA2
20 62693942 62694005 6/9
0
1.78E-02 4.44E-02
PLOD2
3 145879429 145879710 6/2
-147
4.82E-02 1.42E-02
CHORDC1
11 89956572 89956777 6/8
-40
31148369
31148666
4.57E-02
PSORS1C3
6
14/16
8.50E-03
-2,693
PComb-P: combined p value after Sidak multiple testing adjustment, PDMRCate: minimum
adjusted p-value from the CpGs constituting the significant region
DMR analysis in hypertensive subgroup

In the hypertensive subgroup, five DMRs were identified from the reduced model
and seven from the full model, and OSR2 and ATP13A4; ATP13A4-AS1 loci were identified
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in both (Table S4). In the EA specific analysis, nine and twelve associations were identified
from the reduced and full models (Table S5). Irrespective of adjustment models, DMRs at
the PON3, RGMA and ATP13A4; ATP13A4-AS1 loci were identified. Among DMRs
identified in the pooled hypertensive population, DMRs at the ATP13A4/ATP13A4-AS1 and
MIR4291 were replicated in the EA analyses. In the AA specific analysis, ten and eleven
DMRs were identified from the reduced and full models (Table S5). Among them, DMRs
at LDLRAD4, RABL6, SLC36A3, FAM222A, RASIP1 and MUC4 were found regardless of
models. One of ten DMRs at the CCDC57 locus involved the cg02741985 probe, which
was a suggestive signal from our meta-analysis in the AA hypertensive subgroup. The
LDLRAD4 locus was one of the loci found in the hypertensive pooled analysis. None of the
DMRs overlapped between two races.
DMR analysis in normotensive subgroup

In the pooled population, 13 and 16 DMRs were identified to be associated with
WMH in the reduced- and the full-adjustment model, respectively (Table S6). Five regions
at the CHORDC1, FBXO47, LINC01983, NFAM1 and TCEA2 loci were found in both
models. Five (at the DRC7, FBXO47, KDM2B, NRBP1; KRTCAP3 and TCEA2 loci) and
six (at the DRC7, FBXO47, LINC00702, NFAM1, TCEA2 and THBS1 loci) were replicated
in the respective models in the EA population. In the EA population, 10 and 12 DMRs were
found to be associated with WMH in two models, and five loci of CD248, DRC7, FBXO47,
KHDC3L and TCEA2 were identified regardless of adjustment models (Table S7). Among
the ten DMRs identified in the reduced model, a region at the CCDC144NL locus involved
the cg06809326 probe which was identified in a meta-analysis of the pooled population. In
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the AA population, a different set of DMRs were identified from both models (Table S7).
DMRs at the DNHD1, F10, LAMB2, LOC151174; LOC643387, PAPD7, and VTRNA2-1
loci showed significance irrespective of models. Only one DMR at the LINC01983 locus
from the pooled analysis was replicated in AA.
Functional genomics of target probes
Significant correlations (r>0.3 with p-value<0.05) among cg03116124, cg06450373,
and cg18951018 were observed in both ancestries. Correlations among 11 EWAS probes
(“target probes”) are presented in Figure S3. Genomic positions of 11 EWAS probes
(“target probes”) were searched in the RegulomeDB. We identified that cg17577122,
cg06809326 and cg10051414 are situated in the genomic position likely to affect protein
bindings. In umbilical vein endothelial cells, RNA Polymerase II Subunit A (POLR2A) was
found to be likely bound to the genomic positions of three probes: cg17577122
(chr22:19511967), cg04245766 (chr14:54421051) and cg10051414 (chr22:38598733).
Interestingly, the positions of cg06809326 (chr17:20799526), cg10051414
(chr22:38598733) and cg25317585 (chr13:102568886) were likely to be bound by the
CCCTC-binding transcriptional regulator protein (CTCF) in the brain microvascular
endothelial cells. Proteins binding to target probes in brain tissues and endothelial cells are
shown in Table S8. The eFORGE tested enrichment of transcription factor (TF) binding
sites for 11 target probes based on common TF databases. DNase I hypersensitivity signals
surrounding target probes are shown in Figure S4. We observed significant overlap with
transcription factor binding sites at 5 target CpGs: cg06450373, cg06809326, cg17577122,
cg24202936, and cg25317585 (Table S9).
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Genetic sharing with blood pressure, stroke, dementia and white matter-related traits
From the GWAS catalog, we identified 1,990 BP genes, 59 white matter trait genes,
317 stroke genes, 67 dementia genes and 913 Alzheimer’s disease genes as of 03/06/2019.
Among 11 genes identified with suggestive evidence from our EWAS, CDH18 was
reported in the association with blood-pressure. From 159 genes annotated to significant
DMRs, we found 15 BP-related genes (CETP, NRBP1, PRDM8, TM9SF2, WBP1L,
UBE3C, TNXB, TCEA2, MCF2L, HIVEP3, PLEC, IRF6, GRAMD1B, RPTOR and
LOC102546294), four stroke-related genes (SLC44A2, CETP, NRBP1 and SH3PXD2A) and
one Alzheimer’s disease gene (IRF6).
Genetic function enrichment in FUMA
We input four genes, CLDN5, CCDC144NL, TRIM67 and BMP4, mapped to WMHassociated methylation probes for the GENE2FUNC program implemented in the FUMA
platform. Three genes, BMP4, CLDN5 and TRIM67, were enriched in the regulation of cell
development, especially the first two genes were enriched in the regulation of endothelial
cell differentiation (Table 6). We also performed a DMR analysis in CA using summary
statistics. Based on genes mapped to all DMRs we identified, we found enriched pathways
related to lipoprotein metabolism and transport. Genes mapped to the probes found in the
pooled and race-specific analyses, were significantly enriched with previous GWAS
findings in HIV-1 control and squamous cell lung carcinoma.
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Table 6 FUMA gene-enrichment results

Gene Set
Single
Positive regulation of
endothelial cell differentiation
Regulation of endothelial cell
differentiation
Positive regulation of cell
development
Positive regulation of
epithelial cell differentiation
Outflow tract morphogenesis
DMR – all genes
High density lipoprotein
particle remodeling
Regulation of plasma
lipoprotein particle levels

Size P value PFDR

genes

24 2.68E-6

0.020 BMP4, CLDN5

42 8.35E-6

0.031 BMP4, CLDN5

538 1.41E-5

0.035 TRIM67, BMP4, CLDN5

65 2.02E-5
77 2.84E-5

0.037 BMP4, CLDN5
0.042 BMP4, CLDN5

15 1.80E-5

0.040 APOC3, SCARB1, CETP

45 1.85E-5

0.040 APOC3, SCARB1, CETP
APOC3, SCARB1, LMF1,
0.040 RP11-161M6.2, CETP

Reverse cholesterol transport
17 2.68E-5
DMR – excluding stratified analyses
HIV-1 control
22 4.35E-6
Squamous cell lung carcinoma 132 4.15E-5

0.008 RNF39, VARS2, PSORS1C3
0.038 HIVEP3, PLOD2, ZNF311,
VARS2

Shared epigenetics with cognitive ability
In seven CA tests, 61 methylation probes were reported with putative associations
(P value <10E-5).222 For 51 probes also included in our WMH EWAS, we confirmed the
epigenetic associations in both CA and WMH EWASs at the Bonferroni significance
threshold of 9.8E-4 (0.05/51). We identified three methylation probes significantly shared
with both CA and WMH burden. In the reduced model, cg17417856 mapped to PRMT1
(PWMH=2.40E-06 and PCA=1.82E-4 in Digital Symbol). In the full model, cg18676110
mapped to RAF1 (PWMH=1.12E-06 and PCA=3.67E-4 in Vocabulary). In both models,
cg05704155 mapped to PGD was identified for the MMSE test (PWMH=1.07E-06 and
PCA=8.65E-4 in the reduced model; PWMH=1.07E-06 and PCA=4.11E-4 in the full model). A
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multivariate joint analysis of two EWASs identified significant probes shared by both
WMH burden and CA: 115 probes for Digit Symbol, 10 for MMSE, 12 for Verbal Fluency
and 1 for Vocabulary. Weak associations in one trait were strengthened by the other trait
based on the trait correlation (Table S10). In Table 7, we showed the significant shared
epigenetic association which were significant for individual traits (PWMH and PCA < 1E-3).
Two methylation probes, cg17417856 (PRMT1) and cg05704155 (PGD), that we identified
in the comparisons were confirmed with the same CA domains. Especially, PGD was
consistently identified regardless of statistical models. PGD encodes a 6-phosphogluconate
dehydrogenase enzyme which has previously been reported to be involved in
hyperglycemia-induced oxidative stress in the neonatal diabetic brain.240
Table 7 Multivariate joint analysis of CA and WMH epigenetic associations
Test
CpG
Gene
ZWMH, PWMH ZCA, PCA
Pjoint
Qjoint
Reduced model
Verbal cg12582616 JARID2
-3.54, 3.96E-04 -4.15, 3.38E-05 4.66E-08 9.83E-03
Fluency cg12025310 TMPRSS6
3.43, 6.00E-04 -4.05, 5.16E-05 1.36E-06 4.77E-02
MMSE cg05951221
-3.61, 3.12E-04 4.84, 1.29E-06 1.45E-08 6.10E-03
cg25923609
3.59, 3.32E-04 -4.46, 8.17E-06 8.71E-08 7.35E-03
cg05704155 PGD
4.55, 5.26E-06 -3.33, 8.65E-04 1.39E-07 9.75E-03
cg01127300
-3.97, 7.21E-05 3.74, 1.86E-04 3.93E-07 2.37E-02
cg19859270 GPR15
-3.87, 1.09E-04 3.60, 3.18E-04 9.48E-07 4.44E-02
Digit
cg05951221
-3.61, 3.12E-04 5.75, 9,12E-09 4.55E-10 4.79E-05
Symbol cg17417856 PRMT1; C19orf76 -4.72 ,2.40E-06 3.74 ,1.82E-04 3.77E-08 1.22E-03
cg19859270 GPR15
-3.87 ,1.09E-04 4.26 ,2.00E-05 1.54E-07 3.41E-03
cg04885881
-3.34 ,8.48E-04 4.25 ,2.17E-05 9.43E-07 9.02E-03
cg01127300
-3.97 ,7.21E-05 3.42 ,6.33E-04 2.09E-06 1.40E-02
cg04994217 C9orf170
-3.32 ,9.12E-04 3.64 ,2.69E-04 9.07E-06 3.38E-02
Full model
MMSE cg05704155 PGD
4.88, 1.07E-06 -3.53, 4.11E-04 1.42E-08 6.00E-03
Test: A cognitive ability test domain, PWMH: P value estimated in the reduced-adjusted transethnic WMH burden EWAS, PCA: P value estimated in the reduced-adjusted trans-ethnic
cognitive abilities EWAS, Pjoint and Qjoint : P value and local FDR-adjusted P value estimated in
the joint analysis
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In a reduced-adjusted DMR analysis for CA, we identified 130 DMRs associated
with 7 CA tests: 9 for Animal naming, 35 for Digit Symbol, 14 for Logical Memory, 15 for
MMSE, 15 for Trails, 26 for Verbal Fluency, and 16 for Vocabulary. In a fully-adjusted
DMR analysis for CA, we identified 98 DMRs associated with 7 CA tests: 10 for Animal
naming, 21 for Digit Symbol, 12 for Logical Memory, 15 for MMSE, 15 for Trails, 15 for
Verbal Fluency, and 10 for Vocabulary. We identified a DMR within ALPP2 (2q37.1)
shared by Digit Symbol test and WMH burden with reduced-adjustment (Sidak
PWMH=0.028 and Sidak PCA=9.10E-11). In EA subjects, a DMR near SH3PXD2A was
identified in both adjustment models (Sidak PWMH=0.028 and Sidak PCA=3.82E-4 in the
reduced model; Sidak PWMH=0.028 and Sidak PCA=7.55E-4 in the full model).
Aim 2: Genetic control and transcriptional impact of WMH epigenetics
Heritability of the target probes
For 11 methylation probes which we identified from trans-ethnic, race-specific and
stratified meta-analyses, heritability was estimated in two linear models. We found that a
big proportion (48.2%) of DNAm variance at cg06450373 was explained by the additive
genetic variance (Table 8). Moderate heritability was estimated for cg02741985 (36.3%)
and cg06809326 (26.5%). Small, but significant heritability estimates were calculated for
cg24202936 (15.5%), cg25317585 (12.0%) and cg17577122 (14.3%). For cg03116124,
cg07675682, cg10051414 and cg18950108, we could not identify meaningful heritability
estimates. Estimates additionally adjusted for BMI and smoking were not significantly
different from the reduced model estimates.
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Table 8 Heritability estimates of WMH-associated methylation probes

Reduced model
Full model
2
Probe ID
S.E.
P value
h
S.E.
P value
cg02741985
0.363
0.071 2.95E-08*
0.367
0.071 2.06E-08*
cg03116124
0.009
0.069
4.46E-01
0.006
0.069
4.67E-01
cg06450373
0.482
0.075 1.92E-11*
0.480
0.075 2.35E-11*
cg06809326
0.265
0.075 1.03E-04*
0.266
0.075 9.51E-05*
cg07675682
0.000
5.00E-01
0.000
5.00E-01
cg10051414
0.009
0.073
4.51E-01
0.007
0.073
4.64E-01
cg18950108
0.000
5.00E-01
0.000
5.00E-01
cg24202936
0.155
0.073 1.34E-02*
0.158
0.073 1.17E-02*
cg25317585
0.120
0.072 4.31E-02*
0.116
0.072
5.07E-02
cg17577122
0.143
0.078 2.80E-02*
0.150
0.078 2.27E-02*
h2: the narrow-sense heritability in an additive genetic model. S.E.: standard error
h2

Methylation QTLs for target probes
To show genome-wide patterns of genetic control, we performed GWASs of 11
target probes in ARIC study (984 EA and 2,225 AA subjects). Cg04245766 was only
included in the analysis of AA subjects since the probe did not pass the QC criteria in the
EA population. The genome-wide pattern of genetic control in target probes are shown in
Manhattan plots (Figure S5). As shown in the plots, we observed the genetic influence in
cis on cg02741985, cg06450373, cg06809326, cg07675682 and cg24202936 regardless of
ancestry. Cg02741985 showed more amplified cis-genetic influence in AA subjects and
cg03116124 appeared to have cis-influence only in AA subjects. Cis-mQTLs were defined
in EA subjects for a Mendelian randomization analysis. In EA, numbers of markers within
cis-regions of target probes were 5,902 for cg02741985, 5,207 for cg03116124, 5,118 for
cg06450373, 3,070 for cg06809326, 6,538 for cg07675682, 4,346 for cg10051414, 4,475
for cg17577122, 15,062 for cg18950108, 5,903 for cg24202936 and 5,317 for cg2531758.
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The mQTL associations significant at Bonferroni threshold (0.05/number of markers in cisregion) were identified for four target probes: 57 mQTLs for cg02741985, 74 for
cg06450373, 162 for cg06809326 and 2,981 for cg24202936. We validated the same four
probes with mQTLs in the FHS mQTL study,226 the same four target probes were also
identified with significant mQTLs.
Causal relationship from target probes to WMH burden
The forward MR analysis was performed for four target probes having mQTLs. We found a
significant causal relationship from cg06809326 to WMH burden using three independent genetic
proxies. The odds ratio (OR) was estimated as 1.78, indicating that a 1% increase in methylation
level at cg06809326 is associated with a 78% increment in WMH burden unit. Three IVs for
cg06809326 were rs116963987, rs73298018 and rs7501645. In the backward MR analysis, we
confirmed that WMH burden does not significantly influence the methylation level at cg06809326.
In addition, a more causal relationship that a standard deviation increase in WMH burden leads to
14 % higher methylation level was observed at cg03116124 (P value=0.03). Pleiotropy tests for MR
associations in both directions showed non-significant P values except for two backward MR
analyses in cg03116124 and cg06450373. For the analyses with pleiotropy evidence, we took MR
Egger-based estimates as the primary result instead of inverse variance-weighted estimates. Results
from all MR analyses are presented in Table 9.
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Table 9 Bi-directional MR analysis result
Probe ID
No.IV Beta (S.E.)
OR[95%CI]
PMR
Ppleiotropy
Forward
cg02741985 2
-1.56E-2(0.428)
0.98[0.43,2.28]
0.97
NA
cg06450373 2
3.89E-2(0.280)
1.04[0.60,1.81]
0.89
NA
cg06809326 3
0.5751(0.178)
1.78[1.25,2.52]
1.21E-3*
-0.80
cg24202936 3
0.193(0.214)
1.21[0.80,1.85]
0.37
0.56
Backward
cg02741985 18
3.50E-3(1.65E-2)
1.00[0.97,1.04]
0.83
-0.57
cg03116124 18
0.134(5.65E-2)
1.14[1.02,1.28]
3.07E-2*
-1.80E-2*
cg06450373 18
0.100(5.45E-2)
1.11[0.99,1.23]
0.08
-4.88E-2*
cg06809326 18
-2.39E-3(2.36E-2) 1.00[0.95,1.04]
0.92
-0.53
cg07675682 18
1.60E-3(1.77E-2)
1.00[0.97,1.04]
0.93
-0.19
cg10051414 18
2.59E-5(4.38E-3)
1.00[0.99,1.01]
1.00
-0.72
cg17577122 18
3.53E-3(2.81E-3)
1.00[1.00,1.01]
0.21
-0.43
cg18950108 18
-4.84E-3(1.61E-2) 1.00[0.96,1.03]
0.76
-0.12
cg24202936 18
-2.13E-2(1.92E-2) 0.98[0.94,1.02]
0.27
-0.25
cg25317585 18
5.81E-4(1.25E-2)
1.00[0.98,1.03]
0.96
0.40
No.IV: Number of instrumental variables included. OR: Odds ratio, PMR and Beta (S.E.): P
value, effect size and its standard error for the causal direction, primarily based on the
inverse variance-weighted method, or in existence of pleiotropy (Ppleiotropy <0.05) based on
MR Egger method. Ppleiotropy: P value estimated from MR Egger intercept pleiotropy test
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Gene expression associated with target probes
Excluding missing cg04245766, the association between each of 10 target probes
and its nearest gene was tested. As shown in Table 10, we found significant associations
for relationships between cg03116124 and TRIM67 (P value=0.02) and between
cg06809326 with CCDC144NL (P value=0.03).
Table 10 Associations between target probes and the nearest genes
CpG
cg03116124
cg06809326
cg06450373
cg25317585
cg17577122
cg24202936
cg07675682

Gene
TRIM67
CCDC144NL
CDH18
FGF14
CLDN5
LOC441601
SLC26A11

Chr
1
17
5
13
22
11
17

cg02741985 CCDC57

17

cg18950108 DPCR1
cg10051414 MAFF

6
22

Start
231244657
20739760
19473080
102344869
19510550
50205720
78194232
80081038
80059350
30902400
38576894

Stop
231357304
20844644
19988319
103054799
19515068
50280104
78227297
80191192
80111346
30921998
38612509

Coefficient
2.0E-2
-9.7E-3
-9.1E-3
-1.6E-3
-6.1E-4
-3.1E-3
1.7E-3
-1.1E-3
8.8E-4
-8.0E-4
-1.1E-4

SE
8.9.E-3
4.5.E-3
9.6.E-3
1.9.E-3
1.1.E-3
6.6.E-3
4.5.E-3
3.1.E-3
3.2.E-3
2.3.E-3
9.3.E-4

P-value
2.4.E-2*
3.3.E-2*
0.35
0.40
0.59
0.65
0.71
0.72
0.78
0.72
0.91

Next, we performed TWASs of ten target probes to examine both cis- and transeffects. In FHS (n=1,966), 17,873 transcripts were included, and a study-level Bonferroni
threshold was set to 2.80E-6. No gene-DNAm probe association was identified at the
transcriptome-wide significance level in FHS. In RS (n=728), TWASs were performed with
21,238 mRNA transcripts, 1 gene (CHKB; choline kinase-like protein) for cg06809326, 7
genes for cg02741985, 38 genes for cg03116124, 61 genes for cg06450373, 296 genes for
cg18950108 and 4 genes for cg253147585 were identified as significant at the Bonferroni
threshold of 2.35E-6. Among significant associations, three WMH-associated genes232 FCRL6, TGFBR3 and IL4R – were found to be associated with our target probes
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(cg03116124, cg06450373 and cg08950108) (Table 11). However, a meta-analysis did not
find any significant association due to lack of significance in FHS.
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Table 11 TWAS results in target probes for WMH-associated genes
CpG Site
cg03116124
cg06450373
cg18950108
cg18950108
cg18950108

Gene
TGFBR3
TGFBR3
TGFBR3
FCRL6
IL4R

FHS (n=1,966)
CHR T
Q value T
1
0.56
0.858
1
-0.43
0.976
1
-0.22
0.997
1
-1.85
0.250
16
0.97
0.997

RS (n=728)
Q value N
-5.00
0.002
-5.89 2.16E-05
-11.40 2.58E-06
-7.38 2.58E-06
4.72
0.002

Meta-analysis
WMH TWAS
Z-score P value HetP T
Q value
2,683
0
1.00
0.31
4.27
0.036
2,686
-0.99
0.32
0.41
4.27
0.036
2,691
0.24
0.81
0.41
4.27
0.036
5.23
0.003
2,691
1.53
0.13
0.52
-5.50 2.61E-04

CHR: chromosome. HetP: P-value for heterogeneity test (H1:ZFHS≠ZRS). FDR Q: false-discovery rate adjusted P-value
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Aim 3: Integrative genetic analyses of WMH burden
Gene expression as a mediator in DNAm-WMH causal relationship
Previously we confirmed that four of our target probes (i.e. cg02741985,
cg06450373, cg06809326 and cg24202936) are under in cis genetic control. Also, we found
that cg06809326 was associated with the nearest gene CCDC144NL. In the two-step
Mendelian randomization analysis, we confirmed that CCDC144NL mediates the
relationship between cg06809326 and WMH burden in caudate basal ganglia, but not in the
other brain tissues or whole blood (Table 12). The selected instrumental variable for step 1,
rs7501645 was in high linkage disequilibrium (LD) with the instrumental variable for step
2, rs11653586 (r2=0.98).
Table 12 Two-step MR analysis result
Step 1 (CpG -> Gene)
Beta±S.E.
IV
PIV
11.52±2.43 rs7501645 2.13E-6

Step 2 (Gene->WMH burden)
Tissue
Beta±S.E.
IV
PIV
Caudate
0.05±0.03 rs11653586 4.80E-2
basal ganglia
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Meta-analysis of enriched pathways from multi-dimensional associations
Based on independent SNPs, we observed three significantly enriched gene
ontologies: extracellular matrix constituent conferring elasticity, microfibril and camera-type
eye development (Table 13). From epigenetic markers, copulation, insulin secretion involved
in cellular response to glucose stimulus, positive regulation of heat generation, pre-synapse
assembly and negative regulation of dopamine secretion were significantly enriched. Lastly,
from transcriptional markers, we found two ontologies including adaptive immune response
and co-receptor activity enriched. Pathway-based meta-analysis of the three MSEA outputs
identified that multi-omics associations in WMH burden were enriched in extracellular
matrix structural constituent, camera-type eye development, alphaV-beta3 integrin-IGF-1IGF1R complex, retinol dehydrogenase activity and phosphatidylinositol-4-phosphate
binding.
Table 13 Meta-analysis of marker set enrichment

MODULE
GWAS
GO:0030023
GO:0001527
GO:0043010
GO:0035583
GO:0006066
GO:0008090
GO:0060346
GO:0004022
GO:0035276
rctm0368
EWAS
GO:0007620

P

FDR
2.38E-05
3.03E-05
4.70E-05
4.98E-05
1.53E-04
2.04E-04
2.31E-04
2.98E-04
3.14E-04
3.28E-04
7.60E-06

DESCR

4.35E-02 Extracellular matrix constituent conferring elasticity
4.58E-02 Microfibril
4.89E-02 Camera-type eye development
5.01E-02 Sequestering of TGF-beta in extracellular matrix
9.15E-02 Alcohol metabolic process
0.103 Retrograde axonal transport
0.108 Bone trabecula formation
0.118 Alcohol dehydrogenase (NAD) activity
0.120 Ethanol binding
0.120 Elastic fiber formation
0.026 Copulation
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MODULE

P

FDR

GO:0035773
GO:0031652
GO:0099054
GO:0033602
GO:0033685
GO:0034260
rctm0313
GO:0007269
GO:0009450
TWAS
GO:0002250
GO:0015026
M4085
GO:0006955
M6856
GO:0009897

7.86E-06
1.34E-05
1.76E-05
3.48E-05
3.89E-05
4.33E-05
4.64E-05
4.66E-05
4.71E-05

GO:0030020

1.02E-04

rctm0115
GO:0000145
GO:0070371
Combined
GO:0005201
GO:0043010
GO:0035867
GO:0004745
GO:0070273
GO:0006955
rctm1075
M6856
GO:0019841
GO:0032024

1.13E-04
1.28E-04
1.48E-04

rctm0115

4.27E-06
1.10E-05
3.00E-05
3.07E-05
7.03E-05
9.84E-05

4.23E-06
8.26E-06
8.47E-06
9.52E-06
1.99E-05
4.03E-05
6.36E-05
7.41E-05
8.74E-05
1.44E-04
1.77E-04

DESCR
Insulin secretion involved in cellular response to
0.026 glucose stimulus
0.036 Positive regulation of heat generation
0.039 Presynapse assembly
0.049 Negative regulation of dopamine secretion
0.051 Negative regulation of luteinizing hormone secretion
0.052 Negative regulation of GTPase activity
0.053 Degradation of GABA
0.053 Neurotransmitter secretion
0.053 Gamma-aminobutyric acid catabolic process
0.022 Adaptive immune response
0.037 Coreceptor activity
0.068 Primary immunodeficiency
0.069 Immune response
0.134 Hematopoietic cell lineage
0.148 External side of plasma membrane
Extracellular matrix structural constituent conferring
0.150 tensile strength
Antigen activates B cell receptor leading to
0.152 generation of second messengers
0.155 Exocyst
0.157 ERK1 and ERK2 cascade
0.019 Extracellular matrix structural constituent
0.021 Camera-type eye development
0.022 AlphaV-beta3 integrin-IGF-1-IGF1R complex
0.023 Retinol dehydrogenase activity
0.039 Phosphatidylinositol-4-phosphate binding
0.069 Immune response
0.096 SHC-related events triggered by IGF1R
0.101 Hematopoietic cell lineage
0.108 Retinol binding
0.163 Positive regulation of insulin secretion
Antigen activates B cell receptor leading to
0.169
generation of second messengers
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Genetic loci associated with DNAm, gene expression and WMH burden
At the WMH loci identified previously - 23 GWAS, 11 EWAS and 13 TWAS lociwe tested co-localization for each combination of DNAm probe and gene expression. The
numbers of combinations were 182,499 in whole blood and 472 (77 in the same cytoband)
combinations were identified as significant (PPFC>0.8). Significant co-localization
combinations were located for 4 GWAS loci including rs3215395 at 7q22.1, rs6587216 at
17p11.2, rs8071429 at 17q21.31 and rs7214628 at 17q25.1. (Table 14) At 7q22.1, we
observed multi-level QTLs co-localized at MAP11 (microtubule associated protein 11),
MOSPD3 (motile sperm domain containing 3) and SLC12A9 (potassium-chloride transporter
9). At 17p11.2, 10 probes were co-localized with CCDC144A (coiled-coil domain containing
144A), 15 probes with FAM106A (family with sequence similarity 106 member A) and 6
probes with GRAPL (growth factor receptor-bound protein 2-related adaptor protein). At
17q21.3, KANSL1 (lysine acetyltransferase 8 regulatory nonspecific lethal complex subunit
1) and PLEKHM1 (pleckstrin homology domain containing protein family member 1) were
identified as co-localized. At 17q25.1, we identified EXOC7 (exocyst complex component
7); ZACN (zinc activated ion channel), GALK1 (galactokinase 1); ITGB4 (integrin subunit
beta 4), H3F3B;H3F3A;H3F3C (H3 histone family member 3B;3A;3C), TEN1(telomere
length regulation protein TEN1 homolog);TEN1-CDK3 (cell division protein kinase
3);ACOX1 (acyl-CoA oxidase 1), UNC13D (unc-13 homolog D) and WBP2 (WW domain
binding protein 2) co-localized with WMH QTLs and mQTLs. Three genes with full colocalization – UNC13D, ACOX1 and WBP2- were previously reported;150,152 however, other
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reported genes including TRIM47, TRIM67, and FBF1 did not show the full co-localization.
One of the EWAS loci, cg06809326 is also located at 17p11.2, and one of the TWAS loci,
ARL17A is also located at 17q21.31. Significant co-localization at cg06809326 was not
identified; however, 10 methylation probes were co-localized with CCDC144A, which is a
paralog of the gene mapped to the probe, CCDC144NL. We did not conduct the analysis at
ARL17A, since the cis region for this gene does not have any mQTLs.
Table 14 MOLOC result in whole blood
Gene
7q22.1
MAP11
MOSPD3
SLC12A9
17p11.2
CCDC144A; CCDC144B; CCDC144C

FAM106A;FAM106CP;FAM106B

CpG

nsnp PPFC PPFC_SNP

cg21406967
cg04742719
cg17194182

14
23
21

0.87
0.85
0.89

7:100285888
7:100359454
7:100300898

cg01534423
cg15971010
cg21495715
cg13305951
cg16674433
cg04279801
cg13832201
cg27589594
cg20538986
cg11465639
cg15971010
cg21158317
cg13305951
cg21495715
cg01627492
cg16674433
cg04279801
cg01534423
cg22671072
cg27589594
cg13832201
cg14817867

14
6
16
14
16
17
23
25
25
29
9
17
17
17
10
17
17
17
17
17
17
17

0.89
0.89
0.89
0.87
0.86
0.85
0.85
0.85
0.84
0.84
0.92
0.91
0.91
0.91
0.91
0.9
0.9
0.89
0.89
0.89
0.88
0.87

17:19165179
17:19253613
17:19165179
17:19172196
17:19172196
17:19204863
17:19196440
17:19165179
17:19194812
17:19165179
17:19253613
17:19204863
17:19224397
17:19224397
17:19165179
17:19247075
17:19239432
17:19213335
17:19194812
17:19165179
17:19196440
17:19165179
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Gene

GRAPL;GRAP
GRAPL;LOC79999;LOC100132472
17q21.31
KANSL1
PLEKHM1;PLEKHM1P
17q25.1
EXOC7;ZACN

GALK1;ITGB4

H3F3B;H3F3A;H3F3C
TEN1;TEN1-CDK3;ACOX1
UNC13D

WBP2

CpG
cg18633784
cg01735398
cg12137220
cg13305951
cg01534423
cg16674433
cg21495715
cg13305951
cg01534423

nsnp
17
17
17
19
20
23
19
18
20

PPFC
0.85
0.84
0.81
0.88
0.88
0.83
0.89
0.89
0.84

PPFC_SNP
17:19165179
17:19165179
17:19217261
17:19196440
17:19196440
17:19196440
17:19224397
17:19224397
17:19224397

cg17123029
cg14750215
cg16826777

21
46
11

0.89
0.85
0.80

17:43153006
17:43161353
17:43376447

cg16649771
cg02497559
cg04225089
cg19804488
cg05611719
cg10935138
cg08125733
cg10138630
cg09795027
cg03700492
cg18082885
cg00759043
cg18082885
cg26780705
cg00759043
cg23806715
cg00943312
cg19026231
cg10295360
cg20772300
cg24166112
cg26780705
cg11015353
cg15177359
cg00943312
cg23806715

8
10
8
16
18
19
19
9
11
9
36
12
6
14
12
19
13
23
23
38
38
14
6
26
13
19

0.90
0.90
0.90
0.87
0.86
0.83
0.83
0.94
0.89
0.89
0.87
0.86
0.94
0.97
0.97
0.94
0.94
0.92
0.90
0.84
0.82
0.98
0.97
0.97
0.96
0.94

17:73926121
17:73904155
17:73896299
17:73896299
17:73904155
17:73896299
17:73896299
17:73881056
17:73881056
17:73850819
17:73881056
17:73904155
17:73899533
17:73876473
17:73931787
17:73764500
17:73874684
17:73764500
17:73874684
17:73876473
17:73874684
17:73876473
17:73884948
17:73839366
17:73874684
17:73796617
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Gene

CpG
cg10295360
cg24563967
cg00759043
cg19026231
cg06407111
cg04442638
cg24166112
cg14955151
cg20772300
cg09253696
cg03700492
cg04225089
cg10644544
cg18082885
nsnp: number of SNPs included for co-localization test.
most evidence of colocalization

nsnp PPFC
23
0.92
55
0.92
12
0.91
23
0.91
91
0.87
65
0.87
42
0.87
75
0.86
42
0.86
77
0.86
73
0.85
91
0.83
65
0.82
90
0.81
PPABC_SNP:

PPFC_SNP
17:73874684
17:73874684
17:73931787
17:73775825
17:73874684
17:73874684
17:73874684
17:73874684
17:73874684
17:73874684
17:73874684
17:73874684
17:73874684
17:73874770
the SNP with the

Out of 234,336 gene-probe combinations in cortex, significant co-localization
evidence was observed in 22, in 9 of 232358 combinations in frontal cortex, 12 of 230,792 in
anterior cingulate cortex, and 9 of 234,905 in caudate basal ganglia. In cortex, colocalizations at 7q22.1, 17q21.31 and 17q25.1 were observed, some of genes at 17q25.1 were
replicated in other brain tissues – frontal and anterior cingulate cortex tissues and caudate
basal ganglia tissue (Table 15). At 7q22.1, co-localization was identified for non-coding
genes only. Many genes were co-localized at 17q25.1 including TRIM47 in all cortex tissues
and FBF1 in all brain tissues. TRIM47 was not included in the whole blood analysis since
eQTLs at the locus did not have any in cis associations with the gene. There were also tissuespecific co-localizations. In only cortex tissue, we observed co-localization of QTLs, mQTLs
for cg03706109 and eQTLs for DCAKD at 17q21.31. Co-localization at TEN1 was confirmed
in frontal cortex, TRIM65 and CDK3 in anterior cingulate cortex, and WBP2 in caudate basal
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ganglia. We confirmed the genes reported by previous GWASs with full-co-localization DCAKD at 17q21.31, FBF1, TRIM47, TRIM65 and WBP2 at 17q25.1. Except for WBP2,
these genes were not co-localized with whole blood eQTLs.
Table 15 MOLOC result in brain tissues
Symbol
7q22.1
AC069294.1

Tissue

DNAm

nsnp

PPABC PPABC_SNP

Caudate basal ganglia

cg04120578
cg14016363
cg00621899
cg25923345
cg25224090
cg05392513
cg22813798
cg04120578
cg25923345

66
20
53
75
71
81
148
68
79

0.91
0.86
0.86
0.85
0.84
0.81
0.81
0.90
0.82

7:100264893
7:100359797
7:100359797
7:100264893
7:100359797
7:100359797
7:100359797
7:100264893
7:100264893

cg03706109 148

0.87

17:43128906

0.82
0.82
0.92
0.93
0.92
0.92
0.84
0.81
0.91
0.83
0.96
0.96
0.86
0.85
0.85
0.85
0.85
0.83
0.83
0.97

17:73874684
17:73943942
17:73909948
17:73890363
17:73931787
17:73876473
17:73874684
17:73874684
17:73931787
17:73874684
17:73874684
17:73873656
17:73850940
17:73862646
17:73874684
17:73874684
17:73874684
17:73874684
17:73874684
17:73876473

RP11-395B7.2 Cortex
17q21.31
DCAKD
17q25.1
CDK3
FBF1

TEN1
TRIM47

Cortex
Anterior cingulate cortex
Anterior cingulate cortex
Caudate basal ganglia
Cortex

cg00943312
cg00759043
cg00759043
cg00943312
cg00759043
cg26780705
cg10295360
cg24166112
Frontal cortex
cg00759043
Frontal cortex
cg00943312
Anterior cingulate cortex cg00943312
cg26780705
cg08125733
cg10935138
cg04442638
cg09253696
cg06407111
cg04225089
cg10295360
Cortex
cg26780705
70

13
12
12
13
12
19
23
57
12
13
13
19
286
278
180
217
246
279
23
19

cg00943312 13
0.94
17:73874684
cg10295360 23
0.88
17:73876473
cg20772300 57
0.84
17:73876473
cg04442638 180
0.84
17:73874684
cg06407111 246
0.83
17:73874684
cg09253696 217
0.83
17:73874684
cg24166112 57
0.83
17:73876473
cg12714757 188
0.82
17:73876473
cg04225089 279
0.82
17:73874684
cg10935138 278
0.81
17:73862646
cg14955151 136
0.81
17:73874684
cg03700492 98
0.81
17:73876473
cg10644544 79
0.80
17:73876473
Frontal cortex
cg26780705 19
0.96
17:73873656
cg00943312 13
0.95
17:73873656
cg04442638 180
0.87
17:73874684
cg09253696 217
0.86
17:73874684
cg06407111 246
0.86
17:73874684
cg10295360 23
0.85
17:73874684
cg04225089 279
0.83
17:73874684
TRIM65
Anterior cingulate cortex cg00759043 12
0.84
17:73943942
WBP2
Caudate basal ganglia
cg26780705 19
0.89
17:73876473
nsnp: number of SNPs included for co-localization test. PPABC_SNP: the SNP with the
most evidence of colocalization
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DISCUSSION
Our study identified 11 methylation probes associated with WMH burden. These
probes mapped to genes that may have an implication in CSVD etiology. CLDN5 (claudin 5)
mapped to cg17577122 encodes integral membrane proteins that comprise tight junctions
specifically in brain microvascular endothelial cells that regulate blood-brain barrier (BBB)
permeability.241 Claudin-5 is the most enriched tight junction protein at BBB, and its
dysfunction has been implicated in neurodegenerative and neuroinflammatory diseases.242 In
a rat model of WM injury, a decrease in endothelial CLDN5 gene expression was observed in
regions of BBB damage.243 The profile of claudins and tight junction-associated marvel
proteins was studied in rats; up-regulation of Cldn5 after middle cerebral artery occlusion
was paralleled with down-regulated Cldn-1, 3, and 12, and occludin in cerebral capillaries in
pathological ischemia.244 Supporting this, CLDN5 was enriched in the regulation of
endothelial cell differentiation with another EWAS gene, BMP4 (bone morphogenetic
protein 4), in the FUMA gene enrichment analysis. Transforming growth factor beta 1
(TGFB1) is dysregulated in the heredity form of CSVD, CARASIL. BMPs are the largest
group of the TGFB superfamily, and a study using post mortem samples from SVD patients
showed that BMP4 was highly expressed in white matter pericytes and suggested that
ischemic white matter damage evolves in parallel with BMP4 upregulation in pericytes,245
that inhibits maturation of oligodendrocytes and blocks the expression of myelin proteins.246
Accounting for the spatial correlation among DNAm probes, we could enhance
DNAm associations for WMH burden. Among genes mapped to the DMRs, we could
implicate several genes to the WMH pathology. Protein arginine N-methylase 1 (PRMT1)
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transfers methyl group to arginine residues on histones; methylation mediated by PRMT1 is
promoted in genes involved in glioblastomagenesis.247 Generally, arginine methyltransferase
enzymes (PRMT1, PRMT4, and PRMT5) regulate myeloid differentiation.132 Mice lacking
PRMT1 were characterized with severe central nervous system defects, particularly defects in
oligodendrocyte maturation processes.248 PRMT1 is a predominant type I protein arginine
methyltransferase,249 which is mainly expressed in the endothelium and smooth muscle cells
of the cardiovascular system.250 Under oxidative stress, type 1 PRMT enzymes enhanced by
low-density lipoproteins methylate arginine competing against asymmetric dimethylarginine
(ADMA); thus leading to increased level of ADMA that inhibits synthesizing nitric oxide
resulting in endothelial dysfunction.251,252 DNAm at PRMT1 was also identified as the shared
epigenetics between cognitive ability (processing speed in specific) and WMH burden. The
link between DNAm at PRMT1 and cognition-related white matter changes needs to be
further studied; however, the mechanism is likely to be related to ischemia in endothelial
cells. Another DMR was mapped to the mast cell growth factor gene (KITLG, KIT ligand
gene), encoding the ligand of the tyrosine-kinase receptor which is a pleiotropic factor in
neural cell development. The gene is overexpressed by neurons to recruit neural stem cells to
the cerebral injury site for angiogenic response.253
WMH burden-associated DMRs and the probes shared with cognitive abilities
suggested that immunity- or infection- related functions are closely related to the CSVD
etiology. Innate and adaptive immune responses coincide with leukocyte adhesion to the
blood-vessel wall; therefore, the influx of leukocytes through endothelial cells influences the
immune reactions in the tissues.254,255 In this study, genes mapped to DMRs were enriched in
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HIV-1 control (enrichment FDR-adjusted P value =0.008) and squamous cell lung
carcinoma256 (FDR-adjusted P value=0.038) (Table 5). The arginine methyltransferase
enzyme encoded by PRMT1 binds to the intracytoplasmtic domain of the type I interferon
complex; reduced PRMT1 expression was found with the reduced antiproliferative effect of
interferon-beta.257 More DMRs were mapped to genes in infection-related or immune
system-related pathways. Zinc finger protein 311 (ZNF311) is known to be included in the
herpes simplex virus 1 infection superpathway with many other zinc finger proteins.258 In
addition, two genes, UBE3C and KITLG, involved in the class I MHC mediated antigen
processing,259 lymphocyte cytosolic protein 1 (LCP1) associated with B-cell non-Hodgkin
lymphoma,260 human immunodeficiency virus (HIV) type I enhancer binding protein 3
(HIVEP3) and mitochondrial valyl-tRNA synthetase 2 (VARS2) implicated in vaccinia virus
infection,261,262 procollagen-lysine 5-dioxygenase 2 (PLOD2) implicated in decreased HIV-1
infection,276 psoriasis susceptibility 1 candidate 3 (PSORS1C3),263 and solute blood cell
counts (SLC45A4) associated with blood cell counts (plateletcrit, leukocyte and reticulocyte
counts) were mapped to DMRs.264,265 HIVEP3 has been also reported in blood pressure and
eosinophil GWASs.265–268
Cg06809326 mapped to CCDC144NL was identified in the trans-ethnic analysis
when BMI, smoking status and blood pressure measures were not adjusted. Blood pressure is
an important risk factor for WMH burden, and BMI and smoking are known to influence
DNAm levels. To remove false positive signals, the risk factors should be corrected for in the
models; however, the unadjusted association is still meaningful as a crude measure of
DNAm-WMH burden relationship. And we confirmed that cg06809326 or CCDC144NL
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have not been reported in the epigenetic association with BMI269, smoking270, or blood
pressure271. A regional plot at cg06809326 shows that the epigenetic locus is likely to
associate with WMH burden with multiple signals (Figure S5). Correlations among
methylation probes in 1,597 ARIC subjects were shown below the plot, probes making the
association signal at the locus were significantly correlated. The heritability estimate for
cg06809326 was 26.5% and the genetic control indicated by mQTL associations was present
in cis in both EA and AA subjects (Figure S6). The directionality from the DNAm level at
cg06809326 to WMH burden was established by the bi-directional MR analysis. To further
elaborate the cg06809326-linked etiology, we confirmed the direct association with the gene
expression of CCDC144NL as well as the gene’s mediation in the relationship between the
DNAm level at cg06809326 and WMH burden. However, a TWAS in FHS subjects did not
report a significant association between CCDC144NL and WMH burden.232 The
CCDC144NL gene (coiled-coil domain containing 144 family (CCDC144A) N-terminal
pseudogene) is a pseudogene associated with diabetic retinopathies.272 Diabetic retinopathy is
blood vessel damage in the retina, and it shares risk factors with CSVD such as high blood
pressure and cholesterol levels. The coiled-coil protein, vimentin, assembles into filaments
potentially involved in integrin-mediated cell adhesion and angiogenesis.273 In the backward
MR analysis, we could find WMH burden influences the methylation level at cg03116124.
Absence of genetic influence on the probe but association with WMH burden might be
explained by this backward association. The DNAm level at cg03116124 can be the
secondary outcome of WMH burden; and might have a potential as a serum biomarker. The
cg03116124 probe was found to be associated with expression of TRIM67, a member of the
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tripartite motif containing family; previous large-scale GWASs identified other members of
the gene family - TRIM47 and TRIM65 - in the association with WMH burden or
volume.125,150,152,274

Only five of our target probes showed significant genetic components (Table 7), lack
of genetic components may implicate environmental influences. Also, polygenic control was
inferred by that we could not identify the genetic control in cis for heritable probes.
Cg17577122 was mapped to CLDN5, implicated in the CSVD etiology via endothelial cellrelated mechanisms. The heritability estimate for cg17577122 was 14.3%; however, no
mQTLs in cis were identified. Recently, a region-based EWAS reported a DMR mapped to
CLDN5 in the association with cognitive trajectory.275 In the study, genetic variations within
CLDN5 were associated with DNAm, but not with cognitive trajectory. Considering the
correlation between WMH and cognitive function, the result supports our conclusion that
WMH-associated DNAm at CLDN5 is not under in cis genetic control. In our study, genetic
controls over this probe appears to be scattered throughout the genome, especially in AA
subjects multiple mQTL loci were shown (Figure S6). Generally, trans-effects of genetics
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explain only a small portion of genetic control over DNA methylation;225,226 however, it is
still possible that some DNAm is controlled by multiple genetic loci in a polygenic manner.
We studied DNAm levels in whole blood samples and the utility of DNAm probes as
preventive biomarkers can be secured by checking the correlation with the levels in brain
tissues. For 450,000 probes on the Illumina Human450 Methylation BeadChip, correlations
between DNAm level in whole blood and the levels in four brain tissues (i.e. prefrontal
cortex, entorhinal cortex, superior temporal gyrus and cerebellum) were reported on the
Blood Brain DNA Methylation Comparison Tool website
(https://epigenetics.essex.ac.uk/bloodbrain/).276 We searched 11 target probes in the tool, and
marginal to high correlations of DNAm levels in blood and brain tissues were observed at
several target probes (Table S11). The correlation coefficients at cg06809326 were similarly
significant in four tissues from 0.566 to 0.711. At cg04245766, DNAm levels in blood and
the brain were highly correlated (r=0.923 to 0.954). Marginal correlation was confirmed at
cg24202936 in prefrontal and entorhinal cortex and superior temporal gyrus (r=0.324 to
0.398). At some probes, tissue-specific correlation was found - r=0.0494 in entorhinal cortex
(cg02741985), r=0.242 in cerebellum (cg03116124), r= -0.312 in cerebellum (cg10051414),
and r=0.255 in superior temporal gyrus (cg18950108). Probes with high correlated blood and
brain methylation levels are more likely to be eligible as an epigenetic biomarker for WMH
burden.
Integrative genetic analyses provided us novel and additional information about the
CSVD etiology. Using multi-level associations (GWAS, EWAS and TWAS), we metaanalyzed gene-based associations and identified biological functions associated with WMH
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burden. A significant association was identified in the alphaV-beta3 integrin-IGF-1-IGF1R
complex (FDR adjusted P value=0.022) ontology. IGFBP-2, which binds IGF-1 to the
integrin complex, was recently suggested as a biomarker for dementia and Alzheimer’s
disease.277 By co-localizing QTL, mQTL, and eQTL associations at WMH loci, our analysis
linked several GWAS loci with DNAm and gene expression possibly involved in the
pathology. Especially, the well-established WMH locus, 17q25.1, showed co-localization
evidence for multiple genes including GALK1; ITGB4. Co-localization at the integrin subunit
beta 4 gene integrin-related gene (ITGB4) again suggests integrin-mediated cell adhesion and
angiogenesis as a possible etiological mechanism.
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CONCLUSIONS
This dissertation study was designed to investigate the role of DNA methylation, a
kind of epigenetic variations, in WMH burden, a shared pathology among critical public
health burdens including stroke and dementia. As the first step, we have identified DNAm
levels at 11 novel loci in association with WMH burden and implicated biological functions
related to the genes mapped to those loci. In the next step, we characterized the relationship
between DNAm at the identified probes and the genetics or gene expression. We confirmed
significant genetic components in six DNAm probes and identified genetic variants (mQTLs)
associated with four of them. Based on mQTLs, we tested a causal direction between DNAm
and WMH burden in either way. DNAm at cg06809326 was found to influence WMH
burden, while WMH burden influences DNAm at cg03116124. Additionally, expression
levels of the closest genes to these two probes were confirmed to be associated with the
DNAm at the probes (i.e. CCDC144NL for cg06809326, and TRIM67 for cg03116124). The
causal association from the genetics through DNAm and then gene expression towards WMH
burden was also confirmed at cg06809326. We also investigated the WMH etiology utilizing
multi-dimensional data available. We integrated genome-, transcriptome-, and our
epigenome-wide associations and identified a novel ontology related to integrin complex
associated with WMH burden. Had tested co-localization of genetic associations at multidimensions at the reported WMH burden loci, we found significant co-occurrences of mQTL,
eQTL, and QTLs at four GWAS reported loci including ITGB4 (integrin subunit beta 4). This
indicates that some genetic influences lead to WMH burden through related epigenetics and
gene expressions. In conclusion, we found novel loci associated with WMH burden and
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functionally annotated these loci in relation to the etiology, suggesting involvement of the
integrin-mediated pathway.
This is the first epigenome-wide association study of WMH in a large-scale. Aging
influences DNA methylation,278 and WMH burden is known to be associated with older
ages32,35,46–50. Thus, epigenetics might unravel the unknown etiology of WMH burden. In this
study, we identified novel epigenetic loci associated with WMH burden, and these loci might
provide a novel explanation to the aging-related WMH pathology. The main finding of this
study was the integrin-associated pathway. Integrins play a crucial role in cell-to-cell and
cell-to-extra-cellular matrix interactions, and these interactions are essential for effective Tcell-mediated immune response.279 The ageing process often leads to reduced efficiency of
adaptive immunity, while B-cell functions and innate immune system tend to maintain.280
Integrin-mediated functions might be able to explain the shared pathology of ageing and
WMH burden. This study exhibits several limitations as well; however, those can be
overcome with future studies. MetaUSAT multivariate analysis computes a joint statistic
using two sets of summary statistics. In a multi-trait analysis of GWASs, the joint association
becomes stronger when correcting for the correlation structure of SNPs. Likewise, the joint
analysis can improve with a future study in the correlation structure among methylation
probes. Heritability estimates showed that only five of our EWAS probes have genetic
compositions. The target probes with small or non-significant genetic components need to be
studied for their association with environmental factors including blood pressure. We
observed that mQTLs showed underpowered significance in UKBB GWAS, this might
improve with greater sample size. We used the summary statistics from a previous GWAS to
establish directional associations for target probes. Mendelian randomization analysis
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requires the effect size and its standard error for exposure and outcome associations to
compute the statistics for directional association. The largest CHARGE GWAS including
17,936 EA subjects provides Z-scores only, so it was not applicable for MR analyses. We
used the summary statistics from the UKBB GWAS; however, it covers fewer SNPs. Many
mQTLs and eQTLs are not included in the UKBB dataset, and the CHARGE GWAS does
not provide effect size. One of the target probes, cg04245766 mapped to BMP4, was not
included in the causal association analyses since it did not pass QC criteria in EA subjects of
ARIC, FHS, and RS. The EWAS association for cg04245766 was driven by ADNI, ARIC
AA subjects, CARDIA, and SHIP-TREND. When mQTL associations for cg04245766 are
available, we can test the directional association toward WMH burden with or without
mediation of gene expression. In the functional analysis, the BMP4 gene was enriched in
endothelial cell differentiation and regulation; thus, confirming the causal pathway related to
cg04245766 might be a valuable addition to the understanding of the WMH burdenassociated epigenetics. Lastly, the Bayesian method-based co-localization test simply
confirms the co-occurrence of independent associations, not providing the evidence on the
causal pathway. Based on the co-localization results, the etiology of WMH burden involving
genetics, DNAm and gene expression can be further investigated.
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Appendix A. Supplemental Material
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Alzheimer's Disease Neuroimaging Initiative (ADNI)
Study Description
ADNI is a longitudinal, multi-site observational study including Alzheimer’s disease
(AD), mild cognitive impairment (MCI), and elderly individuals with normal cognition
assessing clinical and cognitive measures, MRI and PET scans (FDG and 11C PIB) and
blood and CNS biomarkers.281,282 In 2004, the initial phase, ADNI-1, recruited 400 subjects
with MCI, 200 subjects with early AD and 200 cognitively normal elderly from multiple site
in North America. The study was extended with ADNI-GO in 2009 including 500 ADNI-1
subjects (normal controls and MCI cases) and 200 new early MCI cases. In 2011, one more
extension, ADNI-2, started to study approximately 450-500 ADNI-1 subjects, 200 ADNI-GO
subjects and 650 new cases (150 controls, 150 early MCI cases, 150 late MCI cases and 200
mild AD cases). In this study, 387 normal or early MCI subjects who provided brain MRI
and methylation data were included. Brain MRI for WMH burden assessment was taken at
ADNI-1 in 73 subjects and at ADNI-2 in 314 subjects. Samples for DNA methylation were
drawn in ADNI-GO and ADNI-2 studies. Days between blood sampling and brain MRI were
within 365 days in 85% of subjects (n=329), between a year and two years in 8% (n=31),
between two and three years in 16 subjects and more than 3 years in 11 subjects.
Ethic Statement
The study protocols for the ADNI studies were approved by the Institutional Review
Boards of all the participating institutions.
Acknowledgements
Data collection and sharing for this project was funded by the Alzheimer's Disease
Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and
83

DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded
by the National Institute on Aging, the National Institute of Biomedical Imaging and
Bioengineering, and through generous contributions from the following: AbbVie,
Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech;
BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai
Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La
Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO
Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson &
Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck &
Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies;
Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda
Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health
Research is providing funds to support ADNI clinical sites in Canada. Private sector
contributions are facilitated by the Foundation for the National Institutes of Health
(www.fnih.org). The grantee organization is the Northern California Institute for Research
and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research
Institute at the University of Southern California. ADNI data are disseminated by the
Laboratory for Neuro Imaging at the University of Southern California.

Atherosclerosis Risk in Communities (ARIC)
Study Description
The ARIC Study is a prospective longitudinal investigation of the development of
atherosclerosis and its clinical sequelae in which 15,792 individuals aged 45 to 64 years were
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enrolled at baseline. A detailed description of the ARIC study has been reported
previously.283 At the inception of the study in 1987-1989, participants were selected by
probability sampling from four communities in the United States: Forsyth County, North
Carolina; Jackson, Mississippi (African-Americans only); the suburbs of Minneapolis,
Minnesota; and Washington County, Maryland. Four examinations were carried out at threeyear intervals (exam 1, 1987-1989; exam 2, 1990-1992; exam 3, 1993-1995; exam 4, 19961998). A fifth clinical examination was completed in 2011-2013. Subjects were contacted
annually to update their medical histories between examinations. After QC, 906 EuropeanAmerican and 639 African-American subjects with methylation data and brain MRI were
included in this study.
Ethic Statement
Written informed consent was provided by all study participants, and the study design
and methods were approved by institutional review boards at the collaborating medical
institutions: University of Mississippi Medical Center Institutional Review Board (Jackson
Field Center); Wake Forest University Health Sciences Institutional Review Board (Forsyth
County Field Center); University of Minnesota Institutional Review Board (Minnesota Field
Center); and the Johns Hopkins School of Public Health Institutional Review Board
(Washington County Field Center).
Acknowledgments
The Atherosclerosis Risk in Communities study has been funded in whole or in part
with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of
Health, Department of Health and Human Services (contract numbers HHSN268201700001I,
HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and
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HHSN268201700005I). The authors thank the staff and participants of the ARIC study for
their important contributions. Funding was also supported by RC2HL102419 and
R01NS087541. This study was funded by the NIH contract (5R01NS087541-04) granted to
Myriam Fornage and Eric Boerwinkle.

Coronary Artery Risk Development in Young Adults (CARDIA)
Study Description
Coronary Artery Disease Risk Development in Young Adults (CARDIA) is a
longitudinal study designed to trace the development of risk factors for coronary heart
disease in 5,115 relatively young individuals aged 18-30 (52% African American and 55%
women). The study collected information on anthropometric, lifestyle factors as well as
biomarkers including brain MRI, genetic and DNA methylation data. Baseline measurements
were repeated, and additional measurements performed, at Years 2, 5, 7, 10, 15, 20, and
25.284 DNA methylation level was measured in 1,089 subjects at the examination year 15 and
1,092 subjects at the year 20. In this study, 126 subjects of European and 68 subjects of
African-ancestry with the brain MRI image were contributed from CARDIA.
Ethic Statement
The CARDIA study is multicenter with recruitment in Birmingham, AL; Chicago, IL;
Minneapolis, MN; and Oakland, CA. The study protocol was approved by the institutional
review boards of the coordinating center and the 4 participating field centers, and written
informed consent was obtained from participants at all examinations.
Acknowledgments
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The Coronary Artery Risk Development in Young Adults Study (CARDIA) is
conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in
collaboration with the University of Alabama at Birmingham (HHSN268201300025C &
HHSN268201300026C), Northwestern University (HHSN268201300027C), University of
Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute
(HHSN268201300029C), and Johns Hopkins University School of Medicine
(HHSN268200900041C). CARDIA is also partially supported by the Intramural Research
Program of the National Institute on Aging (NIA) and an intra-agency agreement between
NIA and NHLBI (AG0005).

Cardiovascular Health Study (CHS)
Study Description
The CHS is a population-based cohort study of risk factors for coronary heart disease
and stroke in adults ≥65 years conducted across four field centers in the United States:
Sacramento County, California; Washington County, Maryland; Forsyth County, North
Carolina; and Pittsburgh, Allegheny County, Pennsylvania. The original cohort of 5,201
persons, predominantly of European ancestry, was recruited in 1989-1990 from random
samples of the Medicare eligibility lists. Later, 687 African-Americans were added to the
cohort, making the total cohort of 5,888.285 DNA methylation was measured on a randomly
selected subjects without presence of coronary heart disease, congestive heart failure,
peripheral vascular disease, valvular heart disease, stroke or transient ischemic attack at the
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exam year 5. Post QC, 378 European ancestry and African-American participants with
methylation data and brain MRI were included in this study.
Ethic Statement
Written informed consent to genetic research has been obtained on all individuals
included in this study. CHS was approved by institutional review committees at each field
center and individuals in the present analysis had available DNA and gave informed consent
including consent to use of genetic information for the study of cardiovascular disease. The
DNA methylation dataset from CHS can be requested at https://chs-nhlbi.org/node/6222.
Acknowledgements
Infrastructure for the CHARGE Consortium is supported in part by the National
Heart, Lung, and Blood Institute grant R01HL105756. The CHS research was supported by
NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222,
N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086,
N01HC15103; and NHLBI grants U01HL080295, R01HL087652, R01HL092111,
R01HL105756, R01HL103612, R01HL111089, R01HL116747 and R01HL120393 with
additional contribution from the National Institute of Neurological Disorders and Stroke
(NINDS). Additional support was provided through R01AG023629 and R01AG033193 from
the National Institute on Aging (NIA) as well as Laughlin Family, Alpha Phi Foundation, and
Locke Charitable Foundation. A full list of principal CHS investigators and institutions can
be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the
National Center for Advancing Translational Sciences, CTSI grant UL1TR000124, and the
National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center
(DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.
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The content is solely the responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.

Framingham Heart Study (FHS) offspring cohort
Study Description
The FHS is a single-site, community-based, ongoing cohort study that was initiated in
1948 to investigate prospectively the risk factors for CVD.286–288 The original cohort
(n=5,209) was randomly recruited in the town of Framingham, MA, USA, and examined
every 2 year since 1948; their children and spouses of the children (n=5,124), the offspring
cohort, was enrolled in 1971 and examined approximately every 4 year since 1971. DNA
methylation was measured on 2,846 offspring participants around 8th examination cycle
(2005-2008). This study includes 403 and 1,323 offspring subjects with dse and flair MRI
scans, respectively, as well as DNA methylation data.
Ethic Statement
Written informed consent to genetic research has been obtained on all individuals
included in this study. Ethics permission for FHS and genetic research in FHS was obtained
from the Institutional Review Board of Boston University Medical Campus (IRB number H32132, H-26671)
Acknowledgements
This work was supported by the National Heart, Lung and Blood Institute’s
Framingham Heart Study Contract No. N01-HC-25195 and No. HHSN268201500001I, and
by grants from the National Institute of Aging (R01s AG033193, AG008122, AG054076,
AG033040, AG049607, AG05U01-AG049505), and the National Heart, Lung and Blood
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Institute (R01 HL093029, HL096917). The laboratory work for this investigation was funded
by the Division of Intramural Research, National Heart, Lung, and Blood Institute, National
Institutes of Health, and by NIH contract N01-HC-25195. The analytical component of this
project was funded by the Division of Intramural Research, National Heart, Lung, and Blood
Institute, and the Center for Information Technology, National Institutes of Health.

Genetic Epidemiology Network of Arteriopathy (GENOA)
Study Description
The Genetic Epidemiology Network of Arteriopathy (GENOA) study was designed to
investigate the genetics of hypertension and target organ damage in hypertensive sibships.20
The GENOA study is a community-based study including African Americans from Jackson,
Mississippi and non-Hispanic whites from Rochester, Minnesota.289 The initial GENOA
study, from 1996 to 2001, recruited any members in sibships having more than two
individuals with clinically diagnosed hypertension before age 60. Exclusion criteria of the
GENOA study were secondary hypertension, alcoholism or drug abuse, pregnancy, insulindependent diabetes mellitus, or active malignancy. Eighty percent of African Americans
(1,482 subjects) and 75% of non-Hispanic whites (1,213 subjects) from the initial study
population returned for the second examination (Phase II: 2001-2005). Study visits were
made in the morning after an overnight fast of at least eight hours. Demographic information,
medical history, clinical characteristics, lifestyle factors, and blood samples were collected in
each phase. DNA methylation levels were measured only in African Americans participants.
After quality control, DNA methylation and brain MRI data were available for 356 African
Americans.
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Ethic Statement
Written informed consent was obtained from all subjects, and approval was granted
by participating institutional review boards at the University of Mississippi Medical Center,
the Mayo Clinic, and the University of Michigan.
Acknowledgements
Support for the Genetic Epidemiology Network of Arteriopathy (GENOA) was
provided by the NHLBI (HL054457, HL100185, HL119443, and HL133221) and the NINDS
(NS041558) of the NIH.

Lothian Birth Cohort 1936 (LBC1936)
Study Description
The Lothian Birth Cohorts of 1936 (LBC1936) is a longitudinal study of ageing.
Participants were born in 1936 and mostly live in the Lothain region of Scotland.290,291 The
study was derived of the Scottish Mental Surveys of 1947 that conducted a general cognitive
ability test on nearly all 11 year old children in Scotland. Residents in the Lothian area of
Scotland (n=1,091) were recruited in late-life at mean age 70 and followed-up at their ages
70, 73, and 76. In this study, 230 subjects who provided epigenetic information and brain
imaging, blood biomarkers and anthropomorphic and lifestyle measures were included.
Ethic Statement
Following written informed consent, venesected whole blood was collected for DNA
extraction. Ethics permission for the LBC1936 was obtained from the Multi-Centre Research
Ethics Committee for Scotland (Wave 1: MREC/01/0/56), the Lothian Research Ethics
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Committee (Wave 1: LREC/2003/2/29), and the Scotland A Research Ethics Committee
(Waves 2 and 3: 07/MRE00/58).
Acknowledgements
We thank the cohort participants and team members who contributed to these studies.
Phenotype collection in the Lothian Birth Cohort 1936 was supported by Age UK (The
Disconnected Mind project). Methylation typing was supported by the Centre for Cognitive
Ageing and Cognitive Epidemiology (Pilot Fund award), Age UK, The Wellcome Trust
Institutional Strategic Support Fund, The University of Edinburgh, and The University of
Queensland. Analysis of these data were carried out within the University of Edinburgh
Centre for Cognitive Ageing and Cognitive Epidemiology (CCACE). CCACE is supported
by funding from the BBSRC, the Medical Research Council (MRC), and the University of
Edinburgh as part of the cross-council Lifelong Health and Wellbeing initiative
(MR/K026992/1). Funding from the Australian NHMRC (613608) supported quality control
analysis of the methylation data.

Rotterdam Study III (RS3)
Study Description
The Rotterdam Study is a prospective, population-based cohort study that includes
inhabitants of the well-defined district Ommoord, located in the city of Rotterdam in the
Netherlands.292 The cohort was initiated in 1990 among approximately 7,900 persons aged 55
years and older, who underwent a home interview and extensive physical examination at the
baseline and during the follow-up rounds every 3-4 years (RS-I). The cohort was extended in
2000-2001 (RS-II, 3,011 individuals, aged 55 years and older) and 2006-2008 (RS-III, 3,932
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individuals aged 45 and older). Collected data include genetic information, epigenetic
information, imaging (of heart, blood vessels, eyes, skeleton and brain) and numerous blood
biomarkers, anthropomorphic and lifestyle measures.293,294 Post QC, DNA methylation and
brain MRI used for the analyses were available in 547 subjects from the first visit of RS-III
and 442 subjects from the fifth visit of RS-I, the third visit of RS-II and the second visit of
RS-III. The latter dataset is part of the Biobanking and Biomolecular Resources Research
Infrastructure for The Netherlands (BBMRI-NL), BIOS (Biobank-based Integrative Omics
Studies) project [http://www.bbmri.nl/?p=259]. Whole blood DNA methylation was
quantified in a random subset of 750 individuals with genotyping and RNA expression data
available in the first cohort of RS-III.
Ethic Statement
The Rotterdam Study has been approved by the Medical Ethics Committee of the
Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health,
Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG).
The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR;
www.trialregister.nl) and into the WHO International Clinical Trials Registry Platform
(ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalogue number NTR6831.
All participants provided written informed consent to participate in the study and to have
their information obtained from treating physicians.
Acknowledgements
The generation and management of the Illumina 450K methylation array data (EWAS
data) for the Rotterdam Study was executed by the Human Genotyping Facility of the
Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Netherlands.
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The EWAS data was funded by the Genetic Laboratory of the Department of Internal
Medicine, Erasmus MC, and by the Netherlands Organization for Scientific Research (NWO;
project number 184021007) and made available as a Rainbow Project (RP3; BIOS) of the
Biobanking and Biomolecular Research Infrastructure Netherlands (BBMRI-NL). We thank
Mr. Michael Verbiest, Ms. Mila Jhamai, Ms. Sarah Higgins, Mr. Marijn Verkerk, and Lisette
Stolk PhD for their help in creating the methylation database.
The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University,
Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw),
the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture
and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG
XII), and the Municipality of Rotterdam. The authors are grateful to the study participants,
the staff from the Rotterdam Study and the participating general practitioners and
pharmacists. HHHA is supported by ZonMW grant number 916.19.151.
The Study of Health in Pomerania TREND (SHIP-TREND)
Study Description
The Study of Health in Pomerania (SHIP-Trend) is a longitudinal population-based
cohort study in West Pomerania, a region in the northeast of Germany, assessing the
prevalence and incidence of common population-relevant diseases and their risk factors.
Baseline examinations for SHIP-Trend were carried out between 2008 and 2012, comprising
4,420 participants aged 20 to 81 years. Study design and sampling methods were previously
described.295 The medical ethics committee of the University of Greifswald approved the
study protocol, and oral and written informed consents were obtained from each of the study
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participants. DNA was extracted from blood samples of n=256 SHIP-Trend participants to
assess DNA methylation using the Illumina HumanMethylationEPIC BeadChip array.
Samples were randomly selected based on availability of multiple OMICS data, excluding
type II diabetes, and enriched for prevalent MI. The samples were taken between 07:00 AM
and 04:00 PM, and serum aliquots were prepared for immediate analysis and for storage at 80 °C in the Integrated Research Biobank (Liconic, Liechtenstein). Processing of the DNA
samples was performed at the Helmholtz Zentrum München. After exclusion of subjects who
refused participation or who fulfilled exclusion criteria for MRI (e.g. cardiac pacemaker),
2189 subjects from SHIP-Trend-0 underwent the MRI scanning. After exclusion of scans
with technical artifacts, major structural abnormalities and stroke, full data sets with EWAS
data and MRI scans were available in 214 subjects in SHIP-TREND.
Ethic Statement
SHIP and SHIP TREND were approved by the local ethics committee. After
complete description of the study to the subjects, written informed consent was obtained. The
medical ethics committee of the University of Greifswald approved the study protocol.
Acknowledgements
SHIP is part of the Community Medicine Research net of the University of
Greifswald, Germany, which is funded by the Federal Ministry of Education and Research
(grants no. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as
the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network
‘Greifswald Approach to Individualized Medicine (GANI_MED)’ funded by the Federal
Ministry of Education and Research (grant 03IS2061A). DNA methylation data have been
supported by the DZHK (grant 81X3400104). The University of Greifswald is a member of
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the Caché Campus program of the InterSystems GmbH. The SHIP authors are grateful to
Paul S. DeVries for his support with the EWAS pipeline.
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WMH measurements in each cohort
Study

MRI technology Scanning Protocol

Image Processing

WMH quantification

ADNI296–299

1.5T (ADNI-1)
and 3T (ADNI-2) A series of sagittal T1-weighted
MRI scanners
scans and axial proton-density/
from General
T2- weighted fast spin echo
Electric Medical scans.
Systems, Philips T1-, T2- and PD-weighted MRI
Medical Systems, scans were co-registered, and
or Siemens
skull stripped, then corrected for
Medical
bias field.
Solutions

ADNI-1: Brain images were reviewed by
a neuroradiologist to exclude infarcts and
other abnormalities and graded by a
trained individual. ADNI-2: the
FreeSurfer software package version 4.3
and 5.1 (http://surfer.nmr.
mgh.harvard.edu/) by the Schuff and
Tosun laboratory at the University of
California-San Francisco

ADNI-1: WMH was quantified based on T1-, T2- and PDintensities, the prior probability of WMH, and the probability
of WMH conditioned on the presence of WMH at neighboring
voxels.
ADNI-2: WMH was measured with a Bayesian approach
using segmentation of high resolution 3D T1 and FLAIR
sequences.

ARIC300

CARDIA301

CHS300

FHS

WMHs were estimated as the relative total volume of
periventricular and subcortical WM signal abnormality on
1.5-Tesla
A series of sagittal T1-weighted Images were interpreted directly from a
proton density– weighted axial images by visual comparison
scanners (General scans and axial proton-density, PDS-4 digital workstation consisting of
with eight templates that successively increased from barely
Electric Medical T2- weighted and T1-weighted four 1024 X 1024-pixel monitors capable
detectable WM changes (Grade 1) to extensive, confluent
Systems or Picker scans with 5 mm thickness and of displaying all 96 images
changes (Grade 8). Individuals with no WM changes received
Medical Systems) no interslice gaps.
simultaneously.
Grade 0, and those with changes worse than Grade 8 received
Grade 9.
A sequence of sagittal 3DT2
3T scanners
with slice thickness 1 mm;
Structural MR images were processed
(Siemens Medical
We classified all supratentorial brain tissue into GM, WM, and
sagittal 3D FLAIR with slice
using previously described methods that
Solutions and
CSF. GM and WM were characterized as normal and
thickness 1 mm; and sagittal 3D were based on an automated multispectral
Philips Medical
abnormal (ischemic).
MPRAGE with slice thickness computer algorithm.
Systems)
1mm.
WMHs were estimated as the relative total volume of
periventricular and subcortical WM signal abnormality on
General Electric A series of sagittal T1-weighted Images were interpreted directly from a
proton density– weighted axial images by visual comparison
or Picker 1.5scans and axial PD, T2- weighted PDS-4 digital workstation consisting of
with eight templates that successively increased from barely
Tesla scanners and T1-weighted scans with 5 four 1024 X 1024-pixel monitors capable
detectable WM changes (Grade 1) to extensive, confluent
and Toshiba 0.35- mm thickness and no interslice of displaying all 96 images
changes (Grade 8). Individuals with no WM changes received
Tesla scanner
gaps.
simultaneously.
Grade 0, and those with changes worse than Grade 8 received
Grade 9.
Offspring cohort: 3D T1 and
Analyzed with QUANTA 6.2 at the
For segmentation of WMH from other brain tissues the first
1 or 1.5 T
double echo proton density (PD) University of California–Davis Medical
and second echo images from T2 sequences were summed and
Siemens
and T2 DSE coronal images
Center. Images were analyzed and
a lognormal distribution was fitted to the summed data (after
Magnetom
were acquired in 4-mm
interpreted blind to subject data and in
removal of CSF and correction of image intensity nonscanner
contiguous slices
random order. Semi-automated analysis
uniformities). A segmentation threshold for WMH was
3rd Generation cohort: FLAIR of pixel distributions, based on
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mathematical modeling of MRI pixel
determined as 3.5 standard deviations in pixel intensity above
intensity histograms for CSF, WM, and the mean of the fitted distribution of brain parenchyma.
GM, were used to determine the optimal
threshold of pixel intensity to best
distinguish CSF from brain matter based
on previously published methods. The
intracranial vault above the tentorium was
outlined manually to determine the TIV.

GENOA302

FLAIR images consisting of 48
contiguous 3-mm interleaved
slices with no interslice gap.
1.5 T MRI
Total intracranial volume (head
scanner from
size) was measured from T1General Electric
weighted spin echo sagittal
Medical Systems
images, each set consisting of 32
contiguous 5 mm thick slices
with no interslice gap.

A fully automated algorithm was used to
segment each slice of the edited multislice FLAIR sequence into voxels
assigned to one of three categories: brain,
CSF, or leukoaraiosis.

Interactive imaging processing steps were performed by a
research associate who had no knowledge of the subjects’
personal or medical histories or biological relationships. Total
leukoaraiosis volumes were determined from axial FLAIR
images.

WMH were measured in the cerebral hemispheres, cerebellum
A semi-automatic computational program
and brainstem. Intracranial volume, brain and WMH volume
written specifically for the project,
1.5 T HDx MRI
were extracted and manually corrected as necessary to remove
T1-w coronal and T2-W, FLAIR, MCMxxxVI, a multispectral color fusion
scanner from
false positive lesions in the insular cortex, cingulate gyrus,
LBC1936288
and T2*-weighted axial whole method that combines different pairs of
General Electric
anterior temporal cortex and around the floor of the third
brain images
sequences in red-green color space and
Medical Systems
ventricle, and correct false negatives
performs minimum variance quantization
(http://www.bric.ed.ac.uk/research/imageanalysis.html). All
to highlight different tissues.
focal stroke lesions were manually removed.
WMH volume was quantified using two fully automated
methods, which was described previously in more detail.
The combination of different MR
Either the HASTE, PD and T2 sequences were used, or the
1.5 T scanner
Structural imaging is performed contrasts provided by acquired sequences
FLAIR, T1 and PD sequences. Briefly, cerebrospinal fluid
RSIII and
(GE Signa
with T1-weighted (T1w), proton can be used for automated brain tissue
(CSF), gray matter (GM) and white matter (WM) are
RSI-III
Excite) using an density-weighted (PDw) and
and white matter lesion segmentation. For
segmented by an atlas-based k-nearest neighbor classifier on
293,303
(BBMRI)
8-channel head fluid-attenuated inversion
this purpose, the T1w scan is acquired in
multi-modal magnetic resonance imaging data. This classifier
coil
recovery (FLAIR) sequences.
3D at high in-plane resolution and with
is trained by registering brain atlases to the subject. The
thin slices (voxel size <1 mm3).
resulting GM segmentation is used to automatically find a
WMH threshold in a fluid-attenuated inversion recovery scan.
A series of T1, MP-RAGE/ axial
WMH quantification was based on the following sequences:
1.5-T MR imager plane with the resolution of 1.0 x
SHIPT1, MP-RAGE/ axial plane, TR=1900 ms, TE=3.4 ms, Flip
from Siemens
1.0 x 1.0mm3 and T2 FLAIR / The FreeSurfer 5.1.0 software
TREND304
angle=15°, resolution of 1.0 x 1.0 x 1.0mm^3 and T2 FLAIR /
Medical systems axial plane with the resolution of
axial plane, TR= 5000, TE= 325, voxel= 0,9 x 0,9 x 3,0.
0.9 x 0.9 x 3.0mm3.
Abbreviations: Double spin echo (DSE). Fluid-attenuated inversion recovery (FLAIR). Proton-density (PD). Cerebrospinal fluid (CSF). White matter (WM). Grey matter
(GM). Total (intra)cranial volume (TIV/TCV)
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DNA methylation data collection and association study in each cohort
Technology

ADNI

ARIC305

CARDIA

CHS

Illumina
850K

Illumina
450K

Illumina
850K

Illumina
450K

Tissue
source

NormalizQC methods
ation

Experimental/
Biological covariates

Covariate Assessment

Technical Methods of
Covariate Adjustment for
s
Covariates
Linear mixed
models of
DNAm~WMH
chip ID,
burden adjusted for
chip
biological and
Position
technical covariates.
Technical covariates
as random effects.

Model 1: ICV, age, sex,
removed probes with
WBC, study site, visit,
- a low detection rate (P>0.01 for time between MRI and
>5% of samples)
DNAm visits, early
removed samples with
MCI status, population
- low call rate (P<0.01 for <95% structure (surrogates);
of probes)
Model 2: + Smoking,
BMI SBP, DBP

- Smoking status was coded as
“Yes” or “No”.
- Systolic and diastolic blood
pressure was measured at the
MRI visit.

Blood
BMIQ
leukocytes

In each ancestry,
removed probes with
Model 1: age, sex,
- a low detection rate (P>0.01 for
WBC, technical
>5% of samples)
covariates, population
removed samples with
structure (surrogates);
- low call rate (P<0.01 for <99%
Model 2: + Smoking,
of probes)
BMI, SBP, DBP

- Smoking was obtained at either
Linear mixed
exam 2 or 3 using an interviewermodels of
administered questionnaire and
DNAm~WMH
was classified as current, former, Chip ID,
burden adjusted for
or never.
Chip Row,
biological and
- Blood pressure was assessed at plate
technical covariates.
exam 2 and 3, the average value
Technical covariates
of two visit was used in this
as random effects.
study.

Whole
blood

- excluded 6,209 CpGs with a
detection rate <95%
- excluded 87 samples with the
percentage of low-quality
methylation measurements >5%
- extremely low intensity of
bisulfite conversion probes (less
than mean intensity – 3 ×
standard deviation of the
intensity across samples).

- Smoking status was coded as
“never”, “ex-smoker”, and
“current smoker” based on a selfchip ID,
administered questionnaire.
chip
- Systolic and diastolic blood
position
pressure in mmHg measured at
the same examination as the
DNA sampling.

Linear mixed
models of
DNAm~WMH
burden adjusted for
biological and
technical covariates.
Technical covariates
as random effects.

- Smoking was assessed with a
standard questionnaire during inperson interview at the time of
chip ID,
blood assessment for methylation.
chip
Smoking status was categorized
position
into never, former or current
smoker.
- Systolic and diastolic blood

Linear mixed
models of
DNAm~WMH
burden adjusted for
biological and
technical covariates.
Technical covariates
as random effects.

Whole
blood

BMIQ

RCP

Blood
SWAN
leukocytes

Model 1: age, sex, race,
WBC, technical
covariates, population
structure (surrogates);
Model 2: + Smoking,
BMI, SBP, DBP

excluded samples with
Model 1:age, sex, 4
- a proportion of probes falling
genetic PCs, batch,
detection of greater than 0.5%
WBC estimates, race,
- low median intensities of below
technical covariates
10.5 (log2) across the methylated
Model 2:Model 1 +
and unmethylated channels
Smoking, BMI , SBP,
- QC probes falling greater than
DBP
3 standard deviation from the
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FHS

Illumina
450K

Whole
blood

mean
- with sex-check mismatches
- failed concordance with prior
genotyping or > 0.5% of probes
with a detection p-value > 0.01
Samples were excluded if
- outliers in multidimensional
scaling (MDS) analysis, high
missing rate (>1%), poor
DASEN matching to SNP genotype
(wateRmel Probes were excluded if
on)
- high missing rate (>20%),
mapped to multiple locations,
had SNP (MAF>5% in EUR
1000G) at CpG site or ≤10 bp of
Single Base Extension.

GENOA Illumina 27K

Blood
SWAN
leukocytes

LBC193 Illumina
6306
450K

Whole
blood

minfi

pressure in mmHg measured at
the same examination as the
DNA sampling.

Model 1: age, sex,
WBC, technical
covariates, population
structure (surrogates);
Model 2: + Smoking,
BMI

- Current smoking is defined as
regularly smoking in the past year
which was self-reported at each
chip ID,
examination. Using examination
chip
8 and previous examination data,
position
participants were classified as
current smoker, ex-smoker, never
smoker.

Linear mixed
models of
DNAm~WMH
burden adjusted for
biological and
technical covariates.
Family structure is
also adjusted.

- Smoking status: current smoker
(smokes currently or quit
smoking within the past year), exLinear mixed
smoker (formerly smoked, but
models of
Model 1: age, sex, total quit more than 1 year ago), and
DNAm~WMH
- Remove probe if >5% of
intracranial volume, 4 never-smoker (smoked less than
burden adjusted for
samples have a detection p-value
genetic PCs, WBC,
100 cigarettes in his/her entire
biological and
of >0.01;
plate, row,
technical covariates,
life).
technical covariates.
- Remove sample if >5% of
column
familial relationship;
- Blood Pressure: sitting systolic
Technical covariates
probes have a detection p-value
Model 2: + smoking,
and diastolic blood pressure in
and familial
of >0.01;
BMI, SBP, DBP
mmHg were measured three
relationship were
times with a random zero
treated as random
sphygmomanometer. The average
effects.
of the last two measurement was
used.
Remove probes with
- a low detection rate (P>0.01 for Model 1: age + Sex +
>5% of samples) - low quality ICV+ 4 genetic PCs +
- Smoking status was selfChip,
Linear mixed
(manual inspection)
WBC + technical
reported in three categories:
position, models of
Remove samples with
covariates, Model 2:
current smoker, ex-smoker, never sample
DNAm~WMH
- low call rate (P<0.01 for <95% BMI + current smoking
smoker.
plate,
burden adjusted for
of probes)
+ dbp3sit + sbp3sit +
- Blood Pressure: dbp3sit +
hybridizati biological and
- a poor match between
age + Sex + ICV+ 4
sbp3sit (3rd reading)
on date
technical covariates.
genotypes and SNP control
genetic PCs + WBC +
probes
technical covariates
- incorrect predicted sex.
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RSIII
and
Illumina
RSI-III 450K
(BBMRI)

SHIP- Illumina
TREND 850K

Whole
blood

- Excluded samples with
incomplete bisulfite treatment, a
DASEN low detection rate (<99%), or
(wateRmel gender mismatches.
on)
- Excluded probes with a
detection p-value>0.01 in >1%
samples

- Smoking status: Smoking status
was coded as self-reported “never
Model 1: ICV, age, sex,
smoker”, “ever smoker”, and
array number, array
Array
“current smoker” based on a
position, WBC counts.
number,
home interview.
Model 2: model 1 +
array
- Blood Pressure: Blood pressure
smoking, BMI, SBP,
position.
was measured twice at the center
DBP
visit, and the average of the two
measurements was used.

Linear mixed
models of
DNAm~WMH
burden adjusted for
biological and
technical covariates.
Technical covariates
as random effects.

Whole
blood

- probes with detection pvalue≥1E-16 were set to missing
- arrays with call rates ≤0.95
were excluded
- arrays with observed technical
problems during steps like
CPACOR bisulfite conversion,
hybridization or extension, as
well as arrays with mismatch
between sex of the proband and
sex determined by the chr X and
Y probe intensities were
excluded.

Model 1: ICV, age, sex,
WBC subtypes, 6
genetic PCs, technical
covariates;
Model 2: + smoking,
BMI, SBP, DBP

linear regression
adjusted for all
covariates listed
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- Smoking status: current smoker
determined by questionnaire
control
- Blood Pressure: measured
probe
(mean of 2nd and 3rd
measurement)

Gene expression data description
Study

Technology

Tissue source

Normalization

FHS307

Affymetrix Human Exon
Array ST 1.0

Whole blood

The raw data were quantile-normalized and log2
transformed, followed by summarization using Robust
Multi-array Average. The percentages of each imputed
cell type were then normalized, where the negative
predicted values were set to 0 and the sum of the
percentages for all cell types were set 100%.

RS308,309

Illumina HumanHT12v4
Expression Beadchip

Whole blood

Quantile-normalized to the median distribution and
subsequently log2-transformed. The probe and sample
means were centered to zero and Z-transformed.
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GEO accession
ID

GSE33828

Appendix B. Supplemental Figures

Figure S 1 Manhattan Plots of genome-wide WMH burden associations at each
DNA methylation (DNAm) site in the trans-ethnic meta-analyses. The DNAm
locations are plotted against the –log10(p value). The red line indicates the Bonferroni
threshold (1 x 10-7) for epigenome-wide significance. The blue line marks the putative
threshold (1 x 10-6).
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Figure S 2 QQ plots for observed vs expected –log10 (P value) at each DNAm site in
the trans-ethnic meta-analyses.
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Figure S 3 Spearman correlation among DNA methylation probes associated with
WMH burden in ARIC subjects of European ancestry (ARIC-EA) and of African
ancestry (ARIC-AA). The color scale corresponds to strength of correlation, where
inverse correlations are blue and direct correlations are red.
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To be continued
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Figure S 4 DNase I hypersensitivity signal around EWAS probes
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Figure S 5 Regional Plot of cg06809326
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AA

EA
cg02741985

cg03116124

cg04245766

To be continued
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AA

EA
cg06450373

cg06809326

cg07675682
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To be continued
AA

EA
cg10051414

cg17577122

cg18950108
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To be continued
AA

EA
cg24202936

cg25317585

Figure S 6 Manhattan plots of mQTLs for 11 target probes
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Appendix C. Supplemental Tables
Table S 1 Descriptive statistics of participating cohorts
WMH
burden
0.98/
1.29
ADNI
864,460
EA
387
187 (48.3%) 74.1±7.0 27.2±4.7 274 (70.8%) 158 (40.8%)
0.99
[0.58,2.01]
1.00/
0.69
EA
906
519 (57.3%) 63.1±4.4 26.4±4.6 306 (33.8%) 162 (17.9%)
1.00
[0.69,1.10]
ARIC
483,526
0.97/
0.69
AA
639
413 (64.8%) 61.8±4.5 29.6±5.4 412 (64.5%) 127 (19.9%)
0.99
[0.69,1.10]
442/
1.04/
279 (63.1%)/
1.40
BBMRI
419,938
EA
255 (57.7%) 64.7±5.8 27.4±3.9
63 (14.2%)
404
1.06
269 (66.6%)
[1.03,1.92]
0.71/
0.18
CARDIA
860,628
Pooled
194
88 (45.4%)
50.2±3.5 28.8±5.3 42 (21.6%)
27 (13.9%)
0.73
[0.10,0.41]
1.33/
1.10 [0.69CHS
483,624
Pooled
378
153 (40.5%) 74.6±5.4 27.5±5.0 240 (63.5%) 49 (13.0%)
1.30
1.38]
1,323/
0.96/
764 (57.7%)/
1.18
FLAIR
711 (53.7%) 66.9±8.7 28.0±5.0
101 (7.6%)
1,320
0.99
761 (57.7%)
[0.79,1.69]
FHS
443,314
EA
Offspring
403/
0.98/
186 (46.2%)/
0.46
DSE
230 (57.1%) 60.6±9.6 28.1±5.7
61 (15.1%)
399
1.01
185 (46.4%)
[0.28,0.79]
356/
0.85/
291 (81.7%)/
2.10 [1.81,
GENOA
26,449
AA
259 (72.8%) 66.3±7.19 31.0±5.98
50 (14.0%)
355
0.83
290 (85.4%)
2.56]
1.23/
2.04 [1.33,
LBC1936
450,727
EA
230
107 (46.5%) 72.1±.52 27.7±4.51 190 (82.6%) 13 (5.6%)
1.23
2.76]
547/
1.31/
229 (41.9%)/
1.34
RS3
474,529
EA
291 (53.2%) 62.6±7.3 27.2±4.1
113 (20.7%)
163
1.19
95 (58.3%)
[0.97,1.77]
1.23/
0.74
SHIP-TREND
865,860
EA
214
117 (54.7%) 49.7±13.3 27.2±4.1 84 (39.3%)
42 (19.6%)
1.20
[0.59,0.93]
#Markers: number of markers. No.: Number of subjects in model1 (reduced) /model2 (full). GI: genomic inflation factor in model1 (reduced) /model2 (full).
Female: number of female subjects, %. Age: mean± standard deviation (s.d.) in years. BMI: mean and s.d. of body mass index, kg/m2. HT: hypertensive
subjects, number (%) in model1 (reduced) /model2 (full). Smoking: current smoker, number (%). WMH burden: median and the IQR (interquartile range;
Q1-Q3) of log(WMH+1).
Study

#Markers

Ancestry No.

GI (λ)

Female
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Age

BMI

HT

Smoking

Table S 2 Coefficient point estimates and P values for 11 target probes in the metaanalyses among hypertensive and normotensive individuals
HT
Reduced model
cg03116124
cg24202936
cg17577122
cg06809326
cg04245766
cg06450373
cg18950108
cg07675682
cg10051414
cg25317585
cg02741985
Full model
cg03116124
cg24202936
cg17577122
cg06809326
cg04245766
cg06450373
cg18950108
cg07675682
cg10051414
cg25317585
cg02741985

NT

Z score (S.E.)

N

Z score (S.E.)

N

-2.83(0.005)
3.18(0.001)
3.46(0.0005)
3.34(0.0009)
1.09(0.276)
0.61(0.543)
-1.66(0.097)
-0.49(0.627)
-0.27(0.789)
5.20(2.05E-07)
2.09(0.037)

2,816
3,006
3,006
3,006
798
2,727
3,006
3,296
2,606
3,006
3,006

-3.009(0.003)
2.866(0.004)
3.319(0.0009)
3.289(0.001)
-2.21(0.027)
-5.102(3.36E-07)
-5.059(4.22E-07)
-3.664(0.0002)
3.648(0.0003)
1.061(0.289)
0.019(0.985)

2,599
2,599
2,599
2,599
587
2,437
2,599
2,664
2,204
2,599
2,599

-2.71(0.007)
2.96(0.003)
3.64(0.0003)
3.31(0.0009)
0.82(0.410)
0.53(0.598)
-2.11(0.035)
-0.49(0.624)
-0.56(0.574)
5.14(2.76E-07)
2.13(0.034)

2,668
2,858
2,858
2,858
798
2,589
2,858
3,147
2,458
2,858
2,858

-3.141(0.002)
1.971(0.049)
3.967(7.28E-05)
2.615(0.009)
-2.319(0.020)
-4.623(3.78E-06)
-4.421(9.81E-06)
-4.095(4.22E-05)
3.853(0.0001)
0.185(0.853)
-0.186(0.852)

2,321
2,321
2,321
2,321
587
2,186
2,321
2,386
1,926
2,321
2,321
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Table S 3 Top DMRs identified from race-specific analysis
Chr start
EA
Model 1
19 50191341
17 20799407
12 122018896
3
193272560
5
140515674
16 89894097
10 105428384
13 46757317
8
144451642
11 130185383
1
209921095
9
116861287
17 78800573
Model 2
6
30039129
19 50191341
2
3704500
12 122018896
6
28973317
18 23713728
10 105428384
16 89894097
1
209921030
13 46757317

5

end

Pmin

PSidak

50191882 2.68E-08 6
20799769 7.60E-08 10
122019117 4.47E-05 7

9.46E-14 8.29E-11
1.68E-12 2.19E-09
3.12E-09 6.68E-06

193272869
140515961
89894329
105428818
46757415
144451924
130185670
209921370
116861532
78800806

2.11E-03
0.006
0.003
0.008
0.008
0.013
0.019
1.26E-02
3.15E-02
0.032

4
3
3
5
3
3
3
4
4
4

2.95E-07
3.99E-07
5.54E-07
1.94E-06
2.14E-06
6.14E-06
6.34E-06
7.48E-06
1.20E-05
1.25E-05

4.53E-04
6.59E-04
0.001
0.002
0.010
0.010
0.010
1.28E-02
0.023
0.025

30039600
50191882
3704793
122019117
28973497
23714084
105428818
89894329
209921370
46757415

3.03E-07
1.44E-06
3.25E-06
4.10E-05
4.23E-05
0.001
3.61E-03
6.69E-03
6.69E-03
0.010

21
6
6
7
9
6
5
3
5
3

1.39E-11
5.42E-11
1.65E-10
6.45E-09
1.09E-07
7.31E-07
1.04E-06
2.08E-06
2.16E-06
3.22E-06

1.40E-08
4.75E-08
2.66E-07
1.38E-05
0.0003
0.001
0.001
0.004
3.01E-03
0.015

10

7.57E-06 6.98E-03

4
5
3
3

9.52E-06
1.42E-05
1.67E-05
2.00E-05

140305946 140306458 0.014

3
193272560
14 88621423
15 101093777
8
144451642
AA
Model 1

Size PComb-p

193272869
88621721
101093900
144451924

1.28E-02
2.66E-02
2.95E-02
1.01E-02
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1.45E-02
2.24E-02
6.24E-02
3.31E-02

Gene
PRMT1
CCDC144NL-AS1
KDM2B
ATP13A4
;ATP13A4-AS1
PCDHB5
SPIRE2
SH3PXD2A
LCP1
RHPN1
ZBTB44
LOC101930114
KIF12
RPTOR
RNF39
PRMT1
ALLC
KDM2B
ZNF311
PSMA8
SH3PXD2A
SPIRE2
LOC101930114
LCP1
PCDHA6;PCDHA12;
PCDHA9;PCDHA1;
PCDHA2;PCDHA3;
PCDHA4;PCDHA5;
PCDHA10;PCDHA7;
PCDHA8;PCDHA11;
PCDHAC1;PCDHA13
ATP13A4;ATP13A4AS1
KCNK10
PRKXP1
RHPN1

8
1765065
1765820 1.71E-07 13 4.11E-13 2.57E-10 MIR596
6
32847197 32847845 1.71E-07 24 7.24E-11 5.27E-08 LOC100294145
3
49170495 49171185 1.39E-06 9
9.19E-11 6.29E-08 LAMB2
3
126911726 126911953 6.74E-05 4
7.56E-09 1.57E-05 C3orf56
11 58869662 58870494 0.0002 6
3.49E-08 1.98E-05 FAM111B
16 89118837 89119709 5.96E-04 7
1.14E-07 6.19E-05 ACSF3
6
170732119 170732353 8.19E-04 3
1.54E-07 3.12E-04 FAM120B
15 102501639 102501654 2.25E-03 3
6.09E-07 1.90E-02 WASH3P
1
236557181 236557758 2.35E-03 5
6.75E-07 0.001
EDARADD
10 131669405 131669630 0.003
3
8.08E-07 0.002
EBF3
4
20985622 20985984 0.006
4
2.59E-06 0.003
KCNIP4
13 100217961 100218552 3.63E-03 4
5.79E-06 4.62E-03 TM9SF2
7
42533000 42533414 0.013
5
6.30E-06 0.007
LINC01448
21 15352607 15352983 1.80E-03 7
7.39E-06 0.009
ANKRD20A11P
19 49699495 49700427 0.029
2
9.05E-05 0.045
TRPM4
Model 2
6
32847209 32847845 3.50E-07 23 8.30E-12 6.16E-09 LOC100294145
3
49170495 49171185 4.44E-07 9
1.32E-11 9.01E-09 LAMB2
3
126911726 126911953 4.49E-06 4
3.23E-10 6.73E-07 C3orf56
10 29697904 29698685 9.44E-07 10 8.62E-10 5.21E-07 SVIL-AS1
8
1765295
1765477 7.26E-06 8
3.51E-09 9.11E-06 MIR596
13 100217961 100218552 1.68E-06 4
4.85E-09 3.87E-06 TM9SF2
6
170732119 170732353 1.75E-03 3
4.60E-07 9.28E-04 FAM120B
10 131669405 131669630 0.003
3
9.25E-07 0.002
EBF3
15 102501639 102501654 0.005
3
1.45E-06 0.045
WASH3P
1
236557181 236557758 1.02E-02 5
3.65E-06 2.99E-03 EDARADD
8
145008109 145008397 0.002
3
8.38E-06 0.01365
PLEC
19 49223833 49224454 0.002
5
1.15E-05 0.009
RASIP1
7
116786596 116786870 2.76E-02 3
1.57E-05 0.027
ST7
5
150678161 150678334 2.77E-02 2
1.67E-05 4.45E-02 SLC36A3
13 113633378 113634042 0.014
8
2.00E-05 0.014
MCF2L
2
114341630 114342108 1.23E-02 3
2.31E-05 2.25E-02 WASH2P
17 37893802 37894636 0.028
6
5.74E-05 0.032
GRB7
Pmin: the minimum P value in the DMR. Size: Number of methylation probes in the DMR.
PComb-p: combined Z-score based on Comb_P. PSidak: Sidak multiple-testing corrected P value
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Table S 4 Top DMRs from gene-based analysis in hypertensive subjects
Chr start
end
Pmin
Size PComb-p
Model 1
8
99984349 99985049 6.11E-3 5
1.16E-06
3
193272560
22
45680497
2
210074019
12
125225315
Model 2
18
13611369
19
50191341
9
96623031
8
99984349
12
4918390

PSidak

Gene

193273057
45681036
210074359
125225808

1.23E-2
1.86E-2
3.67E-2
0.048

5
12
3
3

2.57E-06
6.30E-06
1.70E-05
2.74E-05

7.85E-04 OSR2
ATP13A4;ATP13A42.45E-03 AS1
0.00552 UPK3A
2.34E-02 MAP2
0.02598 SCARB1

13611824
50191882
96623674
99985049
4918848

2.94E-5
1.03E-3
0.00136
1.12E-2
1.71E-5

7
6
4
5
2

5.57E-10
1.25E-09
7.50E-08
4.64E-06
9.46E-06

5.81E-07
1.09E-06
5.53E-05
3.14E-03
9.74E-03

LDLRAD4
PRMT1
MIR4291
OSR2
KCNA6
ATP13A4;ATP13A43
193272560 193273057 3.29E-2 5
1.15E-05
1.09E-02 AS1
20
13200684 13201551 1.80E-2 13
4.97E-05
2.68E-02 ISM1
Pmin: the minimum P value in the DMR. Size: Number of methylation probes in the DMR.
PComb-p: combined Z-score based on Comb_P. PSidak: Sidak multiple-testing corrected P value
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Table S 5 Top DMRs from race-specific analysis in hypertensive subjects
Chr start
EA
Model 1
6
31691226
7
95025406
19 843540
3
193272560
15 93580021
18 23713594
1
209979282
5
176755198
9
96623031
17 41924042
Model 2
1
42384389
20 36148619
7
95025735
16 979487
18 77545027
15 93580021
3
193272560
10 104196242
2
210074019
1
209979469
6
168491617
5
147699717
AA
Model 1
6
32118203
17 80059407
7
27183368
18 13611369
9
139715700
5
150678161
12 110156244
19 49223833
3
195489707
8
145730817
Model 2
5
23507029

end

Pmin

Size PComb-p

PSidak

Gene

31692375
95026248
843995
193273057
93580327
23714084
209979779
176755805
96623480
41924577

3.55E-8
2.44E-4
2.13E-5
2.47E-3
0.002
1.38E-2
2.94E-2
0.040
0.014
3.59E-2

29
21
4
5
5
9
12
5
3
11

1.04E-10
1.50E-8
5.24E-8
2.89E-7
3.65E-7
4.15E-6
1.38E-5
2.26E-5
2.91E-5
2.97E-5

4.28E-8
8.42E-6
5.45E-5
2.76E-4
5.64E-4
4.01E-3
1.31E-2
1.75E-2
3.03E-2
2.60E-2

MPIG6B
PON3
PRTN3
ATP13A4;ATP13A4-AS1
RGMA
PSMA8

42384564
36149271
95026211
979662
77545223
93580327
193272869
104196541
210074276
209979779
168491686
147699892

1.28E-5
0.001
8.18E-4
0.002
0.005
5.09E-3
9.77E-3
0.015
3.76E-3
1.38E-2
2.30E-2
0.031

3
29
18
3
3
5
4
3
2
9
3
3

3.39E-8
9.79E-8
2.48E-7
3.60E-7
5.97E-7
7.73E-7
1.69E-6
3.29E-6
4.08E-6
5.70E-6
5.91E-6
9.37E-6

9.17E-5
7.11E-5
2.47E-4
9.75E-4
1.44E-3
1.20E-3
2.59E-3
5.20E-3
7.50E-3
8.67E-3
3.98E-2
2.50E-2

HIVEP3
BLCAP
PON3
LMF1;LMF1-AS1
CTDP1
RGMA
ATP13A4;ATP13A4-AS1
MIR146B
MAP2
IRF6
FRMD1
LOC102546294

32119041
80059540
27184853
13611824
139716599
150678334
110156459
49224454
195490309
145731409

1.53E-6
0.0003
7.11E-4
0.001
0.002
0.004
1.04E-2
1.62E-3
0.010
7.40E-3

17
2
43
7
4
2
5
5
8
3

7.51E-11
1.22E-8
1.93E-8
9.85E-8
3.57E-7
9.82E-7
3.21E-6
4.86E-6
6.19E-6
1.39E-5

4.23E-8
4.33E-5
6.15E-6
1.02E-4
1.88E-4
2.68E-3
7.03E-3
3.69E-3
4.84E-3
1.11E-2

PRRT1
CCDC57
HOXA-AS3
LDLRAD4
RABL6
SLC36A3
FAM222A
RASIP1
MUC4
GPT

LMAN2
MIR4291
CD300LG

23507752 8.01E-7 12 1.61E-11 1.05E-8 PRDM9
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7
3
19
18
5
14
11
12
9
16

1609340
195489305
49223813
13611369
150678161
100203941
123430574
110156244
139716025
87736669

1609908
195490309
49224454
13611824
150678334
100204528
123431162
110156459
139716599
87737091

1.76E-6
2.42E-5
8.04E-5
8.04E0.002
0.005
2.03E-2
0.030
0.016
0.015

11
9
6
7
2
7
5
5
3
4

5.10E-10
1.79E-9
6.19E-9
7.48E-9
3.37E-7
8.87E-7
6.69E-6
1.23E-5
1.40E-5
3.43E-5

4.24E-7
8.40E-7
4.56E-6
7.76E-6
9.19E-4
7.14E-4
5.36E-3
2.67E-2
1.14E-2
3.76E-2

PSMG3;PSMG3-AS1
MUC4
RASIP1
LDLRAD4
SLC36A3
CYP46A1
GRAMD1B
FAM222A
RABL6
KLHDC4

Pmin: the minimum P value in the DMR. Size: Number of methylation probes in the DMR.
PComb-p: combined Z-score based on Comb_P. PSidak: Sidak multiple-testing corrected P value
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Table S 6 Top DMRs from gene-based analysis in normotensive subjects
Chr start
Model 1
20 62693942
2
27665016
17 37123637
3
195576389
12 122018896
1
84326461
22 42828124
11 89956516
16 57728631
2
198650008
10 133946673
7
150498593
19 57742216
Model 2
20 62693656
3
195576389
15 39871807
6
74072241
17 37123637
16 8806530
8
142233381
22 42828124
19 10736005
10 4230412
11 89956572
4
165877874
7
158280409
1
206785999
13
12

end

Pmin

Size PComb-p

PSidak

Gene

62694005
27665306
37123949
195578280
122019117
84326856
42828418
89956777
57728700
198651076
133946881
150498843
57742444

1.39E-08
3.04E-09
2.10E-05
9.28E-03
0.000243
2.80E-04
0.006238
9.21E-04
0.008
9.65E-04
0.031
0.002
0.014

6
7
9
8
7
8
5
7
2
2
3
2
8

4.93E-13
4.73E-12
9.75E-10
1.06E-09
1.44E-08
5.04E-08
1.61E-06
1.97E-06
2.33E-06
2.59E-06
1.35E-05
1.40E-05
1.43E-05

3.71E-09
7.73E-09
1.48E-06
2.66E-07
3.08E-05
6.04E-05
0.002586
3.57E-03
0.01584
1.15E-03
0.0303
2.62E-02
0.02918

TCEA2
NRBP1;KRTCAP3
FBXO47
LINC01983
KDM2B
LINC01725
NFAM1
CHORDC1
DRC7
BOLL
JAKMIP3
TMEM176A
AURKC

62694005
195578280
39872071
74072447
37123949
8807043
142233705
42828516
10736355
4230752
89956777
165878317
158280480
206786222

4.63E-13
3.92E-03
1.13E-06
1.43E-05
2.15E-05
8.69E-05
1.94E-03
6.57E-05
0.005097
0.006747
4.49E-03
2.26E-03
0.0143
1.77E-02

7
8
6
7
9
12
5
7
7
6
6
8
2
6

2.82E-18
9.27E-11
3.34E-10
6.03E-10
1.40E-09
1.11E-08
5.82E-07
6.17E-07
9.67E-07
1.40E-06
2.32E-06
3.13E-06
4.23E-06
5.58E-06

3.83E-15
2.32E-08
6.00E-07
1.39E-06
2.13E-06
1.02E-05
8.51E-04
0.000746
0.001308
0.001948
5.34E-03
3.34E-03
0.02781
1.18E-02

44716512 44716778 0.01952
108168823 108169020 0.01409

2
3

TCEA2
LINC01983
THBS1
KHDC3L
FBXO47
ABAT
SLC45A4
NFAM1
SLC44A2
LINC00702
CHORDC1
FAM218A;TRIM61
PTPRN2
EIF2D
LINC00390;SMIM2AS1;
6.36E-06 1.13E-02 SMIM2-AS1
9.70E-06 0.02305 ASCL4

Pmin: the minimum P value in the DMR. Size: Number of methylation probes in the DMR.
PComb-p: combined Z-score based on Comb_P. PSidak: Sidak multiple-testing corrected P value
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Table S 7 Top DMRs from race-specific gene-based analysis in normotensive
subjects
Chr start
EA
Model 1

end

Pmin

Size PComb-p

PSidak

Gene

17 20799407
2
27665016
17 37123637
20 62693942
12 122018769
6
74072241
16 57728631
7
24323674
11 66085249
10 104535791
Model 2
20 62693942
17 37123637
15 39871807
6
74072241
17 17110119
8
144120334
2
241497411
22 42828124
7
158280409
11 66085249
16 57728631
10 4230481
AA
Model 1
5
135414857
5
6755025
11 6518107
19 37825008
3
49170495
16 56995200
3
195576389
7
24323260
2
239139910
19 58595667
4
81118793
17 79225572

20799769
27665306
37123949
62694005
122019117
74072447
57728700
24323840
66085299
104536052

1.24E-09
1.28E-09
1.53E-06
2.49E-06
2.31E-05
4.99E-05
3.59E-04
2.09E-05
5.39E-03
0.02529

10
7
9
6
8
7
2
6
2
8

3.01E-14
4.31E-12
8.41E-11
2.19E-09
2.25E-09
5.47E-09
4.77E-08
3.68E-07
1.07E-06
1.04E-05

3.94E-11
7.05E-09
1.28E-07
1.65E-05
3.06E-06
1.26E-05
3.27E-04
1.05E-03
1.01E-02
1.87E-02

CCDC144NL-AS1;
CCDC144NL
NRBP1; KRTCAP3
FBXO47
TCEA2
KDM2B
KHDC3L
DRC7
NPY
CD248
WBP1L

62694005
37123949
39872071
74072447
17110353
144120706
241497663
42828418
158280480
66085299
57728700
4230752

4.26E-09
1.04E-06
1.04E-06
4.39E-06
2.35E-06
5.88E-04
5.32E-03
0.007968
9.85E-03
1.10E-02
0.01098
4.00E-02

6
9
6
7
5
7
7
5
2
2
2
5

4.13E-13
4.40E-11
2.15E-10
2.87E-10
1.64E-09
6.10E-07
1.10E-06
2.12E-06
2.83E-06
3.23E-06
3.45E-06
2.84E-05

3.11E-09
6.69E-08
3.86E-07
6.61E-07
3.31E-06
7.77E-04
2.07E-03
0.00341
1.87E-02
3.02E-02
2.34E-02
4.84E-02

TCEA2
FBXO47
THBS1
KHDC3L
PLD6
C8orf31
ANKMY1
NFAM1
PTPRN2
CD248
DRC7
LINC00702

135416613
6755843
6518907
37825679
49171185
56995856
195578280
24323799
239140733
58596261
81119473
79225974

4.67E-25
9.57E-21
1.03E-11
5.20E-08
1.36E-06
7.71E-06
2.47E-02
3.27E-06
2.00E-04
0.001005
1.27E-03
0.00173

20
8
11
8
9
6
8
7
15
3
7
4

1.15E-34
4.39E-25
7.47E-16
8.18E-11
3.00E-10
4.87E-09
7.79E-09
6.64E-08
9.66E-08
2.49E-07
7.53E-07
2.03E-06

3.10E-32
2.54E-22
4.59E-13
5.76E-08
2.05E-07
3.51E-06
1.95E-06
5.82E-05
5.54E-05
0.000198
5.23E-04
0.002379

VTRNA2-1
PAPD7
DNHD1
HKR1
LAMB2
CETP
LINC01983
NPY
LOC151174; LOC643387
ZSCAN18
PRDM8
SLC38A10
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11 65315029
13 113776872
12 132859440
Model 2
5
135415128
6
32063393
5
6755025
11 6518107
1
45965448
13 113776872
2
48844727
3
49170495
2
239139517
21 47717405
20 259897
4
74718977
10 135341869
6
149777805
11 116699588

65315466 7.45E-06 4
113777160 2.52E-02 9
132859951 0.04213 5

2.13E-06 2.30E-03 LTBP3
1.39E-05 2.25E-02 F10
2.77E-05 2.53E-02 GALNT9

135416613
32064212
6755439
6518907
45966115
113777160

2.54E-12
5.43E-10
4.95E-12
1.00E-08
9.51E-08
1.78E-07

19
24
6
11
11
9

1.25E-18
1.79E-14
1.22E-13
9.34E-13
1.02E-11
2.34E-11

3.98E-16
1.04E-11
1.39E-10
5.52E-10
7.22E-09
3.84E-08

48845068
49171343
239140733
47718080
259925
74719597
135342936
149778058
116700049

6.80E-07
1.50E-04
3.21E-08
0.000997
0.005748
6.25E-03
0.01292
0.01522
1.25E-02

8
10
16
5
2
6
6
3
3

1.07E-10
4.17E-08
6.01E-08
3.69E-07
2.85E-06
3.28E-06
1.03E-05
1.09E-05
1.87E-05

1.48E-07
2.32E-05
2.33E-05
0.000258
0.04691
2.50E-03
0.004552
0.02007
1.90E-02
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VTRNA2-1
TNXB
PAPD7
DNHD1
MMACHC; CCDC163
F10
STON1-GTF2A1L;
GTF2A1L
LAMB2
LOC151174; LOC643387
YBEY
C20orf96
PF4V1
CYP2E1
ZC3H12D
APOC3

Table S 8 DNA features and regulatory elements at target DNAm loci
ProbeID
Chr Pos
Score BP
Relevant Tissue*
cg03116124 1
231293208 5
cg24202936 11 50257256 5
cg17577122 22 19511967 2b
POLR2A
umbilical vein endothelial cells
umbilical vein endothelial cells,
cg06809326 17 20799526 2b
CTCF
brain microvascular endothelial
cells, glioblastoma cells
cg04245766 14 54421051 4
POLR2A
umbilical vein endothelial cells
cg06450373 5
19766434 6
cg18950108 6
30920171 5
cg07675682 17 78195515 5
POLR2A
umbilical vein endothelial cells
MAX
umbilical vein endothelial cells
umbilical vein endothelial cells,
cg10051414 22 38598733 2b
CTCF
brain microvascular endothelial
cells
REST
glioblastoma/ astrocytoma
EZH2
astrocytes
umbilical vein endothelial cells,
brain microvascular endothelial
CTCF
cells, glioblastoma cells,
cg25317585 13 102568886 4
neuroblastoma cells
RAD21
neuroblastoma cells
REST
glioblastoma/ astrocytoma cells
YY1
neuroblastoma cells
cg02741985 17 80059408 4
REST
neuroblastoma cells
Chr: Chromosome. Pos: Position. BP: Binding Protein. *Endothelial cells and brain
tissues were reviewed.
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Table S 9 Transcription factors enriched in the fetal brain tissue - eFORGE
ProbeID
cg06450373

cg24202936

cg25317585
cg06809326

cg17577122

Motif Name
ONECUT1_CUT_1
ONECUT1_CUT_2
ONECUT2_CUT_1
ONECUT3_CUT_1
V_MTERF_01
Rara_secondary
Klf7_primary
Ascl2_secondary
V_NRSF_Q4

Binding Site
5:19766428-19766442:5:19766428-19766442:5:19766428-19766442:5:19766428-19766442:11:50257253-50257267:11:50257251-50257267:11:50257254-50257270:+
11:50257254-50257270:+
13:102568875102568894:+
PAX2_PAX_1
17:20799510-20799528:+
PAX5_PAX_1
17:20799510-20799528:+
NRF1_NRF_1
17:20799523-20799535:/+
V_NRF1_Q6
17:20799525-20799535:+
17:20799523-20799533:V_ZFP206_01
17:20799524-20799535:17:20799523-20799534:+
MA0014.1-Pax5
17:20799509-20799529:V_PAX5_01
17:20799505-20799533:Egr3.mouse_C2H2_ 22:19511961-19511976:1
Egr1.mouse_C2H2_ 22:19511961-19511977:1
EGR1_C2H2_1
22:19511962-19511976:-

Database
Taipale/SELEX
Taipale/SELEX
Taipale/SELEX
Taipale/SELEX
TRANSFAC
UniProbe
UniProbe
UniProbe
TRANSFAC

P value
1.75E-07
2.05E-07
2.05E-07
1.65E-07
3.61E-06
1.92E-04
7.55E-03
9.50E-03
1.17E-03

Q value
4.65E-06
4.65E-06
4.65E-06
4.65E-06
6.55E-05
2.18E-03
3.42E-02
3.91E-02
8.16E-03

Taipale/SELEX
Taipale/SELEX
Taipale/SELEX

5.46E-05
6.69E-05
4.64E-04

8.25E-04
8.67E-04
4.21E-03

TRANSFAC

4.63E-04

4.21E-03

TRANSFAC

1.04E-03

7.85E-03

JASPAR
TRANSFAC
Taipale/SELEX

1.66E-03
3.61E-03
8.72E-04

9.50E-03
1.72E-02
7.18E-03

Taipale/SELEX

1.40E-03

9.08E-03

Taipale/SELEX

1.68E-03

9.50E-03

EGR3_C2H2_1
22:19511962-19511977:- Taipale/SELEX 2.49E-03
1.33E-02
Egr1_primary
22:19511962-19511976:- UniProbe
3.31E-03
1.67E-02
Sp4_primary
22:19511962-19511979:- UniProbe
8.92E-03
3.85E-02
V_KROX_Q6
22:19511962-19511976:- TRANSFAC
1.18E-02
4.67E-02
V_SP1_Q6
22:19511966-19511979:+ TRANSFAC
1.72E-02
6.50E-02
TF binding site: Transcription factor binding site. P value: p-value calculated for sequence
overlaps with each of the motifs. Q-value: Multiple-testing corrected p-value with the
Benjamini-Yekutieli method (FDR 0.1%)
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Table S 10 Shared epigenetic associations between white matter hyperintensities (WMH)
burden and cognitive abilities (CA)

CpG
Gene
ZWMH PWMH
ZCA PCA
Pjoint
Qjoint
Reduced model
Digital Symbol
cg05575921 AHRR
-2.79 5.30E-03 6.62 3.59E-11 3.19E-11 1.35E-05
cg18181703 SOCS3
-1.59 1.13E-01 6.62 3.53E-11 2.11E-10 4.29E-05
cg21566642
-2.81 4.99E-03 6.24 4.49E-10 3.06E-10 4.29E-05
cg05951221
-3.61 3.12E-04 5.75 9.12E-09 4.55E-10 4.79E-05
cg12593793
-1.99 4.70E-02 6.20 5.82E-10 1.86E-09 1.57E-04
cg03366574
1.83 6.68E-02 -6.15 8.00E-10 3.09E-09 2.17E-04
cg03636183 F2RL3
-2.92 3.54E-03 5.67 1.47E-08 5.24E-09 3.16E-04
cg06126421
-2.82 4.87E-03 5.60 2.17E-08 9.61E-09 5.06E-04
cg26470501 BCL3
-2.98 2.90E-03 5.34 9.49E-08 2.29E-08 1.07E-03
cg06946797
-1.82 6.95E-02 5.73 1.02E-08 3.43E-08 1.22E-03
cg17417856 PRMT1;C19orf76 -4.72 2.40E-06 3.74 1.82E-04 3.77E-08 1.22E-03
cg17759224
0.79 4.28E-01 5.67 1.47E-08 3.26E-08 1.22E-03
cg22953759 ANKRD33B
-0.73 4.63E-01 5.85 4.88E-09 3.71E-08 1.22E-03
cg00134210 FAM107B
-1.63 1.04E-01 5.65 1.58E-08 6.53E-08 1.73E-03
cg13092901 TYMP;SCO2
-2.90 3.72E-03 5.16 2.50E-07 6.57E-08 1.73E-03
cg17386185 GLYCTK
-2.21 2.71E-02 5.49 4.00E-08 6.31E-08 1.73E-03
cg14943908 BAT2
-1.66 9.70E-02 5.51 3.59E-08 1.35E-07 3.33E-03
cg19405484
-1.26 2.10E-01 5.57 2.57E-08 1.47E-07 3.41E-03
cg19859270 GPR15
-3.87 1.09E-04 4.26 2.00E-05 1.54E-07 3.41E-03
cg01940273
-1.94 5.30E-02 5.39 6.92E-08 1.67E-07 3.47E-03
cg03183540
-1.43 1.54E-01 5.49 4.12E-08 1.97E-07 3.47E-03
cg04987734 CDC42BPB
3.24 1.21E-03 -4.68 2.87E-06 2.19E-07 3.47E-03
cg07195224 AIM2
-1.67 9.57E-02 5.41 6.20E-08 2.21E-07 3.47E-03
cg16594502
-2.64 8.29E-03 5.07 4.08E-07 1.95E-07 3.47E-03
cg21108085 CD82;CD82
-1.61 1.08E-01 5.46 4.90E-08 1.91E-07 3.47E-03
cg22331294 LIMD1
0.99 3.25E-01 5.27 1.35E-07 2.21E-07 3.47E-03
cg25376310 ZDHHC14
-2.36 1.83E-02 5.17 2.29E-07 2.22E-07 3.47E-03
C6orf48;SNORD5
cg01657995 2
-1.05 2.95E-01 5.50 3.92E-08 2.49E-07 3.75E-03
cg07660627 ACACA
-0.56 5.74E-01 -5.36 8.55E-08 2.66E-07 3.86E-03
cg00252813 GAPDH
-1.61 1.08E-01 5.38 7.41E-08 2.82E-07 3.96E-03
cg12142865 ALDH2
-0.82 4.14E-01 5.46 4.80E-08 3.32E-07 4.51E-03
cg01406381 SLC1A5
-1.25 2.12E-01 5.37 7.79E-08 4.21E-07 5.49E-03
cg05673882 POLK
-2.64 8.35E-03 4.89 1.03E-06 4.42E-07 5.49E-03
cg12473916 SHC1
-2.09 3.67E-02 5.14 2.71E-07 4.43E-07 5.49E-03
cg02003183 CDC42BPB
2.41 1.58E-02 -4.99 6.03E-07 4.64E-07 5.58E-03
cg14602222 RAD52
2.59 9.73E-03 -4.89 1.02E-06 4.97E-07 5.82E-03
cg00780520 PVT1
-1.40 1.61E-01 5.30 1.14E-07 5.26E-07 5.99E-03
cg03881294
-0.50 6.18E-01 5.33 1.00E-07 6.95E-07 7.71E-03
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cg02657160 CPOX
cg10475172 CCR9
cg21171320 TRPM3
cg01955153
cg27050612 NFE2L1
cg04885881
cg15095917 CD68
cg11231349 NOS1AP
cg23842572 MPRIP
cg00310412 SEMA7A
cg16736826 EDN2
cg04158018 NFE2
cg06809326 CCDC144NL
cg04973995
cg10721220
cg24202936 LOC441601
cg26140475
cg02068690 DTNB
cg02507296 C10orf95
cg02519286 GAPDH
cg04424621 HIST1H2BJ
cg11146034 ELK3
cg21139312 MSI2
cg26856257
cg01127300
cg07960624 SAMD12
cg09586583 SSBP3
cg00611192 ZNF692
cg02010481 JAZF1
cg09182189 NADK
cg09676630 FBRSL1
cg14277403 ANP32B
cg18006990 GTPBP2
cg14753356
cg19572487 RARA
cg16878214 PLEKHF2
cg02767093 STK24
cg03707168 PPP1R15A
cg05438378 SMAD3
cg26729380 TNF
cg16618104 CHST11
cg24296397 BSN
cg26695387 MAP2K3
cg11344352 ERCC1
cg04949225

-2.59
0.91
-0.35
0.89
-2.28
-3.34
-0.38
-2.02
0.66
-1.65
-2.54
-1.20
4.99
0.82
-0.91
5.08
0.54
0.72
-0.23
-0.43
-1.80
-2.10
0.84
0.41
-3.97
-1.18
-1.66
-2.41
-1.80
-2.19
-4.49
-2.95
-2.22
-1.40
-1.91
-1.79
-3.19
-0.12
-2.43
0.70
0.85
1.31
-1.14
-1.59
-0.95

9.65E-03
3.63E-01
7.24E-01
3.74E-01
2.27E-02
8.48E-04
7.05E-01
4.31E-02
5.06E-01
9.91E-02
1.11E-02
2.32E-01
6.14E-07
4.13E-01
3.64E-01
3.78E-07
5.91E-01
4.75E-01
8.16E-01
6.65E-01
7.16E-02
3.56E-02
4.03E-01
6.79E-01
7.21E-05
2.38E-01
9.72E-02
1.58E-02
7.19E-02
2.89E-02
7.16E-06
3.14E-03
2.65E-02
1.61E-01
5.66E-02
7.36E-02
1.40E-03
9.08E-01
1.53E-02
4.87E-01
3.96E-01
1.91E-01
2.54E-01
1.12E-01
3.41E-01
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4.79
-5.30
5.30
5.06
4.92
4.25
5.26
4.99
-5.25
5.11
4.68
5.14
0.75
4.96
5.15
0.19
5.00
-5.12
5.11
5.13
4.92
4.80
-5.12
5.01
3.42
5.06
-4.56
4.60
4.89
4.71
2.63
4.28
4.70
4.97
4.82
-4.45
4.04
5.01
4.53
4.84
4.79
-4.93
4.95
4.85
4.97

1.68E-06
1.17E-07
1.13E-07
4.26E-07
8.67E-07
2.17E-05
1.44E-07
6.00E-07
1.49E-07
3.30E-07
2.90E-06
2.80E-07
4.52E-01
7.16E-07
2.56E-07
8.47E-01
5.66E-07
2.99E-07
3.20E-07
2.85E-07
8.67E-07
1.57E-06
3.02E-07
5.35E-07
6.33E-04
4.23E-07
5.18E-06
4.26E-06
1.04E-06
2.45E-06
8.54E-03
1.83E-05
2.61E-06
6.73E-07
1.47E-06
8.54E-06
5.34E-05
5.56E-07
5.97E-06
1.31E-06
1.68E-06
8.08E-07
7.28E-07
1.22E-06
6.76E-07

7.64E-07
7.57E-07
7.57E-07
8.25E-07
8.52E-07
9.43E-07
9.63E-07
1.01E-06
1.02E-06
1.06E-06
1.38E-06
1.46E-06
1.47E-06
1.55E-06
1.60E-06
1.74E-06
1.80E-06
1.97E-06
1.98E-06
1.89E-06
2.04E-06
2.05E-06
1.92E-06
1.98E-06
2.09E-06
2.18E-06
2.30E-06
2.57E-06
2.40E-06
2.57E-06
2.47E-06
2.46E-06
2.55E-06
2.74E-06
2.75E-06
2.82E-06
3.17E-06
3.20E-06
3.38E-06
3.40E-06
3.47E-06
3.57E-06
3.73E-06
3.78E-06
3.93E-06

7.86E-03
7.86E-03
7.86E-03
8.28E-03
8.35E-03
9.02E-03
9.02E-03
9.10E-03
9.10E-03
9.30E-03
1.19E-02
1.21E-02
1.21E-02
1.26E-02
1.27E-02
1.36E-02
1.38E-02
1.39E-02
1.39E-02
1.39E-02
1.39E-02
1.39E-02
1.39E-02
1.39E-02
1.40E-02
1.44E-02
1.49E-02
1.53E-02
1.53E-02
1.53E-02
1.53E-02
1.53E-02
1.53E-02
1.59E-02
1.59E-02
1.60E-02
1.77E-02
1.77E-02
1.83E-02
1.83E-02
1.85E-02
1.88E-02
1.94E-02
1.94E-02
2.00E-02

cg00415665 ZHX2
cg17577122 CLDN5
cg19940644
cg21241410
cg03116124
cg05168229
cg06285727 ATG16L2
cg15705273 NCLN
cg16346032
cg08620426
cg10717214 TNF
cg25375916 SLC33A1
cg13854219
cg27115863
cg07092212 DGKZZ
cg12966875 SLPI
cg00144180 HDAC4
cg13709639 TUBA1B
CCNL2;LOC1484
cg24837149 13
cg26079320 POGK
cg15030712 CHN2
cg02610723 FAM38A
cg05492306 ERCC1
cg25648203 AHRR
cg10021364 MYADM
cg25607249 SLC1A5
cg03535253 BTBD7
cg16253157 CYB561D1
cg27067618 CYP4F3
cg04994217 C9orf170
cg02656560
cg00711496 C19orf76;PRMT1
MMSE
cg01127300
cg03636183 F2RL3
cg05575921 AHRR
cg05704155 PGD;PGD
cg05951221
cg06126421
cg19859270 GPR15
cg21450381
cg22529900 PARK7
cg25923609
Verbal Fluency

0.55
4.89
-2.80
0.89
-4.91
-0.41
0.46
2.53
-0.02
-0.31
0.83
0.51
1.28
-1.41
-0.61
0.71
0.60
-1.80

5.85E-01
1.02E-06
5.13E-03
3.71E-01
9.32E-07
6.84E-01
6.47E-01
1.16E-02
9.88E-01
7.61E-01
4.05E-01
6.08E-01
2.02E-01
1.59E-01
5.44E-01
4.78E-01
5.47E-01
7.16E-02

-2.41
-0.52
0.06
0.98
-1.43
-0.64
-2.49
-0.46
0.01
-0.22
-0.09
-3.32
-2.39
-4.12

1.58E-02 4.38 1.21E-05 6.49E-06 2.65E-02
6.03E-01 4.89 1.02E-06 6.48E-06 2.65E-02
9.55E-01 4.84 1.28E-06 6.66E-06 2.70E-02
3.27E-01 4.62 3.80E-06 6.98E-06 2.78E-02
1.52E-01 4.76 1.93E-06 6.94E-06 2.78E-02
5.20E-01 4.87 1.15E-06 7.24E-06 2.85E-02
1.29E-02 4.28 1.84E-05 7.89E-06 3.07E-02
6.43E-01 4.85 1.21E-06 7.95E-06 3.07E-02
9.96E-01 -4.83 1.38E-06 8.28E-06 3.17E-02
8.25E-01 -4.80 1.58E-06 8.50E-06 3.23E-02
9.30E-01 4.83 1.39E-06 8.65E-06 3.25E-02
9.12E-04 3.64 2.69E-04 9.07E-06 3.38E-02
1.69E-02 4.30 1.68E-05 9.65E-06 3.57E-02
3.86E-05 2.69 7.11E-03 9.98E-06 3.66E-02

-3.97
-2.92
-2.79
4.55
-3.61
-2.82
-3.87
-0.13
-4.47
3.59

7.21E-05
3.54E-03
5.30E-03
5.26E-06
3.12E-04
4.87E-03
1.09E-04
8.98E-01
7.87E-06
3.32E-04
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-4.98
-1.37
4.26
4.74
1.22
4.96
4.85
-4.41
4.93
-4.87
4.73
4.82
4.53
4.82
4.92
4.74
-4.90
4.67

3.74
4.97
5.14
-3.33
4.84
4.60
3.60
-5.72
-2.53
-4.46

6.43E-07
1.70E-01
2.05E-05
2.16E-06
2.22E-01
6.91E-07
1.23E-06
1.01E-05
8.22E-07
1.12E-06
2.20E-06
1.47E-06
5.86E-06
1.42E-06
8.89E-07
2.12E-06
9.42E-07
2.99E-06

1.86E-04
6.78E-07
2.77E-07
8.65E-04
1.29E-06
4.31E-06
3.18E-04
1.04E-08
1.15E-02
8.17E-06

4.18E-06
4.14E-06
4.06E-06
4.17E-06
4.39E-06
4.44E-06
4.28E-06
4.30E-06
4.41E-06
4.58E-06
5.04E-06
5.08E-06
5.40E-06
5.40E-06
5.49E-06
5.76E-06
6.04E-06
6.15E-06

3.93E-07
7.13E-08
4.38E-08
1.39E-07
1.45E-08
5.47E-07
9.48E-07
7.45E-08
1.12E-06
8.71E-08

2.03E-02
2.03E-02
2.03E-02
2.03E-02
2.03E-02
2.03E-02
2.03E-02
2.03E-02
2.03E-02
2.07E-02
2.25E-02
2.25E-02
2.35E-02
2.35E-02
2.36E-02
2.45E-02
2.54E-02
2.57E-02

2.37E-02
7.35E-03
7.35E-03
9.75E-03
6.10E-03
2.88E-02
4.44E-02
7.35E-03
4.74E-02
7.35E-03

cg04987734 CDC42BPB
cg07102705 HTR4
cg10313673 CILP2
cg10922280 DPEP2
cg12025310 TMPRSS6
cg12507869 INPP5A
cg12582616 JARID2
cg13696609 FOXE1
cg14945937 PLEKHF1
cg15909981 TMPRSS6
cg16201957 MAML3
cg23722790 SLC35D1
Vocabulary
cg04513006 ESRP2
Full model
MMSE
cg05704155 PGD
cg21450381
Verbal Fluency
cg12507869 INPP5A
cg16201957 MAML3

3.24
3.08
1.75
1.23
3.43
-0.04
-3.54
-1.21
-1.95
-1.49
1.17
0.47

1.21E-03
2.07E-03
7.99E-02
2.20E-01
6.00E-04
9.69E-01
3.96E-04
2.27E-01
5.16E-02
1.36E-01
2.44E-01
6.39E-01

-4.47
-4.48
-5.07
-5.59
-4.05
-5.81
-4.15
-4.97
-4.79
-4.88
-5.67
-5.56

7.89E-06
7.56E-06
3.90E-07
2.33E-08
5.16E-05
6.44E-09
3.38E-05
6.66E-07
1.68E-06
1.06E-06
1.41E-08
2.71E-08

4.75E-07
7.23E-07
9.85E-07
1.31E-07
1.36E-06
3.78E-08
4.66E-08
8.40E-07
4.19E-07
7.64E-07
8.45E-08
1.97E-07

2.86E-02
3.54E-02
3.78E-02
1.38E-02
4.77E-02
9.83E-03
9.83E-03
3.54E-02
2.86E-02
3.54E-02
1.19E-02
1.66E-02

0.41 6.85E-01 -5.65 1.60E-08 1.18E-07 4.96E-02
4.88 1.07E-06 -3.53 4.11E-04 1.42E-08 6.00E-03
-0.05 9.57E-01 -5.66-1.55E-08 1.15E-07 2.43E-02
-0.82 4.11E-01 -5.96 2.47E-09 8.79E-09 3.71E-03
1.35 1.78E-01 -5.46 4.71E-08 1.80E-07 3.79E-02
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Table S 11 Correlation between Methylation Levels in Blood and Brain
Brain tissues

cg02741985

cg03116124

cg04245766

cg06450373

cg06809326

cg07675682

PFC (n=74)

-0.053, 0.652

0.292, 1.16E-02

0.923, 1.38E-31

0.227, 0.052

0.566,1.49E-07

-0.114, 0.333

EC (n=71)

0.248, 3.68E-02

0.177, 0.141

0.954, 6.89E-38

-0.037, 0.763

0.711, 3.83R-12

-0.078, 0.518

STG (n=75)

0.049, 0.674

0.218, 6.00E-02

0.924, 4.17E-32

-0.036, 0.763

0.601, 1.15E-08

-0.048, 0.686

CER (n=71)
Brain tissues

0.202, 9.17E-02
cg10051414

0.242, 4.2-E-02
cg17577122

0.939, 1.16E-33
cg18950108

0.003,0.982
cg24202936

0.582, 1.02E-07
cg25317585

-0.070, 0.562

PFC (n=74)

-0.102, 0.388

-0.158, 0.178

0.122, 0.302

0.327,0.005

0.102, 0.389

EC (n=71)

-0.158, 0.189

0.122, 0.311

-0.010, 0.937

0.398, 5.81E-04

0.043, 0.724

STG (n=75)

0.066, 0.575

0.051, 0.666

0.255, 2.73E-02

0.324, 4.60E-03

-0.123, 0.295

CER (n=71)
-0.312, 8.18E-03 0.122, 0.311
0.106, 0.380
0.158, 0.189
0.020, 0.871
Correlation r and P value. PFC: prefrontal cortex, EC: entorhinal cortex, STG: superior temporal gyrus and CER: cerebellum
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